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Abstract 
Heart failure places a global strain on healthcare provision. It has an increasing 
incidence and represents the endpoint of a variety of cardiovascular diseases. The 
preceding decades have carved out a clear management algorithm for the use of 
pharmacotherapies (neurohormonal antagonists), device-based therapies 
(Implantable Cardioverting Defibrillator (ICD) and Cardiac Resynchronisation 
Therapy (CRT)) and mechanical therapies including left ventricular assist devices 
and heart transplantation. While heart transplantation remains the gold standard 
for the suitable few, the advancement of healthcare systems and improved 
working conditions and safety regulations have changed the demographics of the 
typical organ donor which traditionally were young brainstem death donors (DBD) 
with minimal other comorbidities. Nevertheless, transplantation confers a 
substantial survival benefit for selected patients with advanced heart failure, 
achieving a 1-year survival rate of ≥80%. 
The primary cause for early mortality in recipients remains primary graft 
dysfunction (PGD). The incidence of PGD throughout the UK and the world are 
variable due to the lack of a standardised definition until 2014.  
My research explored the true incidence of PGD throughout the UK using data 
collected from each of the 6 transplant centres alongside the National Health 
Service Blood and Transplant database. I then looked at risk factors for PGD which 
culminated in the largest PGD study recorded at the time of writing. I also looked 
into the role of mechanical circulatory support to bridge patients in cardiogenic 
shock post-myocardial infarction in Scotland. I finally developed 2 scoring systems, 
1 for Primary Graft Dysfunction (PREDICTA) and 1 using the modified Delphi 
Method of a consensus agreement (GTS) to factor in elements of frailty which had 
been garnering increasing interest at conferences I had attended. 
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NT-proBNP N-terminal pro-brain natriuretic peptide 
 
BSA  Body surface area 
 
DBD  Donation after brainstem death 
 
DCD  Donation after circulatory death 
 
ECG  Electrocardiogram 
 
ECHO  Echocardiogram 
 
ECMO   Extracorporeal Membranous Oxygenation 
 
Euroscore  European System for Cardiac Operative Risk Evaluation 
 
HTx  Heart transplant 
 
IABP  Intra-aortic balloon pump 
 
ICU  Intensive care units 
 
IL  Interleukin 
 
LT-LVAD  Long-term(implantable) Left Ventricular Assist Device 
 
LV  Left Ventricle 
 
LVEF  Left ventricular ejection fraction 
 
MTOR  Mammalian/ Mechanistic target of rapamycin  
 
NHSBT National Health Service Blood and Transplant 
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OCS  Organ Care System TM 
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1 Introduction 
1.1 Thesis overview 
The primary aim of this thesis is to provide an overview of heart transplantation 
in the United Kingdom in the recent era (2012-2018) with an in-depth focus on 
Primary Graft Dysfunction(PGD) as defined by the International Society of Heart 
and Lung Transplantation (ISHLT) in a consensus statement (2014)(Jon 
Kobashigawa et al. 2014). A detailed overview of PGD is provided in 1.12. The 
lack of a consensus statement made identification and comparison of PGD 
difficult. The first aim of the thesis was to ascertain the true incidence of PGD in 
the UK. The findings of these were included in chapter 3. This represents the 
largest multicentre study of its kind at the time of writing and was presented as 
an oral presentation at the PGD plenary session at ISHLT’s annual meeting in 
2017. This study also identified risk factors that were considered based on the 
consensus statement from previous studies with centre-specific defined criteria 
for PGD.  
The consensus definition currently permits comparison studies to be performed. 
The 2nd aim of this thesis was to, therefore, propose a scoring system for PGD. 
The scoring system had to be ubiquitous, easy to use and reproducible to allow 
benchmarking of PGD rates using observed vs expected analysis as a statistical 
quality control assessment. The utility in the scoring system would be to replace 
conventional, retrospective assessment of PGD outcomes that lacked continuous 
monitoring resulting in delayed recognition of practices/therapeutic options that 
lead to better than expected outcomes. One method that could be used would 
be variable life adjusted displays (VLAD)(Lovegrove et al. 1997), which is a 
relatively straightforward depiction of data that permits continuous surveillance 
of PGD outcomes. VLAD was established to highlight differences between 
observed and expected mortality in cardiac surgery using the Parsonnet score. It 
is sometimes referred to as the expected-observed cumulative sum (CUSUM) 
plot. In its original iteration, it plots the cumulative difference in observed 
mortality from expected mortality on the y-axis against individual cases in the 
chronological order that they occur on the x-axis. Hence if the expected 
outcome rate is equal to the observed rate(actual rate), it is seen as zero and a 
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rising line is indicative of an observed rate being lower than the expected rate 
and vice versa.  
Figure 1-1 5000 operations between 1992 and 1996 divided into six contemporaneous series 
according to the perfusion technician running the bypass.  
Reproduced with permission from ‘Lovegrove J, Valencia O, Treasure T, Sherlaw-Johnson C, 
Gallivan S. Monitoring the results of cardiac surgery by variable life-adjusted display. The Lancet. 
997;350(9085):1128-30’. 
Figure 1-1 is an example of the VLAD plot in practice. While regional variations 
in practices that are unaccounted for remain, the VLAD plot could serve as a 
useful centre specific tool for monitoring performance. The PREDICTA score 
described in chapter 4 highlights the scoring system developed based on this 
study which will permit the VLAD analysis once it has undergone further 
multicentre validation. 
The next aim of this thesis is to identify candidates that may be potentially at 
risk. Adverse donor and recipient profiles are highlighted in section 1.12.3 of the 
Introduction. There are however limitations to candidate selection due to the 
limited availability of organs. However, identifying candidate factors allows 
identification of high-risk patients to allow resource allocations such as the early 
institution of advanced Mechanical Circulatory Support(MCS), adequate provision 
of trained staff and appropriate tailoring of early post-transplant management 
strategies, such as using nitric oxide or inhaled prostaglandins prophylactically. 
Transplants frequently occur outwith ‘normal’ working hours, hence the 
importance of identifying high-risk combinations to permit the best possible care 
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within the settings of a nationally-funded healthcare system such as the National 
Health Service (NHS). 
Chapter 5 incorporates the clinical findings of a single centre study compared to 
the national cohort. The aim of this study was to highlight the role of 
amelioration of warm ischaemic time to reduce the rate of PGD. This innovative 
yet cost-effective strategy was presented at several meetings with encouraging 
feedback.  
The Glasgow Transplant Score (GTS) in Chapter 7 is an inventive depiction of 
individualised facets of care for patients. It employs a modified Delphi method 
to identify factors that were not identified in the ISHLT consensus statement 
such as frailty assessment. The aim of this study was to highlight the modified 
Delphi method as a tool for achieving a consensus-based on expert opinion, in 
the absence of other levels of evidence.  
1.2 Core Methodology 
The PGD incidence study approved by the Cardiothoracic Advisory Group(CTAG) 
Audit Committee headed by Dr. Nicholas Banner. A previous study on PGD was 
performed by Dr. Vamsidhar Dronavalli which looked at a locally derived PGD 
definition. The aims of our study are highlighted in section 1.1. The study was 
approved by CTAG. I obtained an honorary contract with NHSBT and each 
respective transplant centre for access to data. The study was supported by 
each of the 6 adult heart transplant centres in the UK. As the study was 
approved by the audit department of NHSBT, I was restricted to clinical data 
that were routinely collected by NHSBT. 
I first performed a literature review to identify candidate variables of interest. 
The project proposal with all the variables of interest was submitted to the 
CTAG audit committee. I then liaised with NHSBT to identify variables that were 
routinely collected. I then formulated a password protected spreadsheet and 
obtained an encrypted USB stick. Following this, I arranged site visits for data 
collection with the heads of departments and the transplant coordinators at 
each site. Source data were collected from a combination of patient notes, 
operative and perfusion charts, ICU patient management systems and electronic 
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patient records. I underwent training at each centre to familiarise myself with 
the different platforms. I also consulted Human Tissue Authority Forms A and B 
stored in the medical records departments at each transplant centre to identify 
different timings for accurate accrual of ischaemic times. Data were 
interrogated at the source to ensure no missing data was recorded in the final 
spreadsheet. I performed data collection and entry myself to ensure data 
collection was consistent. PGD was defined either by echocardiographic 
parameters or pulmonary artery catheter measurements and had to be evident 
for at least 1 hour within the first 24 hours in the absence of secondary graft 
dysfunction (other causes highlighted in section 1.12.1). The raw data was then 
validated using the collected data on the NHSBT database, during my visit to the 
NHSBT statistical office in Bristol at the end of each data collection run. I 
performed a total of 3 data collection cycles and visited the NHSBT office on 5 
occasions. The data collected was also used to supplement missing data within 
the NHSBT database itself. 
1.2.1 Statistical Methodology 
I attended lectures on statistical methodology and Endnote referencing at the 
University of Glasgow hosted by the Information Technology (IT) department. My 
statistical supervisor, Ms. Sally Rushton also provided lecture notes and 
supervised my analysis. To ensure the analysis was robust and reproducible, I 
performed the analysis on Minitab and this was replicated by Ms. Rushton using 
the SAS/STAT software, Version 14.1 of the SAS System for Microsoft Windows 
Copyright © 2015 SAS Institute Inc, Cary, NC, USA.  
To generate the receiver operating characteristic (ROC) curves as seen in 
Chapters 4 and 7, I used the SPSS software package, IBM SPSS Statistics for 
Windows, Version 24.0. Armonk, NY: IBM Corp. IBM Corp. 
  
1 Introduction 24 
 
1.3 Organ transplantation and ancient history  
One of the notable advances in modern-day medicine is organ transplantation. 
None more so than the heart. A complex interaction between physiology, 
surgery, and immunology that spanned decades, involving the hard work of many 
pioneers in their fields. We revisit the contributions of the pioneers as well as 
marvel at the paradigm shifts in medicine that have made heart transplantation 
safe and reproducible with more than 4000 transplants done yearly today.  
Organ transplantation initially stemmed from historical experimentation to 
become a mainstay of treatment for many chronic conditions and continues to 
do so in spite of improvements in device technology. Organ donation, however, 
underwent several challenges initially with cultural acceptance, ethics and 
legality, and political pressure. It has since evolved with the merging of 
improvements in the donation-allocation-procurement process, advances in 
technology, refinement of surgical technique, scientific breakthroughs in organ 
preservation, cognitive and methodical improvements in immunology and 
immunosuppression alongside expertise in managing adherent complications of 
organ transplantation. 
In ancient civilisations, the practice of removal of organs/tissues for a multitude 
of reasons (beautification or therapeutic) was initiated. Hindu texts from 3 
millennia ago provided detailed accounts of skin grafting from fatty regions 
(buttocks) or protrusions (chin) for the reconstruction of mutilated noses 
incurred during wars or punishments (Bergan 1997).  
One of the earliest records of organ transplantation, Bian Que, a reported 
clairvoyant during the Han Dynasty in ancient China reportedly performed an 
exchange of hearts. He felt that the attainment of balance was possible by 
exchanging organs between men of ‘strong will’ but ‘weak spirit’ with that of 
one with opposite traits by intoxicating a ‘patient’ with fortified wine prior to 
“cutting their breasts removing their hearts and applying numinous 
medicine”(Salguero 2014).  
The New Testament describes several cases of auto-transplantation by today’s 
definition; Jesus of Nazareth reattached the ear of a servant after it had been 
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cut by Simon Peter’s sword. It also describes how Saint Mark re-implanted an 
amputated hand of a soldier (Linden 2009). Archaeological records have revealed 
that in the Bronze age, the term ‘trephination’ was first revealed whereby bone 
segments were temporarily removed to decompress brain swelling(Goodrich 
2014). 
Jacopoda Varagine (348 AD) described the ‘miracle of the black leg’ where a 
gangrenous leg of Justinian (Roman deacon) was replaced with that of a dead 
Ethiopian man (Gutkind 1988). 
In 1688, Job van Meeneren successfully grafted a segment of bone from the skull 
of a dog to a defect in a human patient’s cranium (Hewitt et al. 2008). A Russian 
aristocrat had a fragment of canine skull tissue inserted during a repair after an 
injury. He had it explanted due to threats of excommunication from the 
church(Hewitt et al. 2008). Such accounts of events highlighted the initial 
inquisitiveness with the concept of transplantation.  
1.4 The pre-transplant era 
Although organ transplantation had not taken place yet, the early 20th century 
witnessed the first skin and corneal transplants. The initial work behind corneal 
transplant is attributed to Franz Reisinger who experimented with ‘keratoplasty’ 
in 1818 (Crawford et al. 2013). 20 years later, Samuel Bigger performed the first 
successful corneal transplant in a gazelle. The first attempted corneal 
xenotransplantation on a human was performed in 1838 was unsuccessful. 
Improvements in antisepsis, anaesthesiology and surgical technique played a 
pivotal role, alongside ongoing animal experimentation. This subsequently led to 
the first successful human corneal transplant in 1905 by Eduard Zirm (1887-1948) 
in Olmutz near Prague (Crawford et al. 2013). The first successfully grafted 
tissue, however, was performed by Jacques-Louis Reverdin, who transplanted 
small detached skin grafts onto a wound and noted hastened granulation of 
wounds on 8th December 1869 (Davis 1941). Solid-organ transplantation would 
follow a similar path with years of experimentation before successful results 
were noted. 
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French President Marie François Sadi Carnot died from a severed portal vein in 
1894. This had a profound effect on a young surgeon, Alexis Carrell (Merchant 
and Tan 2013). He mastered vascular anastomotic suturing methods and 
introduced smaller needles. Carrel coated his needles, instruments, and thread 
with petroleum jelly to reduce the thrombogenicity of the foreign material. He 
also perfected the concept of eversion thereby allowing blood within the vessels' 
continuous endothelial contact. He also revolutionised antisepsis in surgery and 
pioneered methods of extracorporeal tissue preservation, by using salt solution 
at freezing point (Aida 2014).   
In 1902, he successfully performed the first heterotopic kidney transplant by 
inserting a dog’s kidney into its own neck. He noted that the kidney began 
producing urine immediately (Merchant and Tan 2013). He later successfully 
transplanted organs, including kidneys, ovaries and thyroid glands between 
different dogs. In 1912, he became the first surgeon to win a Nobel Prize “in 
recognition of his work on vascular sutures and the transplantation of blood 
vessels and organs” (Sade 2005).  
Carrell famously noted that despite success in the technical aspects of 
transplantation, there were consistent hostile host responses to the foreign 
allografts especially during xenotransplantation(Shayan 2001) 
“Should an organ, extirpated from an animal and replanted into its owner by 
a certain technique, continue to functionate normally, and should it cease to 
functionate normally when transplanted into another animal by the same 
technique, the physiologic disturbance could not be considered as brought 
about by the organ but would be due to the influence of the host, that is, 
the biological factors” 
Despite Carrell’s observations, between 1905-1910, several surgical peers such 
as M Princeteau, Mathieu Jaboulay, and Ernst Unger in this era attempted 
xenotransplantation of rabbit, pig and macaque kidneys to humans with 
disastrous results(Cooper et al. 1997). 
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1.5 Pre-immunosuppression era 
Leo Loeb first noted that the strength and timing of rejection in skin homografts 
on rodents were potentially caused by the genetic disparity between donor and 
recipient and highlighted the involvement of lymphocytes in the 1930s (Barker 
and Markmann, 2013). He theorised that this genetic disparity did not occur in 
identical twins thus they would accept exchanged skin grafts. Unfortunately, his 
findings were ridiculed due to his inbreeding of mice. Contemporaries such as 
Peter Medawar dismissed the importance of lymphocytes and adopted the 
humoral theory of rejection (Barker and Markmann, 2013). The ensuing two 
decades were fraught with failed attempts at kidney transplantation in both 
human and animal models by Voronoy (1937), Simonsen (1953) and Dempster 
(1953) who even used radiation in organ transplant recipients (Dempster, 1953). 
Medawar’s renewed interest in transplant rejection brought him to the Burns 
Unit at Glasgow Royal Infirmary (Gibson and Medawar, 1943) with Thomas 
Gibson. He remained convinced that skin grafts in burn victims failed because of 
humoral rather than cellular immunity (Brent, 2005). His work with Rupert 
Billingham and Hugh Donald revealed that even fraternal twin cows accepted 
skin grafts, not just identical twin cows (Anderson et al., 1951). Across the 
Atlantic, Ray Owen at the University of Wisconsin noted a hybrid of blood cell 
types in fraternal twins. He concluded that there was a persistence of chimerism 
from the intrauterine transfer of stem cells was probably responsible for this 
(Barker and Markmann, 2013). Medawar, Billingham, and Leslie Brent induced 
chimerism and homograft acceptance in mice by injecting inoculating 
intrauterine foetuses with donor strain spleen cells (Billingham et al., 1953). 
This was ultimately successful and resulted in a Nobel Prize in 1966 for Peter 
Medawar. They later discovered that some of the immunocompetent cells from 
the splenic tissues ‘attacked’ the lymphoid tissue of the host (Graft-Versus-Host-
Disease), thereby proving the role of cellular immunity as first theorised by Loeb 
(Barker and Markmann, 2013).  
Meanwhile, Joseph Murray and his team performing the first successful kidney 
transplant in 1954 using as a donor the recipient’s identical twin bypassing the 
issues with immunity (Harrison et al., 1956). This generated a lot of interest in 
the field of transplantation. Joan Main and Richmond Prehn attempted to 
recreate Medawar’s stem cell inoculation. They radiated mice to allow induction 
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of bone marrow from a donor. Murray’s team used this method with poor 
outcomes as 11 of the 12 patients who underwent kidney transplantation with 
total body irradiation died within a month (Barker and Markmann, 2013). The 
survivor maintained adequate function of his fraternal twin’s kidney for 20 years 
thereby becoming the first successful non-identical twin kidney transplantation. 
Jean Hamburger and René Küss from Paris performed 4 successful kidney 
transplants using total body irradiation without marrow inoculation (Dempster, 
1953). 
1.6 Early Immunosuppression 
Robert Schwartz and William Dameshek discovered that 6-mercaptopurine (6-
MP), which was primarily used for the treatment of malignancies, also reduced 
the antibody response of rabbits to bovine albumin (Barker and Markmann 2013). 
Roy Calne used 6-MP on canine kidney homografts and noted that it significantly 
prolonged survival (Calne 1960). His findings, however, were not replicated 
when 3 kidney transplant recipients treated with 6-MP died. Calne began a 
research fellowship with Joseph Murray and despite the ongoing trend of total 
body irradiation, pursued work with 6-MP and later azathioprine (Barker and 
Markmann 2013).  
In 1963, at a National Research Council conference in Washington, the 
preliminary results of total body irradiation versus immunosuppressive drugs had 
reached equipoise with few patients surviving beyond 1 year. The practice of 
transplantation was questioned due to its poor long-term survival. Every 
represented centre demonstrated poor survival bar one. Thomas Starzl, 
combining azathioprine with prednisone achieved >70% survival kidney graft 
survival at 1-year follow up (Hamilton et al. 2012). He noted that large doses of 
prednisone could reverse early rejection that occurred and this could then be 
tapered down. This led to the formation of 50 new transplant centres in the 
United States alone that year (Brent 2005) and remained the mainstay of 
immunosuppression for the next 20 years. Immunosuppression also brought a 
new pathology, opportunistic infections, and malignancy. Starzl himself noted 
that there was a high rate of bacterial, viral, fungal and protozoal infections 
found in post-mortem examination (Hill et al. 1967).  
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Antilymphocyte serum (ALS) was first discovered by Elie Metchnikoff in 1899. In 
1961, Byron Waksman identified that lymphocytic depletion could suppress 
delayed hypersensitivity reactions(Waksman et al. 1961). Combining the two 
concepts, Michael Woodruff demonstrated that ALS administration alongside 
thoracic duct drainage via a fistula extended skin allograft survival in rodents, a 
finding later replicated by Medawar (Woodruff and Anderson 1963; Levey and 
Medawar 1966). In 1966, Polyclonal antilymphocyte globulin(ALG) was 
successfully synthesized from human leukocyte inoculated horses and became 
the staple of a triple regimen alongside steroids and azathioprine (Starzl et al. 
1967). 
1.7 History of Cardiac Surgery and Transplantation 
Unlike its other surgical counterparts, cardiac surgery was a relatively unknown 
subspecialty in the early 20th century. In 1881 at the Vienna Medical Society, 
Theodore Billroth once proclaimed. 
“No surgeon who wished to preserve the respect of his colleagues would ever 
attempt to suture a wound of the heart.” (Weisse 1991) 
The first cardiac procedure of the modern era was performed by Henry C. Dalton 
in St. Louis to repair a pericardial wound in a victim of a stabbing (Weisse 2011). 
In 1923, Elliot Carr Cutler and Samuel A. Levine successfully relieved a stenotic 
mitral valve in a 12-year-old girl. F. John Lewis, performed the first successful 
repair of an atrial septal defect in 1952 using hypothermia to protect the 
myocardium(Lewis and Taufic 1953). C. Walton Lillehei performed 45 open heart 
surgeries utilizing a technique called controlled cross-circulation using parents of 
the children as ‘pump oxygenators’(Lillehei et al. 1986). 
The introduction of the cardiopulmonary bypass circuit revolutionised cardiac 
surgery. John Gibbon perfected the device in 1953 and subsequently performed 
the successfully performed an atrial septal defect closure(Gibbon 1978). John 
Kirklin modified the pump and achieved relative success in small series of 
patients at the Mayo Clinic(Kirklin et al. 1955). However, it was Richard DeWall’s 
cardiopulmonary bypass device with a disposable bubble oxygenator and simple 
pump action that enabled the correction of cardiac conditions under direct 
vision (Dewall et al. 1956). 
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The ensuing period saw numerous attempts to correct myocardial ischaemia 
until Robert Hans Goetz successfully grafted the right internal mammary artery 
to the right coronary artery, thereby performing the first coronary artery bypass 
graft in 1960, much to the chagrin of the medical and surgical fraternity at the 
time (Konstantinov 2000). 
Inspired by the work of Carrel and Loeb, Frank C Mann identified 2 techniques 
for heterotopic cardiac transplantation(Mann et al. 1933). In his experimental 
model, he described using either a distal or proximal end of a divided carotid 
artery to supply blood to the aorta and assist circulation. The coronary sinus 
blood returned to the right atrium with both the vena cavae closed off and 
drained into the right ventricle. The pulmonary artery was anastomosed to the 
jugular vein. They noted that the pulse generated by the heart gradually faded 
with the longest-lasting heart failing after 8 days.  
Vladimir Demikhov, a visionary surgeon developed a mechanical device too large 
to be inserted entirely within the thorax of a dog, but it functioned as a 
substitute for the heart for as long as 5.5 hours. Till 1946, intrathoracic 
transplantation had never been accomplished in a warm-blooded animal. The 
first issue encountered was the ongoing nourishment of the heart using 
arterialised blood. Demikhov ligated the aorta, venae cavae, azygos vein, 
brachiocephalic and left subclavian arteries in succession to maintain adequate 
pressure in the isolated heart-lung model. He then perfused the heart with 
arterialised blood via the left atrium after passing through the pulmonary circuit 
and delivered by the left ventricle into the coronaries. He used this method in 
around 300 experiments and maintained the heart in good condition for up to 4 
hours (Shumacker 1994).  
Despite multiple initial failures of intrathoracic transplant of the heart, one dog 
survived for 32 postoperative days. Perhaps his greatest achievement was a 
series of orthotopic heart transplants that he performed without hypothermia or 
the use of a cardiopulmonary bypass machine. He performed and end-to-side 
anastomosis of the donor aorta, pulmonary artery and venae cavae to the 
corresponding recipient vessels and reattached the pulmonary veins to the 
recipient’s left atrium closed off with purse strings. He reported survival times 
of up to 15.5 hours, thereby creating the first model of an orthotopic heart 
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transplant providing the entirety of the pumping function (Cooper 1968). 
Demikhov’s research was not published in English until 1962. 
Interest in Frank C Mann’s work was rekindled in 1951. Marcus et al created a 
technique using 3 dogs, a donor, a recipient and a receptacle for the donor heart 
when disconnected from the circulation (Marcus et al. 1951). The final model 
was not too dissimilar to the cross-circulation utilized by Lillihei.  This "interim 
parabiotic perfusion," was used to place the heart in the 2 previously mentioned 
configurations as described by Mann. In 1953, Marcus and associates managed to 
achieve a survival time of 48 hours for heterotopic heart transplantation (Cooper 
1969). Wilfred Neptune and colleagues were the first to utilise hypothermia with 
a heart-lung block and achieved a survival time of 6 hours in a canine model 
(Piciche and Carpentier 2013).  
Webb, Howard, and Neely produced 12 successful orthotopic heart transplants 
surviving as long as 7.5 hours using a different method of anastomosing the 
pulmonary veins of the donor to recipient compared to Demikhov (Webb et al. 
1959).  The first involvement of British cardiac surgeons occurred in 1959 when 
Cass and Brock described a series of methods for autotransplantation while 
including leaving the recipients atria and septal crest behind to avoid pulmonary 
vein and vena cavae anastomosis(Cass and Brock 1959). 
In 1960, Lower and Shumway published results of their experiments with 
orthotopic homotransplantations using an oxygenator and partial atrial 
preservation as described by Cass and Brock. They yielded excellent results with 
5 of the 8 dogs experimented on surviving between 6-21 days(Lower and 
Shumway 1960). To date, the bi-atrial anastomosis is still noted as the Shumway 
Technique.  
Shumway paid meticulous attention to surgical technique and myocardial 
protection using isotonic saline at 4⁰C.  In addition, they introduced the concept 
of assistance time whereby the recipient dogs were left on the cardiopulmonary 
bypass for a short period of time to ease the heart into assuming the circulatory 
load(Lower et al. 1961).  
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Shumway’s group also described initial issues such as the incidence of complete 
atrioventricular block.  On learning lessons from rejection in renal transplant 
patients, Reemtsma et al attempted to use methotrexate for heterotopic heart 
transplantation in 21 canines, and prolonged survival up to 26 post-operative 
days (Reemtsma et al. 1962). Blumenstock mimicked the findings of Reemtsma’s 
group with one canine in their cohort surviving for up to 42 days in 1963 
(Blumenstock et al. 1963). 
The first ethical dilemma faced by the fraternity was the concept of the donor 
as  “the definition of irreversible coma” was only established in 1968  by an Ad 
Hoc Committee of Harvard Medical School on Brain Death('A definition of 
irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical 
School to Examine the Definition of Brain Death'  1968). A patient presented with 
a large thrombus that had embolised to the left side of the heart and placed on 
mechanical coronary perfusion. The likelihood of a potential donor dying at 
exactly the same time as the patient needing a heart was minute and a decision 
was made that the team would not halt ventilation of the patient in January 
1964 but instead would utilise a chimpanzee as a donor (Hardy et al. 1964). The 
chimpanzee's heart was explanted and implanted into the patient.  Despite 
initially beating well, it became apparent that the heart was not able to support 
the larger volume of human circulation and the patient died within an hour of 
weaning from cardiopulmonary bypass.  
Dr. Christiaan Barnard had worked alongside Shumway in Minnesota. He had also 
performed the first successful kidney transplant in South Africa to understand 
transplant immunology and geared for heart transplantation. On 14 September 
1967, Louis Washkansky was admitted to the Groote Schuur Hospital in Cape 
Town, South Africa. Dr. Velva Schrire (Chief Cardiologist) recommended 
Washkansky as the appropriate case for transplant. On December 2, 1967, a 24-
year-old female, Denise Ann Darvall was pronounced dead after sustaining a 
massive cerebral injury following a collision. Both patients were brought to 
theatres A and B where and mutual consent was obtained (Kalra et al. 2016).  
“If you can't save my daughter, you must try and save this man.” 
- Edward Darvall (Denise’s Father) 
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On 3rd December 1967, Dr. Christiaan Barnard performed the first successful 
human-to-human orthotopic heart transplantation. Her heart was taken via the 
Shumway technique with the heart cooled to 10⁰C. He used a combination of 
local irradiation, azathioprine, prednisone, and actinomycin C as his 
immunosuppression regime. Although the post-operative course of the patient 
was very promising, he contracted Pseudomonas pneumonia and died on the 
18th post-operative day (Barnard 1967).  
Dr. Adrian Kantrowitz and his team performed the 2nd heart transplant (the first 
in a paediatric patient) in Brooklyn. Kantrowitz was already well known for 
designing the first intra-aortic balloon pump and had conducted considerable 
laboratory experiments in puppy hearts believing that the immune system of a 
younger heart may offer less allogenic resistance. On 6 December 1967, He 
transplanted an anencephalic donor heart into a 3-week-old patient diagnosed 
with tricuspid atresia. He performed the operation in hypothermic conditions 
under circulatory arrest. Despite initial recovery into sinus rhythm, the recipient 
developed irreversible acidosis and died (Kantrowitz et al. 1968).  
Norman Shumway and his team performed their first heart transplant a month 
after Kantrowitz. The recipient developed chronic and progressive heart failure 
after “post-viral myocardial fibrosis” and coronary artery disease. The procedure 
was complicated by size mismatch with the donor heart being much smaller than 
the recipient’s. The recipient received a combination of methylprednisolone and 
azathioprine preoperatively and post-operatively with the addition of 
prednisolone. However, the patient did not succumb to rejection. Shumway 
noted that in the initial post-operative period the patient was mildly 
hypotensive and oliguric into the second postoperative day despite 
administration of isoproterenol and temporary digitalization. The patient 
developed a consumptive coagulopathy before succumbing to multiorgan 
dysfunction and bronchopneumonia (Stinson et al. 1968). 
Across the Atlantic, Dr. Donald Ross, who worked with Lord Russell Brock, 
performed the first heart transplant in the United Kingdom. The patient, a 45-
year-old man, survived for 46 days before succumbing to infection. He 
performed 2 more unsuccessful transplants before a moratorium was declared 
(Cooley 2014). 
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Denton Cooley’s group reported moderate success early on at Baylor with 7 of 10 
patients surviving 4.5 months (Cooley et al. 1969). To reduce the risk of 
rejection, they used blood-group compatibility, lymphocyte crossmatch studies 
(histocompatibility) as described by Dr. Paul Terasaki, and developed a matching 
system to predict the likelihood of a good outcome post-transplant (Patel and 
Terasaki 1969). They also administered anti-lymphocyte globulin in addition to 
other anti-rejection medications. 
1.8 Early Issues with Heart Transplantation 
Within a year of Barnard’s feat, 102 heart transplantations were performed 
internationally(Patterson and Patterson 1997). Shumway famously quipped  
“Suddenly heart transplants were being done in places where one 
would hesitate to have his atrial septal defect closed” 
The early promise of heart transplantation however soon diminished as the 
number of transplants rapidly fell from 100(1968) to 18(1970), with many 
inexperienced units abandoning the procedure. Kantrowitz, who was on the 
review panel for the National Institute of Health agreed to support Shumway and 
his unit in their ongoing research (DiBardino 1999). In 1971, they identified 
several identifiers of acute rejection (Griepp et al. 1971).  
1) Electrocardiographic findings 
i. Increased QRS voltage  
ii. Arrhythmia 
iii. Right axis deviation 
iv. ST-T wave changes 
2) Clinical Findings 
i. Appearance of gallop rhythm 
ii. Decreased precordial activity 
iii. Hypotension 
3) Echocardiography findings 
i. Increased thickness of left ventricular wall 
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ii. Increased right ventricular diameter 
Using the above-mentioned criteria, they successfully treated 57 of 60 patients 
with methylprednisolone, actinomycin D and ALG. As the experience of long-
term survival in heart transplants increased, Shumway noted a condition he 
titled ‘chronic rejection’(Clark et al. 1971). It manifested as diffuse allograft 
vasculopathy and led to episodes of sick sinus syndrome or myocardial infarction, 
usually proving fatal.  
In 1962, Dr. Souji Konno developed the catheter-type endomyocardial biopsy 
(EMB) allowing samples of the myocardium of patients suspected of having 
intrinsic musculature abnormality to be taken using a bioptome inserted via a 
peripheral vein or arterial cutdown(Nishikawa et al. 2017). It was initially 
developed for diagnoses of cardiomyopathies as opposed to limited thoracotomy 
approaches. The bioptome usually provided samples containing endocardium and 
myocardium, usually sufficient for microscopic examination.  
In 1971, a young cardiothoracic surgeon, Dr. Philip Caves undertook a British 
American Research Fellowship at Stanford to work with Shumway. While there, 
he worked with instrument maker Werner Schulz to create the Stanford-Caves 
Schulz bioptome which transformed the management of heart transplant 
patients. There were 2 Stanford bioptomes that differed in size and length.  The 
longer and thinner bioptome was used for left ventricular biopsy and the shorter 
and thicker one for right ventricular biopsy (Caves et al. 1973; Melvin and Mason 
1982). The samples obtained were between 1-3 mm in diameter. He noted that 
changes seen in endomyocardial specimens matched those seen in grafts at post-
mortem examinations. The samples taken from the endomyocardial surface were 
also free of post-operative inflammatory changes that complicated sub-
epicardial samples taken during thoracotomy. Finally, he noted that the 
pathologic changes of cardiac allograft rejection were more prominent in the 
endomyocardial surface (as the graft came in direct contact with the host’s 
circulation). Philip Caves also worked with Margaret Billingham who was a 
pathologist at Stanford. In 1974, they developed a standardised histological scale 
to pathologically grade the severity of cardiac rejection based on the extent of 
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infiltrates (Caves et al. 1974). This was incorporated into routine practice and 
significantly improved the survival of heart transplant recipients at Stanford. 
1.9 Immunosuppression in Heart Transplantation 
1.9.1 Cyclosporin 
Another notable feat in transplantation during this era was the discovery of 
cyclosporin A. In 1976, J.F Borel reported the immunosuppressive effects of a 
fungal metabolite (Tolypocladium inflatum) isolated from Swiss soil samples. He 
noted that skin graft rejection in mice and graft-versus-host disease in mice and 
rats were considerably delayed by cyclosporin A. He also noted that it had a 
direct antilymphocytic effect by targeting an early stage of mitogenic triggering 
of the immunocompetent lymphoid cell and lacked the myelosuppressive effects 
of cytostatic drugs used at the time (Borel et al. 1976). Roy Calne, who 
previously worked on azathioprine, conducted in vivo immunosuppression with 
cyclosporin A on porcine cardiac allografts. His group stated that  
“Cyclosporin A is more effective in suppressing rejection than any other drug 
that we have used in pigs with orthotopic cardiac allografts” (Calne et al. 1978) 
Terence English, a South African born surgeon who previously worked with Lord 
Russell Brock and Donald Ross, nearly abandoned medicine to be a mining 
engineer. He visited Stanford on the advice of his friend Philip Caves in 1973 
(Morris 2017). He was truly impressed with the outcomes of heart transplant 
recipients at the unit. In 1978, Dr. Terence English sought approval from the 
Transplant Advisory Panel of the Department of Health but was informed that 
there were no funds for a transplant programme (Newton 2015). Given the 
moratorium, the panel was not keen on ‘one-off’ operations. He duly persisted 
but his initial attempt was unsuccessful as the donor had arrested prior to 
implantation and sustained an irreversible brain injury. He persevered and in 
July 1979, performed the first successful heart transplant in the United 
Kingdom. The recipient, Keith Castle lived for 5 and a half years(English 2011).  
“He subsequently became the best possible advertisement for cardiac 
transplantation except for his inability to give up smoking” 
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- Sir Terence English on Keith Castle (English 2011) 
Although initial reports on cyclosporin were favourable, the improvements came 
with a price. Cyclosporin was nephrotoxic when used over a long period (Myers 
et al. 1984). Other side effects include, including hypertension, hepatotoxicity, 
gingival hyperplasia, hypertrichosis, involuntary tremor, and an increased risk of 
malignancy (Patel and Kobashigawa 2007). With the improvements in survival 
after the initial transplantation, the recipients were at risk of nephrotoxicity and 
morbidities associated with immunosuppression primarily infections. These 
drawbacks, however, did not offset the positive impact cyclosporin offered over 
previous methods. Immunosuppression formed the initial challenges in cardiac 
transplantation with suboptimal immunosuppressive regimens either causing 
allograft rejection or infectious complications from over-immunosuppression. 
A European Multicentre trial evaluating renal graft survival at 1-year showed 
that cyclosporin alone as a first-line immunosuppressive agent was more 
effective than with azathioprine and steroids (European Multicentre Trial 1983). 
Stanford’s group meanwhile reported one- and 5-year survival rates of 83% and 
55%, respectively using a 3-drug protocol of Cyclosporin A, azathioprine, and 
prednisone(Starnes and Shumway 1987).  
1.9.2 Tacrolimus 
Tacrolimus (Tradename: Prograf®, Astellas Pharma US, Inc. Northbrook, IL) a 
calcineurin inhibitor like cyclosporin was discovered from a soil sample from the 
foot of Mount Tsukuba in Tokyo in 1984. It was cultured from an actinobacter, 
Streptomyces tsukubaensis (Fung 2004). It suppresses interleukin-2 production 
associated with T-cell activation, thus inhibiting the differentiation and 
proliferation of cytotoxic T cells.  Thomas Starzl once again led research into the 
safety and efficacy of Tacrolimus at the University of Pittsburgh Medical School 
(Starzl et al. 1989).  Tacrolimus had a more limited adverse effect profile and 
comparative studies suggest superiority over cyclosporin in preventing allograft 
rejection while causing less antibody suppression (Behr et al. 1998; Jurcevic et 
al. 1998). The pharmacokinetics were far more predictable than for micro-
emulsion cyclosporin (Wang et al. 2004). 
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Numerous randomized controlled trials comparing tacrolimus to cyclosporin have 
been done. Two multicentre studies comparing tacrolimus to oil-based 
cyclosporin (Tradename: Sandimmune® Oral Solution, Novartis Pharmaceuticals 
Corporation, East Hanover, New Jersey) showed no significant difference 
between the groups at 12 months. Graft survival, renal function, and infection 
rates were not significantly different between the groups although more patients 
in the cyclosporin group developed hypertension and hypercholesterolaemia 
(Reichart et al. 1998; Taylor et al. 1999).  
A microemulsion formulation of cyclosporin (Tradename: Neoral® Oral Solution, 
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936) was 
developed and was shown to have a better bioavailability profile with more 
predictable pharmacokinetics compared to the oil-based preparations (Cooney et 
al. 1998). A multi-centre, randomized study of both preparations of cyclosporin 
revealed fewer episodes of rejection requiring antilymphocyte antibodies and 
fewer study discontinuations for treatment failures in the micro-emulsion based 
cyclosporin cohort of patients compared to those treated with oil-based 
cyclosporin without any adverse events (Eisen et al. 2001). 
When compared to tacrolimus, micro-emulsion based cyclosporin (alongside 
cytolytic induction) and a tapered steroid regime showed equivalent patient and 
graft survival at 19 months. However, there was an increased incidence of 
biopsy-proven acute rejection in the cyclosporin group at 6 months. Tacrolimus 
was associated with a higher incidence of new-onset diabetes mellitus, lower 
rates of post-transplant hypertension and lower incidences of dyslipidaemia 
(Grimm et al. 2006). Similar findings were noted in another trial without 
cytolytic induction (Kobashigawa et al. 2006b). 
1.9.3 Mycophenolate mofetil  
Another agent that is commonly used is mycophenolate mofetil (MMF; CellCept, 
Roche Laboratories, Nutley, NJ). It is an effective anti-proliferative agent that 
improves rejection and survival when used as part of combination therapy. Its 
active metabolite, mycophenolic acid, is a non-competitive inhibitor of inosine 
monophosphate dehydrogenase (IMPDH) in the de novo pathway for purine 
synthesis (Allison and Eugui 2000). Therefore, MMF has some selectivity for 
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lymphocytes over other cell types as lymphocytes rely on this pathway for DNA 
replication and proliferation. Studies have shown that heart transplant patients 
receiving MMF therapy had lower levels of C-reactive protein, circulating B 
lymphocytes, activated T lymphocytes and natural killer (NK) cells compared to 
patients receiving azathioprine (AZA) (Eisen et al. 2005).  
1.9.4 Mechanistic target of rapamycin (mTOR) inhibitors 
Everolimus (Tradename: Certican, Novartis Pharma Schweiz AG, Bern, 
Switzerland) and Sirolimus (Tradename: Rapamune, Wyeth Europa Ltd., 
Maidenhead, UK) are mechanistic target of rapamycin (mTOR) inhibitors 
(MacKeigan and Krueger 2015). They work by inhibiting proliferation signals by 
suppressing the cytokine-driven T-lymphocyte proliferation, resulting in an 
arrest of the cell cycle. Unlike the calcineurin inhibitors, they demonstrate little 
or no nephrotoxic side effects. Recent studies have even shown a reduction in 
the incidence of chronic allograft vasculopathy (CAV) with Everolimus as 
measured by IVUS among heart-transplant recipients after 1 year (J.A. 
Kobashigawa et al. 2013; Andreassen et al. 2014). Sirolimus, however, is linked 
to an increase in total cholesterol and triglyceride levels (Lindenfeld et al. 2004; 
Wlodarczyk et al. 2005). Everolimus, on the other hand, is linked with an 
increase in total cholesterol levels, without increased triglyceride levels, but a 
significant increase in HDL which may explain its attenuation of CAV (Tenderich 
et al. 2007).  
1.9.5 Cytolytic induction therapy 
Cytolytic Induction therapy comprises of immunosuppressive drugs that have 
been introduced into clinical transplantation directed against human lymphoid 
cells. Several different forms of cytolytic induction therapy have been used as 
identified in Table 1-1. 
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Substance Origin Dosages 
Applied 
Routes 
Investigated 
Monoclonal/ 
Polyclonal 
Horse Antilymphocyte-
Globulin  
Horse Various 7–14 
days 
IM Polyclonal 
Rabbit Antithymocyte-
Globulin  
Rabbit 1–3 mg/kg per 
day  
1–10 days 
IM/IV Polyclonal 
Muromunab CD3 
antibody (OKT 3 
Antibody) 
Mouse 5–10 mg/day 
4–14 days 
IV Monoclonal 
IL-2 receptor 
antagonists – 
(basiliximab or 
daclizumab)  
Basiliximab- 
chimeric 
Daclizumab-
Humanized 
Mouse/Human 
Basiliximab 
- 20mg on day 
0 and day 4 
Daclizumab 
-1 mg/kg with 
repeated doses 
every 2 weeks 
for a total of 5 
doses: 
IV Monoclonal 
Anti-CD52 antibodies 
Alemtuzumab 
 
Rat 30mg 
intraoperatively 
IV Mono 
clonal 
Table 1-1 Different types of Cytolytic Induction Therapy Available (adapted with permission 
from “Cytolytic Induction Therapy in Heart and Lung Transplantation: The Protagonist Opinion, 
Transplantation Proceedings, Volume 30, Issue 4, 1100 – 1103” (Wahlers 1998) 
In heart transplantation, kidney dysfunction has been demonstrated to be a risk 
factor for early death(Wahlers et al. 1989; Odim et al. 2006). Cytolytic induction 
allows post-operative renal recovery from a pre-renal aetiology without the 
negative impact of high nephrotoxic cyclosporine/tacrolimus levels. It 
effectively allows bridging of immunosuppression until a steady state is reached 
for the regular immunosuppression medications. Most centres use a combination 
of the abovementioned immunosuppressants to achieve adequate 
immunosuppression. In 2006, Kobashigawa led a trial comparing 3 different 
immunosuppression regimes, micro-emulsion cyclosporin with MMF, tacrolimus 
with MMF or tacrolimus with sirolimus (Kobashigawa et al. 2006a). 
The 343 heart transplant recipients in this trial were randomized to receive 
corticosteroids and one of the mentioned regimes. Cytolytic induction therapy 
was used for up to 5 days. The primary endpoint of moderate rejection or 
haemodynamic compromise rejection requiring treatment showed no significant 
difference between the three groups at 6 months and 1 year. The probability of 
treated rejection was significantly lower in both the tacrolimus groups compared 
with the micro-emulsion cyclosporin/mycophenolate mofetil group. The 
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tacrolimus/sirolimus group had more fungal infections and more impaired wound 
healing.  
On the other hand, recent trials involving combinations with everolimus have 
shown promising results including reduced cytomegalovirus infections(J. 
Kobashigawa et al. 2013), reduced cutaneous cancer incidence(Euvrard et al. 
2010), and CAV attenuation effects (Eisen et al. 2013). 
Other induction agents that have also been used include interleukin-2 receptor 
antagonists (Basiliximab) 
Figure 1-2 shows the different targets of the immunosuppression medications 
alongside the initiation of the adaptive immune response against the donor 
graft. The step is initiated by recognition of an alloantigen by a naive T-cell, 
followed by T-cell activation, proliferation, and differentiation. 
 
Figure 1-2 Immunosuppressive agents targeting stages of T cell differentiation and 
proliferation alongside selected cytokines. 
APC-antigen-presenting cell, MHC – Major Histocompatibility Complex, rATG - rabbit 
antithymocyte globulin, hATG - horse antithymocyte globulin, CN-I – calcineurin inhibitors, 
G1-cell cycle gap phase 1, G2-cell cycle gap phase 2, IL-2 -interleukin-2, M-cell cycle mitosis 
phase, mTOR-mammalian target of rapamycin, mTORi - mammalian target of rapamycin 
inhibitor, AZA- Azathioprine, MMF-Mycophenolate Mofetil, NFAT-dephosphorylated nuclear 
factor of activated T-cells, NFAT-P-phosphorylated nuclear factor of activated T-cells, S-cell 
cycle synthesis phase, TCR- T-cell receptor. (dotted line indicates inhibition).  
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1.10 Current status of heart transplantation 
Heart transplantation is considered to be the ‘gold-standard treatment’ for 
refractory advanced heart failure in carefully selected patients (Mehra et al. 
2016; Ponikowski et al. 2016; Yancy et al. 2016). A major limiting factor of 
transplantation is the emerging gap between the number of donors (available 
grafts) and the number of patients on the waiting list. This issue is apparent 
even in neighbouring France (Dorent et al. 2017). The utilization of marginal 
donors or expanded-criteria donors has steadily increased over the decades. Part 
of the decision-making process currently between physician, surgeon, and 
patient includes discussing the potential options available. Currently, the 
choices include continued medical therapy (5% to 10% weekly mortality risk), 
mechanical circulatory support (10% to 15% operative risk), or a transplant which 
may or may not include a clause for marginal organs. 
 
Figure 1-3 Deceased donor heart programme in the UK, 1 April 2007 - 31 March 2017, 
Number of donors, transplants, and patients on the active transplant list at 31 March 
The ‘Standard Donor’ or ‘Traditional Criteria’ for a donor as suggested by 
Copeland (Copeland 1995) is as follows 
Source: Transplant activity in the UK, 2016-2017, NHS Blood and Transplant
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1. Age < 50 years 
2. echocardiogram showing no important segmental 
abnormalities or global hypokinesis, ejection fraction 
greater than 50%, and normal valves 
3. Inotropes less than 15 µg/kg/min of dopamine  
4. Donor to recipient weight ratio of 1.5 to 0.7 
5. Cold ischemic time less than 4 hours 
6. No donor infection 
7. Negative serology for hepatitis B, hepatitis C, and 
human immunodeficiency Virus 
8. a normal electrocardiogram or minor ST-T wave 
abnormalities, with no conduction system disease. 
 
The rising number of patients listed for heart transplantation has resulted in an 
increased number of donors from beyond the ‘standard criteria’ pool as a result 
of the undersupply of available organs. ‘Marginal Donors’ as they are termed 
would, under conventional transplant guidelines, be declined as potential organ 
donors (Brock et al. 2001). Median waiting times in the UK for hearts on the non-
urgent list is currently 1280 days and 26 days for the urgently listed(NHSBT 
2017d).  
Forays into xenotransplantation as a potential pool of organs to solve the 
problem of donor-organ supply were also touted but to date, these remain in the 
experimental phase(Cooper et al. 2000).  
The decision to accept a marginal donor organ is made on a recipient focused 
individualized basis rather than specific values, parameters or conditions. 
(Potapov et al. 1999; Blanche et al. 2002) 
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Figure 1-4 Timeline of events where modifications of ‘Standard criteria’ toward more 
marginal donors were implemented 
The number of ‘standard donors’ for kidney transplants was first notably 
reduced after the implementation of the compulsory wearing of seat belts in the 
United Kingdom, which was approved by parliament in 1982 and became law on 
1 February 1983 (Thompson et al. 1983). Other legislation includes zero-
tolerance drinking-and-driving law resulting in fewer traffic accidents with fatal 
victims (Calil et al. 2009). During this time period, the United Kingdom 
Transplant Support Service Authority demonstrated a 12% increase in the number 
of cardiac donors aged greater than 41 years between 1988 and 1995 (Mercer et 
al. 1997). The initial reluctance to use organs from older donors especially the 
heart was due to longstanding dogma that older hearts were thought to more 
susceptible to the catecholamine flood that accompanies brain death (Young 
1999). Internationally, gun crime has also been closely associated with donor 
organ availability. Studies in Brazil have shown a direct correlation between 
urban violence and gun crime to organ donors(Rodrigues et al. 2014; Silva et al. 
2014). 
Initial studies exploring the extended age criteria showed no significant 
difference in terms of left ventricular function and the incidence of infection 
and rejection (Drinkwater et al. 1996; Mercer et al. 1997). The risk of dying on 
the waiting list outweighed that of receiving an organ from an older donor 
(Bennett et al. 1998).  
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Some surgeons also opted to accept hearts with mild-to-moderate mitral or 
tricuspid insufficiency or secundum-type atrial septal defects as these could be 
repaired immediately or post-operatively with good results (Massad et al. 1996). 
As our understanding of myocardial protection improved, the use of mildly 
hypertrophic left ventricles with short ischaemic times was also proposed with 
the caveat that there were no ECG changes (D. Marelli et al. 2000). 
Patients with underlying malignancies were previously never considered donor 
candidates. However, the risk of metastasis from a primary intracranial tumour 
is low. A German study in one of the earliest studies evaluating the outcomes of 
recipients receiving organs from donors with intracranial malignancies showed 
good follow up outcomes of more than 5 years (Hornik et al. 2004).  
Donation after circulatory death will be discussed in greater detail in later 
sections. 
Transplantation also requires commitment from the patients and health care 
providers as it involves a long-term programme of treatment including 
pharmacological immunosuppression and regular surveillance (Banner et al. 
2011). Clinical decisions, therefore, should consider a patient’s ability to adhere 
to the demands of ongoing treatment. Alternatives to transplantation include 
the use of Ventricular Assist Devices (VADs). These are however limited in the 
National Health Service (NHS) due to the limited health care funding. In North 
America, the Food and Drug Administration recently approved VADs as 
destination therapy(Stewart and Mehra 2014). In its current form, heart 
transplantation confers a significant survival advantage with a 1-year survival of 
84.5% and 5-year survival of 72.5% which is significantly improved as compared 
to the 76.9% 1-year survival and 62.7% 5-year survival in the 1980s. (Lund et al. 
2014; Wilhelm 2015) 
1.11 Primary Diagnostic Indications for Transplant 
The most frequent indications for heart transplantation in adults are chronic 
heart failure secondary to dilated cardiomyopathy or ischaemic heart 
disease(Banner et al. 2011). There is also a significant number of 
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patients(approximately 3%) with adult congenital heart disease (ACHD) who 
present with advanced heart failure in adulthood (Burchill 2016). These patients 
are slightly more complex to manage both surgically (due to the abnormal 
anatomy, complex adhesions) and medically (due to human leucocyte antigen 
(HLA) sensitisation, potentially elevated pulmonary vascular resistance 
secondary to univentricular circulations and erythrocytosis secondary to 
cyanosis) (Banner et al. 2011; Burchill 2016). Coronary artery disease is the most 
important contributor to heart failure with a population-attributable risk of 65% 
in men and 48% in women(Lund et al. 2016). Most of the patients, however, can 
be classified into ischaemic or non-ischaemic cardiomyopathies. 
1.12 Primary Graft Dysfunction after Heart 
Transplantation 
Worldwide, more than 4000 adults undergo heart transplantation annually (Lars 
H. Lund et al. 2017a). It remains the closest resemblance to a ‘cure’ for end-
stage heart failure. Whilst survival after cardiac transplantation has improved 
over the past four decades, primary graft dysfunction (PGD) is the leading cause 
of 30-day mortality post-transplant. The incidence of PGD is yet to be accurately 
delineated given the lack of an international consensus regarding its definition. 
Reports to date vary widely with respect to diagnostic criteria and definitions, 
therefore making incidence and outcomes difficult to compare between centres 
and regions. Prior to 2014, the International Society of Heart and Lung 
Transplantation (ISHLT) registry noted a 30-day mortality of 10 % in all heart 
transplants done since 1982 (Lund et al. 2013). The 90-day mortality was and 14 
%. Almost 70% of these deaths were coded as ‘graft failure’ or ‘multi-organ 
failure’ for which a large majority would likely constitute contemporary PGD. 
Here, we provide a comprehensive overview of PGD in heart transplantation.  
1.12.1 Definition 
PGD presents as severe ventricular dysfunction of the donor graft which fails to 
meet the circulatory requirements of the recipient in the immediate post-
transplant period. It may manifest as either single or biventricular dysfunction 
with low cardiac output and hypotension despite adequate filling 
pressures(Segovia et al. 1998; Russo et al. 2010; Iyer et al. 2011). In 2014, 
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Kobashigawa et al provided a consensus definition and grading system based on 
the modified Delphi method (Jon Kobashigawa et al. 2014). This agreement upon 
a uniform definition allowed subsequent studies to outline its true incidence and 
further explore and identify the potential multifactorial aetiologies underpinning 
PGD. ` 
PGD is defined as being a separate entity from secondary graft dysfunction, 
which is when a discernible cause for allograft dysfunction is identified. Such 
causes can include hyperacute rejection, graft dysfunction secondary to 
pulmonary hypertension or a recognised intra-operative complication. The 
diagnosis of PGD is made within 24 hours post-transplantation and is separated 
into PGD-LV, for PGD affecting the left ventricle or biventricular failure; and 
PGD-RV for isolated right ventricular involvement (Jon Kobashigawa et al. 2014). 
A severity scale applies to PGD-LV. For the mild and moderate categories, it 
relies on the requirement of inotropic support with a composite score as 
described by Wernovsky et al (<10 = mild, ≥10 = moderate) alongside either using 
echocardiography to identify ventricular dysfunction or right heart 
catheterisation to demonstrate haemodynamic compromise (Wernovsky et al. 
1995b). For the echocardiography criteria, the left ventricular ejection fraction 
<40% is considered diagnostic for PGD (in the absence of secondary causes). With 
regards to haemodynamic parameters, high filling pressures i.e. a right atrial 
pressure (RAP) >15mmHg, and pulmonary capillary wedge pressure (PCWP) 
>20mmHg indicate PGD if occurring in the context of a low cardiac index (CI) 
(<2.0 L/min/m2) lasting at least 1 hour. The requirement of an intra-aortic 
balloon pump signifies moderate PGD-LV, whereas requirement of 
extracorporeal short-term mechanical circulatory support in the form of 
extracorporeal membrane oxygenation (ECMO) or Ventricular Assist Devices 
(VADs) in any form (percutaneous/surgical) is diagnostic of severe PGD-LV (Jon 
Kobashigawa et al. 2014).  
PGD-RV does not have a severity scale and is diagnosed based on the requirement 
of a Right-sided short-term VAD (RVAD) or right heart catheter measured 
haemodynamics in keeping with isolated right-sided dysfunction (RAP > 15 mm Hg, 
PCWP < 15 mm Hg, CI < 2.0 L/min/m2, TPG <15 mm Hg and/or pulmonary artery 
systolic pressure < 50 mm Hg) (Jon Kobashigawa et al. 2014). 
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Previous studies had used the need for mechanical circulatory support as a 
criterion for diagnosis of primary graft dysfunction, however, the timing of 
initiation of therapy and endpoints differs from these studies, leading to 
significant variation in incidence reporting (2.3-32.4%) (Ibrahim et al. 2007; Oto 
et al. 2008; D'Alessandro et al. 2010; Russo et al. 2010; Dronavalli et al. 2015). 
With an increasing trend towards utilisation of extended criteria donor organs 
due to increasing waiting list pressures, a resultant reduction in threshold for 
initiation of ECMO support in certain patients to support the graft in the initial 
phase of reperfusion (first 24 hours) may result in an over-estimation of the 
incidence of PGD (Chew et al. 2014). This is especially true in high-risk 
recipients with a significant inflammatory milieu as a result of receiving a 
combination of in-hospital inotropic or short or long-term mechanical circulatory 
support pre-transplant.  
1.12.2 Pathophysiology of PGD 
The donor heart is exposed to a multitude of physiological insults at 4 specific 
time points; brainstem death, hypothermic ischaemia, warm ischaemia, and 
ischaemia-reperfusion injury.  
1.12.2.1 Brainstem death 
The first insult occurs during the declaration of brainstem death in donation 
after brainstem death (DBD). Raised intracranial pressure (ICP) invariably is the 
final pathway in DBD donors in which case the aetiology of death is usually a 
result of an intracerebral haemorrhage, hypoxia leading to oedema, 
inflammation or a space-occupying lesion in the cranium. The cerebral perfusion 
pressure is usually maintained by homeostatic mechanisms which result in 
increased arterial pressure. Due to the limited plasticity of the brain within the 
confines of the cranium, brain herniation ensues resulting in pontine ischaemia 
(Gordon and McKinlay 2012). This causes a surge in the adrenergic response, 
resulting in pulmonary and systemic hypertension which increases the afterload 
in both ventricles causing myocardial ischaemia. In some patients, stimulation of 
baroreceptors results in the classic Cushing’s response characterised by 
hypertension and bradycardia (Shivalkar et al. 1993; Dictus et al. 2009).  
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Vasomotor tone is reduced to the loss of spinal cord sympathetic activity 
resulting in unopposed vasodilatation, further reducing preload and indirectly 
afterload, affecting coronary blood flow and reducing myocardial perfusion. In 
response, there is an intense release of myocardial noradrenaline immediately 
after brain death that results in mitochondrial and cytosolic calcium overload to 
increase contractility to counteract this unopposed vasodilatation (Shivalkar et 
al. 1993).  Pituitary ischaemia may also result occur during brain herniation 
resulting in significant endocrine derangement (Souter et al. 2017).  
These patients are also prone to metabolic disturbances due to acidosis, 
hypomagnesaemia or hypokalaemia secondary to mannitol initiation to reduce 
ICP, catecholamine administration, all of which contribute to increased 
myocardial oxygen demand or reduced myocardial perfusion(Souter et al. 2017). 
This initial surge may also cause catecholamine depletion leading to a vicious 
circle of impaired myocardial oxygenation and increasing myocardial oxygen 
demand (Gordon and McKinlay 2012).  
Early donor management may reduce the deleterious effects of the 
abovementioned phenomenon. Early administration of vasopressors is aimed at 
reducing the unopposed vasodilatation (Rosendale et al. 2003). 
Methylprednisolone administration has been shown to reduce lung injury 
independently from its anti-inflammatory activity in animal studies as well as 
reduce extravascular lung water and reduce PCWP in DBD donors 
(Venkateswaran et al. 2008; Meers et al. 2011). It is also used in conjunction 
with insulin to ensure normoglycemia in the donor (Wood et al. 2004). The role 
of thyroid hormone replacement is uncertain during donor management with 
current consensus suggesting triiodothyronine(T3) administration only in 
depleted donors (Venkateswaran et al. 2008; Novitzky et al. 2015; Kumar et al. 
2017; Souter et al. 2017). 
1.12.2.2 Hypothermic ischaemia 
Despite advancements in normothermic ex-vivo perfusion devices, cold storage 
remains the mainstay of transportation after organ retrieval. Organ retrieval 
often has two distinct phases, a warm phase, and a cold phase. The warm phase 
involves dissection of the heart and exposure of the innominate artery and the 
1 Introduction 50 
 
two cavae with variations in the degree of dissection depending on whether the 
lungs are to be retrieved as well. The retrieval surgeon also palpates the 
coronary arteries for potential disease. The aorta is prepared for administration 
of cold cardioplegia for the commencement of the cold phase.  
Depending on the size of the patient and type of cardioplegic solution 
administered, the volume of administration may differ. The retrieval surgeon 
then performs a left atriotomy by lifting the heart. Once the aortic cross-clamp 
is applied, cold cardioplegia is infused via the aortic root at approximately 4oC. 
The retrieval process is completed with the heart placed in a cold storage 
container. Cold storage induces hypothermic arrest of metabolism and maintains 
viability during this reduced metabolic state, therefore abating cellular swelling 
and minimalizing reperfusion injury (Schipper et al. 2016). At these 
temperatures, and with limited oxygenation, the heart switches from aerobic to 
anaerobic metabolism. This can have deleterious effects on the stored organs as 
ATP is slowly depleted. However, it should be noted that in the hypothermic 
state (0-4oC), there is a 12-fold decrease in metabolic rate (Belzer and Southard 
1988). The overall goal is to reduce the accumulation of mitochondrial by-
products of metabolism such as oxygen-free radicals. Cold storage is also based 
on the assumption that there is no variation in temperature and the heart is 
uniformly cooled. In elderly patients whereby, pathologic LV hypertrophy may be 
noted, especially in those with a clinical history of hypertension, this may not be 
possible, possibly explaining why these hearts are more susceptible to ischaemic 
injury (D. Marelli et al. 2000; Russo et al. 2010). The length at which the hearts 
are kept in cold storage may also play a part in the formation of these free 
radicals. Cellular swelling and lactic acidosis occur in prolonged cold storage, 
causing a rise in intracellular H+ ions (Anaya-Prado and Delgado-Vazquez 2008). 
The Na+/H+ exchanger is activated resulting in an increase in intracellular Na+ 
which activates the Na+/Ca2+ exchanger (Vigne et al. 1985; Karmazyn et al. 
1999). The final pathway is the accumulation of cytosolic Ca2+. This will play a 
major role in the pathogenesis of ischaemic-reperfusion injury.  
1.12.2.3 Warm ischaemia 
On arrival at the recipient centre, the heart is removed from cold storage and 
inspected. The period in which the heart is removed from cold storage or from 
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ex-vivo normothermic perfusion to the final release of the recipient aortic cross-
clamp is termed warm ischaemic time. The heart is exposed to warmer 
temperatures which slowly increases its metabolic rate, resulting in increased 
formation of oxygen-free radicals. In a study by Marasco et al, warm ischaemic 
time and increasing donor age were independent predictors of early survival, 
suggesting an acceleration of the deleterious effects described during the cold 
ischaemic phase (Marasco et al. 2012). Similar findings were noted by Banner et 
al, despite a broader definition of warm ischaemic time termed surgical implant 
time (i.e. arrival of heart to the theatre to release of recipient aortic cross-
clamp).  
1.12.2.4 Ischaemia-reperfusion Injury (IRI) 
IRI is defined as cardiomyocyte damage secondary to myocardial restoration of 
blood flow (Braunwald and Kloner 1985). On release of the recipient cross-
clamp, the donor heart is re-perfused which leads to further calcium overload. 
This alongside the release of oxygen-free radicals activates the formation of 
mitochondrial permeability transition pores (MPTP) which are non-specific, thus 
allowing free movement of apoptotic factors across the cell membrane 
(Morciano et al. 2017). This causes a cascade of myocardial damage, causing loss 
of cardiomyocyte function and viability; all of which are most pronounced 
immediately after reperfusion (Penna et al. 2013). Post-conditioning may play a 
role in attenuating the effects of IRI by inhibiting MPTP formation. Cyclosporine 
A, a known MPTP desensitizer, has been shown to induce appreciable protection 
in acute myocardial infarction (Argaud et al. 2005). However, a recent 
metanalysis failed to show any benefit of Cyclosporine A post-infarction 
(Upadhaya et al. 2017). Other forms of preconditioning have also been suggested 
in an attempt to inhibit MPTP formation have shown some promise in animal 
studies (Liu et al. 1991; Birnbaum et al. 1997; Hausenloy et al. 2004). However, 
larger clinical trials in surgical revascularisation studies have revealed mixed 
results with some studies showing clinical improvements (Thielmann et al. 2013) 
and others showing minor biochemical improvements with no clinical benefit 
(D'Ascenzo et al. 2012; Hausenloy et al. 2015; Benstoem et al. 2017; Pierce et 
al. 2017; Meybohm et al. 2018). The proponents of ischaemic preconditioning 
have suggested that the duration of ischaemia in these studies probably limits 
the effect of preconditioning with prolonged ischaemia showing greater benefit 
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of preconditioning (Kleinbongard et al. 2016). To date, no studies have been 
performed in human heart transplants, with animal models of orthotopic heart 
transplants showing promising results potentially highlighting its benefits in 
prolonged ischaemia(Konstantinov et al. 2005). 
Animal studies do however highlight attenuation of IRI using preconditioning in 
diabetics (Ishihara et al. 2001; Nieszner et al. 2002; Kristiansen et al. 2004), 
females (Crisostomo et al. 2006; Heinen et al. 2018), LV hypertrophied hearts 
(Moolman et al. 1997), obesity (Kristiansen et al. 2004), hypertensives (Ebrahim 
et al. 2007) and in the elderly (Bartling et al. 2003; Ebrahim et al. 2007; Heinen 
et al. 2018); all of which have been noted to be risk factors for PGD.  
Another mechanism of IRI is hyper-contracture-mediated sarcolemmal rupture 
(HMSR). During the ischaemic phase, the low cytosolic ATP concentrations are 
quickly exhausted resulting in myofibrillar shortening that remains fixed as all 
cross-bridges between actin and myosin remain in an attached state (Nichols and 
Lederer 1990). This causes a moderate contracture with little structural damage 
but leads to cytoskeletal defects and increasing the cardiomyocytes fragility to 
mechanical damage which is reversible with early reperfusion (Schluter et al. 
1996).  
Reperfusion induced hyper-contracture occurs after prolonged ischaemia. There 
is greater myofibrillar shortening and cytoskeletal damage when compared to 
the ischaemic phase alone. It causes a marked rise in end-diastolic pressure with 
increased ventricular wall stiffness. It is shown to be due to Ca2+ overload which 
develops during ischaemia and is rapidly re-energised, as it would on release of 
the cross-clamp (Piper et al. 2004). In cellular studies, re-perfused infarcts 
consist almost exclusively of contraction band necrosis (Piper et al. 2004). 
Sarcolemmal rupture occurs due to the degradation of structural proteins like α-
fodrin (Inserte et al. 2005) and ankyrin (Garcia-Dorado et al. 2006), impairing 
the Na+/Ca2+ exchanger pumps. Sarcolemma rupture also results in increasing Na+ 
influx into cardiomyocytes via gap junctions and may propagate to adjacent cells 
(Garcia-Dorado et al. 2004). 
Couchani (Chouchani et al. 2014) developed a comparative in vivo metabolomic 
analysis to identify pathways for mitochondrial ROS production during IRI. They 
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identified selective accumulation of the citric acid cycle (CAC) intermediate 
succinate as the metabolic signature of ischaemia in a range of tissues and as 
the driver for mitochondrial ROS production during reperfusion. Ischaemic 
succinate accumulation is caused by the reversal of succinate dehydrogenase, 
driven by other metabolic pathways (excessive fumarate from purine nucleotide 
breakdown and partial reversal of the malate/aspartate shuttle). Succinate is 
then rapidly oxidised by succinate dehydrogenase, perpetuating extensive ROS 
generation. The separate pathways driving succinate accumulation is highlighted 
in Figure 1-5.  
 
Figure 1-5 Metabolic model identifying pathways that can become activated by tissue 
ischaemia to drive succinate accumulation.  
(GDP = Guanosine Diphosphate, GTP = Guanosine Triphosphate, NAD+= Nicotinamide adenine 
dinucleotide (oxidised), NADH = Nicotinamide adenine dinucleotide (reduced), ADP = Adenosine 
Diphosphate, ATP= Adenosine Triphosphate, GABA=Gamma Aminobutyric Acid, TCA cycle = 
Kreb’s cycle, NADP+ = Nicotinamide adenine dinucleotide phosphate (Oxidised), NADPH = 
Nicotinamide adenine dinucleotide phosphate (reduced). Adapted with permission from ET 
Chouchani et al. Nature 000, 1-5 (2014) doi:10.1038/nature13909 
Couchani et al demonstrated that succinate levels had a direct correlation with 
the extent of mitochondrial reperfusion injury by the addition of dimethyl 
succinate to ischaemic primary cardiomyocytes. Conversely, this may also serve 
as a future pharmacotherapeutic option with inhibition of certain pathways 
abolishing the level of ischaemic succinate, and in turn, ameliorated the IRI 
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effects. This was shown by infusing dimethyl malonate, a precursor of the 
succinate dehydrogenase inhibitor malonate, which reduced the extent of 
cardiac IR injury in an in vivo mice model(Chouchani et al. 2014). Figure 1-6 
(next page) shows how the accumulation of ischaemic succinate drives this 
process from a mitochondrial to the cellular level and finally the myocardial 
stunning. 
 
  
 
 
Figure 1-6 The pathophysiological mechanism of ischaemic reperfusion injury at mitochondrial, cellular and myocardial levels 
Fumarate, aspartate, and malate rise during ischaemia resulting in accumulation of ischaemic succinate which drives Reactive Oxygen Species (ROS) generation. 
This, in turn, drives the movement of apoptotic factors across the cell membrane with cascading injuries as described.  
 
  
 
 
1.12.2.5 Donation after Circulatory Death (DCD) 
Donation after Circulatory Death (DCD) provides a different set of insults to the 
donor heart. The heart is placed in a hypoxemic and hypercarbic environment 
following the withdrawal of life support (White et al. 2018). This causes 
pulmonary vasculature constriction, with increased pulmonary vascular 
resistance imposed on the right heart (White et al. 2016). Although the 
catecholamine surge of brainstem death is not present, the hypoxemic 
environment induces an adrenergic response. This quickly depletes the 
myocardial energy stores – leading to circulatory arrest. A mandatory standoff 
period ensues as part of the guidelines for the declaration of circulatory death 
(Manara et al. 2012). The heart is exposed to a period of warm ischaemic time 
that is present until the institution of either normothermic regional perfusion 
(NRP) or ex-vivo normothermic perfusion using the Organ Care System device 
(TransMedics Organ Care System (OCS), Andover, MA, USA)(Page et al. 2018).  
This prolonged ischaemic period causes intracellular acidosis which causes 
activation of the Na+/H+ exchanger in a pathway similar to the warm ischaemic 
period described above, with a net result of an accumulation of intracellular 
Ca2+ and follows the ischaemic-reperfusion pathway on reperfusion. 
1.12.2.6 Recipient factors 
Some recipient factors may also predispose a patient to PGD. Recipients, 
especially patients who have been on inotropic support and mechanical devices, 
have activation of their systemic inflammatory response, which causes intense 
vasodilation, thus lowering the systemic vascular resistance. The net result is a 
hypotensive state despite adequate filling and high cardiac output that is 
refractory to vasopressor support (Chan et al. 2017). The exact pathogenesis of 
this is poorly understood to date, some mechanisms have been postulated. 
Vasodilation is believed to be caused by the unopposed activation of vascular 
smooth muscle adenosine triphosphate-sensitive potassium channels (KATP 
channels). Endogenous nitric oxide, a potent vasodilator is also implicated in the 
pathogenesis alongside vasopressin deficiency (Omar et al. 2015).  
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Prolonged ischaemic time has been shown in previous studies to correlate with 
complications occurring after cardiopulmonary bypass(Chan et al. 2017). This 
association is thought to be due to the summative effect of the exposure of 
blood to synthetic surfaces of the cardiopulmonary bypass circuit which 
potentiates a cascading inflammatory response. This, in turn, could explain the 
increased incidence in recipients on advanced mechanical circulatory support 
(ECMO or Short-Term VAD). The ischaemic time may also be prolonged in some 
patients whereby careful dissection is necessitated following a previous 
sternotomy, highlighting the importance of communication with the retrieval 
team to potentially delay the retrieval procedure to minimise ischaemic time  
(Rylski et al. 2010).  
Another pathogenic mechanism that has been suggested in the past is recipient 
pulmonary hypertension. The donor heart in its ischaemic state is exposed to a 
relatively high pulmonary vascular resistance, giving rise to right-sided heart 
failure. Due to the poor adaptability of the right ventricle to a sudden change in 
vascular resistance, biventricular dysfunction ensues due to a reduced left-sided 
preload, thereby reducing coronary perfusion and end-organ perfusion in the 
systemic circulation (Stobierska-Dzierzek et al. 2001).  
1.12.3 Risk Factors for PGD 
Several risk factors have been suggested that may contribute to PGD. These 
include donor factors, recipient factors, and procedural factors.  
1.12.3.1 Donor factors 
1.12.3.1.1 Donor Age 
Donor age has been shown to be a risk factor in several different studies. This 
may have been due to the poorer tolerance for long ischaemic times in hearts 
from older donors (Mark J. Russo et al. 2007). They noted that among younger 
donors, there was no significant correlation between ischaemic time and 
survival. However, as the donor age increased, there was a statistically 
significant correlation between ischaemic times and survival in donor ages>20. 
Other studies have also shown a direct correlation between donor age and low 
cardiac output states post-operatively, which were likely PGD, however, were 
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not characterised as such due to the lack of a definition at the time of 
publication (Potapov et al. 1999; Loebe et al. 2000; Blanche et al. 2002; Lietz et 
al. 2004).  
1.12.3.1.2 Gender Mismatch 
Female-Donor to Male-Recipient gender mismatch has been suggested as a risk 
factor for PGD (J. Kobashigawa et al. 2014). The exact mechanism is poorly 
understood as this persisted despite organ size matching. Male-donor to female-
recipients did not result in an increased PGD rate. Gender mismatched organs 
also had a poorer survival at up to 5 years(S. Avtaar Singh et al. 2018b). In liver 
transplantation recipients had poorer graft survival in female donor: Male 
Recipient cohorts compared with other donor-recipient gender groups despite 
adjustment for donor risk factors and recipient variables (Croome et al. 2014). 
The role of H-Y minor histocompatibility antigens has been implicated. Several 
haematopoietic stem cell studies have shown an increased relapse rate in 
patients undergoing stem cell transplants in female donor: male recipient 
cohorts (Gratwohl et al. 2001; Kongtim et al. 2015).  
1.12.3.1.3 Cause of Death in the Donor 
Intracranial haemorrhage is the most common cause of death for DBD donors in 
the UK (S. Avtaar Singh et al. 2018b). One study showed increased PGD rates in 
organs retrieved from donors with intracranial haemorrhage compared to donors 
with traumatic causes of death (Yamani et al. 2004). The exact mechanism is 
not clear, although it is thought to be due to prolonged exposure to the 
catecholamine surge (Yamani et al. 2004). Animal studies have shown a direct 
correlation between increased intracranial pressure and worsening myocardial 
function(Shanlin et al. 1988; Shivalkar et al. 1993). Another study showed an 
association with early mortality with a lower survival to discharge rate in 
patients transplanted with hearts from donors with atraumatic intracranial 
haemorrhage(Tsai et al. 2002). 
1.12.3.1.4 Donor Left Ventricular Hypertrophy 
Donors with hypertension often have a degree of left ventricular hypertrophy 
(LVH). This is more apparent across Europe where the average age of the donor 
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is older compared to North America(Lars H. Lund et al. 2017a). The use of 
donors with LVH has resulted in mixed results with some centres having 
favourable results (Daniel Marelli et al. 2000; Felker et al. 2005; B. Lima et al. 
2006; Goland et al. 2008; Pinzon et al. 2011) but others reporting an increased 
incidence of early graft failure or poorer survival (Aziz et al. 1997; Kuppahally et 
al. 2007; Stehlik et al. 2010a). The reason for the varying results is likely due to 
the association of LVH to age, which is an independent predictor of PGD. 
Hypertrophied hearts with associated hypertension are more susceptible to 
ischaemic injury (Dunn and Pringle 1987). Therefore, the ischaemic time for 
donors with hypertrophied hearts should be kept to a minimum. The Harefield 
team reported their experience in using marginal donors with mild LVH with 
normothermic ex-vivo perfusion (García Sáez et al. 2014). They showed 
promising short-term outcomes when utilising marginal hearts with continuous 
normothermic perfusion using the OCS device. The ISHLT guidelines also cite the 
level of evidence C for a class IIa recommendation stating that “it would seem 
appropriate to use hearts from donors with LVH and LV wall thickness <14 mm 
provided that it is not associated with ECG findings of LVH” (Costanzo et al. 
2010). 
1.12.3.1.5 Donor Inotropic Requirement 
Inotropic support is sometimes needed during the donor organ retrieval process 
due to the depletion of catecholamine and/or a systemic inflammatory 
phenomenon as described above. Noradrenaline use can cause left ventricular 
dysfunction in the absence of brain death (Movahed et al. 1994). It also has a 
dose-dependent detrimental effect on the right ventricle in DBD donors (Santise 
et al. 2009; D'Alessandro et al. 2011b; Segovia et al. 2011). The use of 
vasopressin and terlipressin is currently recommended as first-line treatment to 
reduce the noradrenaline requirement (McKeown et al. 2012). It treats two 
conditions that occur commonly in DBD donors, neurogenic diabetes insipidus 
and reduction in systemic vascular resistance (Yoshioka et al. 1986). 
Venkateswaran et al showed that vasopressin use could result in the elimination 
or reduction of noradrenaline use in more than 50% of donors (Venkateswaran et 
al. 2009b). 
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1.12.3.2 Recipient Factors 
1.12.3.2.1 Pre-operative Mechanical Circulatory Support 
Pre-operative recipient ECMO/VAD usage has also been linked to PGD post-
operatively(Young et al. 2001; Russo et al. 2010; D'Alessandro et al. 2011b; Hong 
et al. 2011). Several factors have been suggested as potential causes which have 
been discussed under the pathophysiology section above. 
A recent study by Truby and colleagues highlighted the role of continuous-flow 
LVAD (CF-LVAD) in recipients as a risk factor for severe PGD (Truby et al. 2018). 
This is of particular interest as CF-LVADs have contributed significantly to the 
growth and success of mechanical circulatory support for advanced heart failure 
for bridging to transplant and as destination therapy. CF-LVADs also currently 
account for more than 95% of VAD implants (Kirklin et al. 2017). 45 out of 
56(80.4%) patients with severe PGD were bridged to transplant (BTT) using CF-
LVADs in Truby’s study (Truby et al. 2018). It should be noted however there 
were significant other contributory factors as the severe PGD patients were 
older, had a higher percentage of previous amiodarone exposure, had higher 
creatinine levels, spent longer time on the waiting list and had higher CVP/PCWP 
ratios which were possibly indicative of subclinical right ventricular dysfunction.  
1.12.3.2.2 Recipient Diabetes Mellitus 
The role of recipient diabetes as a predictor of PGD is evident in multiple 
studies(Segovia et al. 2011; Nicoara et al. 2017). However, Segovia’s study was 
unable to account for recipient diabetes as a predictor of PGD when using robust 
statistical analysis (overfitting of regression models)(Foroutan and Ross 2019). 
However, recipient diabetes seems to be a predictor of graft loss within and 
beyond the first-year post-transplant (Foroutan et al. 2018). This may be due to 
direct glucose-mediated endothelial damage, oxidative stress from superoxide 
overproduction and production of advanced glycation end-products, which may 
result in changes in endothelial permeability, excessive vascular protein 
deposition and altered blood flow (Funk et al. 2012). Taghavi et al revealed 
diabetic recipients were older and would be more likely to receive organs from 
diabetic donors who were who themselves were more often females and older 
(Taghavi et al. 2013). 
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1.12.3.2.3 Recipient Age 
Several studies have associated advancing recipient age with PGD and mortality 
(D'Alessandro et al. 2011b; Segovia et al. 2011). A risk prediction model 
assessing in-hospital mortality for post-heart transplant patients included 
recipient age but utilised it as a categorical variable. The c-statistic of less than 
0.7, however, suggested poor performance (Singh et al. 2012). ISHLT registry 
data also highlighted advancing recipient age with having slightly higher long-
term mortality. This may probably reflect the higher incidence of comorbidities 
such as hypertension and diabetes in this cohort of patients as well (Yeom et al. 
2013). Some studies have attributed this to the increased fatal infection rate in 
the elderly (Bull et al. 1996; Tjang et al. 2008). 
1.12.3.2.4 Recipient Re-sternotomy 
A recipient re-sternotomy indicates previous surgery, most commonly for durable 
Ventricular Assist Device implantation, previous congenital cardiac surgery or 
previous coronary bypass or valvular surgery (Morales et al. 2010). The dissection 
process in the recipient who has undergone a previous sternotomy often is more 
complex and hazardous with the potential for significant injury (Kuralay et al. 
2004). One study showed that patients with prior sternotomies had an almost 3-
fold increase for PGD risk (S. Still et al. 2018). The increased technical difficulty 
of the surgery may result in longer ischaemic times and are associated with 
higher rates of blood transfusion and subsequent need for reoperation for 
bleeding (Kansara et al. 2014a; Awad et al. 2015; S. Still et al. 2018). Patients 
with prior sternotomies were also more likely be older (S. Still et al. 2018) and 
have spent longer time on the waiting list (S. Still et al. 2018), possibly 
indicating durable VAD implantation (Awad et al. 2015) in these patients as a 
bridge to candidacy/transplantation. 
1.12.3.2.5 Recipient pre-operative amiodarone therapy 
Amiodarone is a Class III antiarrhythmic used for a variety of arrhythmias 
including both ventricular, supraventricular and atrial tachyarrhythmias. Its 
mechanism of action is primarily by prolonging the refractory period 
myocardium. Arrhythmias are highly prevalent in advanced heart failure patients 
(Santangeli et al. 2017). The evidence regarding PGD and the use of amiodarone 
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in recipients appear to be conflicting. Studies have shown that patients who had 
received amiodarone before transplantation had significantly lower heart rates 
post-transplantation (Macdonald et al. 1991; Chelimsky-Fallick et al. 1992), 
required atrial pacing for a longer time after transplantation (Macdonald et al. 
1991) but had no increased inotropic requirements (Macdonald et al. 1991) and 
no increased mortality post-operatively (Macdonald et al. 1991; Chelimsky-
Fallick et al. 1992; Rivinius et al. 2016). Other studies have indicated a dose-
dependent (Wright et al. 2017) or duration-dependent (Chin et al. 1999) link 
between amiodarone use and PGD post-transplant.  
1.12.3.3 Procedural Factors 
1.12.3.3.1 Ischaemic Time 
In DBD donations, the ischaemic time consists of the placement of the donor 
aortic cross-clamp until the release of the recipient aortic cross-clamp (Halazun 
et al. 2007). For DCD donations, the ischaemic time is possibly under-estimated 
with a period of functional warm ischaemia (starting when systolic blood 
pressure is less than 50 mm Hg) till the heart is re-perfused on an ex-vivo 
perfusion device(OCS) (Page et al. 2018). The 2nd period of ischaemia ensues 
from the removal of the heart from the OCS till the release of the aortic cross-
clamp from the recipient. 
Cold ischaemic time consists of time spent in cold storage and warm ischaemia 
ensues once the heart is removed from cold storage or the OCS rig up to release 
of the aortic cross-clamp. Prolonged ischaemic time is associated with an 
increased rate of PGD (Russo et al. 2010; Segovia et al. 2011; Marasco et al. 
2012; Squiers et al. 2017a). Banner et al noted that longer ischemia time was a 
risk factor for 30-day mortality after heart transplantation. They also noted that 
the surgical implant time (i.e. warm ischaemic time) was an independent risk 
factor for 30-day mortality (Banner et al. 2008). The direct ischaemic insult of 
warm ischaemia is explained in the pathophysiology above. Marasco et al also 
noted found that poorer survival with a warm ischemia time (WIT) of >80 
minutes (Marasco et al. 2012). Ischaemic time is also closely related to donor 
age. Older donor organs are more susceptible to ischaemic injury compared to 
younger donor organs (Mark J. Russo et al. 2007; Wong et al. 2017).  
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1.12.3.3.2 Cardiopulmonary Bypass (CPB) Time 
Prolonged CPB duration independently predicts postoperative morbidity and 
mortality after general cardiac surgery (Salis et al. 2008). Kirklin and colleagues 
alluded to a systemic inflammatory response following CPB (Kirklin 1980). The 
mechanism of injury from CPB and ischaemic-reperfusion of the myocardium is 
similar; both producing a hyperdynamic circulatory state due to a low systemic 
vascular resistance, platelet and coagulation factor dysfunction, inflammatory 
pathway activation triggered by leucocytes and endothelial cells and finally 
cytokine release and formation of oxygen-free radicals (Anselmi et al. 2004). It 
is also linked to an increased blood product requirement which is associated with 
both infection and ischaemic postoperative morbidity, increased hospital stay, 
increased early and late mortality, and increased hospital costs (Kuduvalli et al. 
2005; Koch et al. 2006; Murphy et al. 2007). Therefore, prolonged CPB time may 
contribute to the worsening of the ischaemic injury caused by PGD. 
1.12.3.3.3 Size Mismatch 
The size of the donor graft has many implications for the recipient. It is a 
powerful predictor of survival with recipients receiving undersized grafts having 
an increased 1-year mortality, and a 36% increased mortality within the first 30 
days (R. M. Reed et al. 2014). Smits showed inferior survival in donors who were 
undersized by more than 20% using data from the Eurotransplant database (Smits 
et al. 2003). This study however also showed an inferior survival amongst gender 
mismatched donors, which were more likely to be undersized in female donors 
to male recipients. Patel et al refuted the findings in an analysis of the UNOS 
database, suggesting increased pulmonary resistance as a confounder (Patel et 
al. 2008). Another analysis of the UNOS database several years later concluded 
that donor: recipient BMI ratio <0.75 was associated with an increase in post-
transplant mortality in univariate analysis but not in multivariate analysis, 
highlighting gender mismatch as a confounder (Weiss et al. 2009). Other multi-
institutional studies have also highlighted donor-recipient weight difference to 
be significant, but only in older grafts which were gender mismatched (Stehlik et 
al. 2010b). Jayarajan and colleagues noted that donor weight mismatching by up 
to 40% had no bearing on the outcome in non-gender mismatched patients 
(Jayarajan et al. 2013). The significance of size mismatching is hard to elucidate 
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from studies but smaller single centre data suggest poorer outcomes such as an 
increased length of stay(Murphy et al. 2016) and increased LV hypertrophy 
(Kertesz et al. 1995). The direct link between PGD and size mismatch, however, 
remains elusive.  
1.12.3.4 Investigations and Biomarkers 
The current definition for PGD is based on the treatment options utilised. 
Several biomarkers have been suggested as potential predictors of PGD, although 
to date none are used in routine care.  
1.12.3.5 Inflammatory markers 
The pro-inflammatory state accompanying PGD supports the use of inflammatory 
markers as potential predictive biomarkers. Tumor Necrosis Factor-α(TNF-α), 
Interleukin-6 (IL-6), Neutrophils and Procalcitonin (PCT) have all been suggested 
as potential biomarkers. 
1.12.3.5.1 TNF-α (Donor) 
Tumor necrosis factors are produced by lymphocytes and macrophages that 
cause cell lysis (Locksley et al. 2001). TNF-α has been implicated in the 
pathogenesis of numerous inflammatory conditions including arthritis (Cui et al. 
2018), asthma, chronic obstructive pulmonary disease (COPD), acute respiratory 
distress syndrome (ARDS) (Mukhopadhyay et al. 2006), myocarditis (Sack 2002) 
and congestive heart failure (Levine et al. 1990).  
Birks and colleagues noted increased expression of TNF-α in unused donor hearts 
due to poor function and compared them with donors with good ventricular 
function (used donors) pre-retrieval and in patients with advanced heart failure 
(HF) (Birks et al. 2000). In lung transplantation, a recent study highlighted the 
role of intravascular donor monocytes in the pathophysiology of IRI and PGD in 
lungs (Tatham et al. 2018). Another group showed a reduction in PGD rates post-
lung transplantation after leukocyte depletion during implantation(Schnickel et 
al. 2006). Venkateswaran et al highlighted poorer biventricular function in 
donors with elevated levels of TNF-α using serum immunoassays (Venkateswaran 
et al. 2009a). 
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A Brazilian group showed recipients receiving grafts from donors expressing 
lower concentrations of plasma soluble tumour necrosis factor receptors 2 
(sTNFR2) and IL-6, required more inotropic support post-transplantation (Braulio 
et al. 2016).  
1.12.3.5.2 IL-6 (donor and recipient) 
Interleukin 6 (IL-6), is produced in response to infections and tissue injuries by 
stimulation of acute-phase responses. It bridges the adaptive and innate immune 
responses and plays a major role in autoimmune conditions (Tanaka et al. 2014; 
Fontes et al. 2015). Birks et al noted IL-6 mRNA expression was 2.4-fold higher in 
the unused donor hearts than in those used for transplantation in pre-retrieval 
samples, with levels almost 5 times higher than in the potential recipients with 
advanced heart failure (Birks et al. 2000). The used donor hearts had an almost 
2-fold increase of IL-6 mRNA levels compared to the recipients. These findings 
were also noted by Plenz and colleagues, who noted a significant rise in IL-6 and 
IL-6 receptors in DBD donors, comparable to patients with advanced heart 
failure in comparison with a control group not compromised by the sequelae of 
brain death. This may explain the close association of elevated IL-6 serum levels 
and acute allograft dysfunction in the early post-operative period (Plenz et al. 
2002). 
IL-6 was also shown to be associated with PGD post-lung transplantation. The 
serum and bronchioalveolar lavage concentrations of IL-6 were higher in 
transplant recipients with PGD than those without (Moreno et al. 2007). 
Animal models have shown that ischaemic cardiac myocytes in watershed viable 
zones of a myocardial infarction exhibited reperfusion-dependent expression of 
IL-6 mRNA after reperfusion (Kukielka et al. 1995; Gwechenberger et al. 1999).  
1.12.3.5.3 Procalcitonin (Donor) 
Procalcitonin(PCT) is a 116 amino acid peptide that has an approximate molecular 
weight of 14.5 kDa and belongs to the calcitonin (CT) superfamily of peptides(Jin 
and Khan 2010). It is a biomarker that exhibits greater specificity than other 
proinflammatory markers in identifying patients with sepsis(Jin and Khan 2010). 
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In transplantation, PCT was used to differentiate bacterial infection from organ 
rejection. PCT levels are elevated in both conditions but significantly higher in the 
presence of infections (Yu et al. 2014; Sandkovsky et al. 2015). It has important 
prognostication value in heart transplantation with low levels signifying an 
uneventful course, and a higher value indicating increased mortality in the early 
post-operative period (Madershahian et al. 2008). Venkateswaran et al noted that 
elevated donor serum PCT levels were associated with poorer donor cardiac index 
and worse biventricular function despite early donor management during pre-
retrieval optimisation (Venkateswaran et al. 2009a). The authors demonstrated that 
pre-optimisation baseline PCT levels of less than or equal to 2ngmL-1 was a 
potentially useful tool in predicting the end-management heart usability for 
transplantation. Similar findings were noted by Wagner and colleagues with 
increased 30-day mortality and early graft dysfunction in hearts utilised from donors 
with elevated PCT levels (Wagner et al. 2001). The increased early graft failure rate 
was also noted in renal (van Ree et al. 2009), but not in liver (Eyraud et al. 2008) or 
lung transplantation (Sammons and Doligalski 2014). 
1.12.3.5.4 Neutrophil‐to‐lymphocyte ratio (NLR) (Recipient) 
Both NLR and Platelet-to-Lymphocyte ratio (PLR) have been used as markers of 
inflammation with prognostic value in coronary artery disease (Bhat et al. 2013; 
Ucar et al. 2016) and other conditions. NLR ratios have been shown to be 
independently related to mortality in patients hospitalized for acute heart 
failure with LVSD (Huang et al. 2017). Implantation of LVAD in patients with 
heart failure showed reversibility of NLR which reflects the reversal of various 
HF mediated inflammatory processes (Yost et al. 2017). 
A group in Argentina studied the relationship between the two ratios and 
survival after heart transplantation (Seropian et al. 2018). They noted NLR 
(baseline and at 6 hours) to be a good predictor of early mortality post-heart 
transplantation but not PLR. The number of patients in this single centre study 
was relatively small (n=111). A Polish single centre study noted similar findings 
in their renal transplant cohort, with NLR showing good predictive value of early 
graft dysfunction (Hogendorf et al. 2018). Another recent study showed a good 
correlation between NLR and survival after ECMO institution in non-transplant 
patients presenting with cardiogenic shock (Yost et al. 2018). However, patients 
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in the increased NLR ratio arm of this study were also significantly older with a 
higher blood urea nitrogen level.  
1.12.3.5.5 Troponin (Donor) 
Cardiac troponins are regulatory proteins that control the calcium-mediated 
interaction between actin and myosin. The measurements of serum cardiac 
troponin I (cTnI) and cardiac troponin T (cTnT) have been shown to be sensitive 
and specific markers of myocardial damage (Sharma et al. 2004).  
The pathophysiology of brainstem death results in a catecholamine storm that is 
believed to cause transient myocardial ischemia and injury (Vamsidhar B. 
Dronavalli et al. 2010). Circulating cardiac troponin concentrations may, 
therefore, be elevated in the donor.  
Several studies, however, have shown that elevated serum troponin levels in 
donors may predict adverse outcomes post-transplantation. Increasing cTnT 
levels have been shown to be associated with a reduction in left ventricular 
ejection fraction in the donor (Riou et al. 1995). Potapov et al showed in a 
single centre observational study that increased donor cTnT levels were 
associated with an increased rate of early allograft failure (Potapov et al. 2003). 
They showed a similar association with PCT indicating a coexistent 
proinflammatory state in these donors. PCT and cTnT levels, however, showed 
poor specificity. There was also no correlation between PCT and cTnT values and 
there was no significant interaction between the two markers using a logistic 
regression model (P=0.28). Vijay et al conducted a similar study, using 
endomyocardial biopsy-proven rejection at 1 year as the primary endpoint. They 
noted a linear correlation between the grade of rejection at 1-year and donor 
cTnT levels (Vijay et al. 1998). Another study by Potapov et al showed an 
association between increasing cTnI levels in donors to early graft dysfunction 
post-transplantation (Potapov et al. 2001). 
In donors with subarachnoid haemorrhages, cTnI was a good indicator for left 
ventricular dysfunction, however, this was reversible, and did not affect 
outcomes post-transplant (Deibert et al. 2000; Deibert et al. 2003). 
Boccheciampe et al noted that cTnI values in donors were not associated with 
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PGD or post-transplant survival (Boccheciampe et al. 2009). Other larger studies 
of donor serum troponin have shown no association between elevated levels and 
PGD (Khush et al. 2007; Madan et al. 2016).  
A recent study of cTnI in the preservation solution(University of Wisconsin 
solution and Custodiol) during transportation of heart grafts, however, showed 
that elevated cTnI (scaled to the corresponding LV mass) was predictive of post-
transplant PGD (Schechter et al. 2016). They also noted a poor correlation 
between preservation fluid cTnI levels and donor serum cTnI levels. They raised 
the possibility that incomplete myocardial preservation may play a role in PGD 
pathogenesis. However, there were only 43 patients in the study, and only 
ischaemic time was noted to be a predictor of PGD in their logistic regression 
model. 
1.12.3.5.6 Brain natriuretic peptide (BNP)/ N-terminal pro–B-type natriuretic 
peptide (NT-proBNP) (Donor) 
BNP and its amino-terminal pro-fragment, NT-proBNP is commonly used for 
diagnosis and prognostication in heart failure (Yamamoto et al. 1996; Groenning 
et al. 2004). They are released by the myocardium in response to increasing 
ventricular wall stress (Krittayaphong et al. 2008). They have been shown to 
correlate well with ventricular dilation (Krittayaphong et al. 2008), adverse 
remodelling (Giallauria et al. 2008), and death after acute myocardial infarction 
(de Lemos and Morrow 2007). Dronavalli et al showed that elevated NT-proBNP 
correlated well with poor echocardiographic and haemodynamic findings of 
cardiac function in potential DBD donors (V. B. Dronavalli et al. 2010). Vorlat et 
al linked increased BNP levels to a lower cardiac output post-transplant and a 
prolonged hospital stay (Vorlat et al. 2012). They noted that a donor serum BNP 
of >160 pg/ml had 89% accuracy to predict poor cardiac performance in the 
recipient (cardiac index <2.2 litres/min/m2). The authors, however, could not 
show a correlation between post-operative inotropic support and BNP levels. 
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1.12.3.6 Others 
1.12.3.6.1 SWItch/Sucrose NonFermentable, a matrix-associated, actin-
dependent regulator of chromatin subfamily a-like 1 (SMARCAL1) 
(Donor) 
SMARCAL1 is an intracellular protein that acts as a DNA-dependent ATPase 
involved in transcription, DNA repair, and chromatin dynamics (Vamsidhar B. 
Dronavalli et al. 2010). Aharinejad et al noted that elevated serum SMARCAL1 
levels in their cohort of 336 donors were predictive of recipient PGD (Aharinejad 
et al. 2009). In addition, SMARCAL1 levels correlated well with survival at 3 
months, 1-year and 5-year survival. Using a donor serum cut off of ≥1.25 ng/ml, 
they demonstrated a 96% sensitivity and 88% specificity for predicting PGD. Pre-
and post-aortic donor cross-clamp serum SMARCAL1 concentrations were the 
best markers of PGD risk. To date, no other validation studies have been 
performed. 
1.12.3.6.2 Donor myocardial hypoxia inducible factor (HIF)-1α (Donor) 
HIF‐1 is a heterodimeric α, β transcription factor that mediates tissue responses 
to hypoxia (Jiang et al. 1996). Aharinejad et al performed a series of assays 
using 857 donor LV myocardial biopsies obtained before and after aortic cross‐
clamping in the donor, and at 10, 30 and 60 min following reperfusion 
(Aharinejad et al. 2007). In the cDNA array, only HIF‐1α mRNA expression after 
aortic cross‐clamping in donors and at 10 min following the release of the aortic 
cross‐clamp in the recipient were significant predictors of PGD. The authors 
hypothesize that the release of cytokines and inflammatory chemokines 
activated by ischemia and reperfusion injury reach the highest peaks prior to 
cross-clamping and just after reperfusion. Other studies have demonstrated the 
protective signalling of HIF-1 against ischemia-reperfusion injury in the heart 
(Loor and Schumacker 2008; Amaral and Okonko 2015). To date, however, there 
have been no further studies linked HIF-1α to PGD. 
1.12.3.6.3 Heme-oxygenase-1 (Recipient) 
The HOT study (NCT01430156) was a randomised placebo-controlled trial 
evaluating the effect of the drug human hemin (Heme Arginate [HA]) on heme 
oxygenase-1 (HO-1) upregulation and renal function in recipients of deceased 
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donor kidney transplants(Thomas et al. 2016). HO-1 is involved in the 
degradation of heme and plays a protective role in IRI. The objective of this 
Phase IIb trial was to ascertain if hemin could induce HO-1 and therefore 
potentiate its beneficial effects against IRI. The study showed that hemin 
successfully induced HO-1 upregulation safely.  Larger studies are currently to 
identify if HO-1 upregulation translates to improved organ function and survival. 
1.12.3.6.4 Serum exosome proteomics (Recipient) 
Several published abstracts have highlighted the role of serum exosome 
proteomic analysis in the recipient as a potential biomarker for PGD (Giangreco 
et al. 2017; Fine et al. 2018). Giangreco et al noted that pretransplant serum 
exosome analysis revealed an inflammatory phenotype and complement 
activation in patients who later developed PGD which could be identified by the 
absence or presence of the biomarkers alone. Fine et al showed this could be 
further used to differentiate patients who would later develop PGD RV from PGD 
LV. In their study, significant upregulation of angiotensinogen (AGT) and 
adiponectin (ADIPOQ) signalling pathways were noted in the PGD LV group 
whereas hepatic growth factor activator (HGFAC) and insulin-like growth factor 
binding protein 3 (IGFBP3) pathways were both upregulated in the PGD RV 
group. The significance of these findings may hopefully shed light on the 
pathogenesis of PGD in the near future. 
1.12.3.7 Prevention of PGD 
A single administration of cold flush preservation fluid remains the gold standard 
for myocardial protection during transplantation. It confers reliable protection 
for a limited amount of ischaemic time in young donor hearts (Jon Kobashigawa 
et al. 2014). The increasing use of extended criteria donors, however, 
necessitate more aggressive protection strategies to attenuate the ischaemic 
effects on hearts. In a study conducted by the Hamburg group, they noted that 
the use of a leukocyte depleting filter alongside additional regular antegrade 
administration of Buckberg cold blood cardioplegia in intervals of 20 minutes 
resulted in a reduction of PGD rates (Wagner et al. 2013). Similar findings were 
noted by a group from the Czech Republic, utilising continuous cold blood 
cardioplegia followed by controlled reperfusion of warm blood (Cerny et al. 
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2002). The Glasgow group utilised a similar variation with continuous antegrade 
perfusion in a contemporary cohort of patients, resulting in a significant 
reduction in PGD rates compared to a historical group of patients and the 
national UK cohort (Morcos et al. 2018). The exact mechanisms by which 
additional cardioplegia administration reduces PGD remains uncertain. It may 
play a role in pre-conditioning, mitigating the impact of reperfusion or 
preventing generation and propagation of inflammatory pathways (Habertheuer 
et al. 2014). 
1.12.3.8 Treatment and Management of PGD 
Treatment of PGD thus far is still primarily supportive care. In a consensus 
statement by Kobashigawa et al, the treatment and management of PGD across 
5 high volume transplant centres were evaluated. PGD is initially managed by 
using inotropic support using catecholamines and phosphodiesterase inhibitors. 
The most common escalation therapy that follows inotropic use is an intra-aortic 
balloon pump. Following this, advanced mechanical support is initiated which is 
usually directed by the expertise of the transplant units themselves. The most 
common mode of support is extracorporeal membranous oxygenation with both 
central and peripheral cannulation strategies utilised. The heart should be 
allowed to eject to prevent stasis and thromboembolic complications 
For primary RV-PGD, nitric oxide may be used to reduce pulmonary vascular 
resistance. Following a period of support on ECMO, a short-term ventricular 
assist device is then implanted depending on the level of support needed (L-VAD, 
R-VAD, BiVAD ± oxygenator, Total Artificial Heart). Where possible, the patient 
is then re-evaluated for redo-orthotopic heart transplantation. 
1.12.3.8.1 Levosimendan 
Levosimendan is a calcium sensitizing agent and an inodilator which increases 
cardiac contractility. Its primary mode of action is by increasing the sensitivity 
of troponin-C to calcium during systole thereby increasing cardiac performance 
without increasing myocardial oxygen consumption. It also reduces peripheral 
vascular resistances by the opening of adenosine triphosphate–dependent K+ 
channels (Russ et al. 2007). It was initially used for treatment of cardiogenic 
shock post-acute myocardial infarction(Russ et al. 2007). However, SURVIVE, a 
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multicentre RCT evaluating levosimendan vs dobutamine in acute 
decompensated heart failure, revealed no differences in survival outcomes 
between the two groups (Mebazaa et al. 2007). There was an initial reduction in 
plasma B-type natriuretic peptide levels in patients in the levosimendan group 
compared with patients in the dobutamine group. Florian Weis and colleagues 
report a case series of 12 patients with PGD who received 0.1 µg/kg/min 
levosimendan for PGD with a centre specific definition of LVEF<30% on 
transoesophageal echocardiogram with a combination of adrenaline> 0.1 
µg/kg/min and the milrinone > 0.3 µg/kg/min (Weis et al. 2009). 11 of the 12 
patients survived beyond 30 days, with significant reductions in inotropic support 
without requiring mechanical circulatory support. However, follow-up studies by 
the same group showed significantly lower 1-year and 3-year survival rates 
(Beiras-Fernandez et al. 2011). 
The inotropic effects of levosimendan may often take hours to develop, which 
may be offset by its potent vasodilation capacity (Sundberg et al. 1998). It may 
however also play a role in protecting cardiomyocytes against 
ischaemic/reperfusion injury by activating adenosine triphosphate-sensitive 
potassium channels in mitochondria as shown by numerous studies although to 
date, no studies have been done on pre-or post-conditioning in a heart 
transplant setting (Cammarata et al. 2006; Papp et al. 2006; Du Toit et al. 2008; 
Hönisch et al. 2010; Hasslacher et al. 2011). 
1.12.3.8.2 Plasmapheresis 
Plasmapheresis is a process by which whole blood is passed through a filter to 
separate the plasma components from the larger cellular components of red 
blood cells, white blood cells, and platelets(Nguyen et al. 2012). Its use in 
transplantation was primarily for hyperacute or acute humoral rejection, 
whereby adjunctive therapeutic plasma exchange has been used alongside 
immunosuppression and intravenous immunoglobulins to improve survival of 
incompatible organs compared to compatible organs. Plasmapheresis rapidly 
reduces the circulating antibodies and thereby improves cardiac function (Wang 
et al. 2006). Plasmapheresis was used for primary allograft dysfunction after 
liver transplantation with encouraging results(Mandal et al. 2000; Ince et al. 
2013). A study by a group in Taiwan revealed treatment with pulsed steroid and 
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plasmapheresis improved the ejection fraction and NYHA status of >70% of the 
patients treated(Chou et al. 2012). However, the definitions of PGD in this 
cohort were not discernible from acute rejection due to the study methodology 
and lack of biopsy-proven rejection at the time of treatment as treatment was 
started empirically in all 35 patients who were in NYHA functional class III or IV 
requiring pharmacological or mechanical circulatory support. The Cedars-Sinai 
Heart Institute group performed a similar study in patients with severe PGD. In 
their cohort of 15 patients, 66% of whom underwent plasmapheresis post-
transplantation had significantly improved outcomes compared to the 33% of 
severe PGD patients who did not. They concluded that the potential role of 
inflammatory molecule depletion in these patients may play a role in the 
pathophysiology of PGD(Chang et al. 2017). The exact role of plasmapheresis in 
PGD is still speculative and may potentially be clearer with ongoing research.  
1.12.4 Conclusion 
PGD is the leading cause of early morbidity and mortality following heart 
transplantation. It is thought to be multifactorial in origin and several risk 
factors implicated. The search for an accurate biomarker, however, remains 
elusive. Treatment options to date remain supportive with no definitive 
pharmacological agents identified as of yet. Plasmapheresis may have a role in 
the depletion of inflammatory chemokines and cytokines for the treatment of 
PGD.   
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2.1 The role of NHSBT in organ donation 
There are 6 adult heart transplant centres and 2 dedicated paediatric heart 
transplant centres in the United Kingdom. In the preceding decade, around 150 
hearts were implanted per year nationally. 
 
Figure 2-1 Deceased donor heart programme in the UK, 1 April 2007 - 31 March 2017 
(source: NHSBT Annual Report 2017) 
This represents a 50% reduction from the number of heart transplants performed 
in the early 1990s. This is commonly attributed to the decreasing number of 
patients dying from brain stem death as a consequence of improvements in 
health care provision and safety initiatives. (Kompanje et al. 2011) 
Alongside limited organ pools, heart failure medical therapy has also improved in 
the past 20 years. This has significantly changed the listing criteria for patients 
and impacted transplant listing decision-making. A study of waiting list patients 
in the US over a 15-year period showed improved survival of urgently listed 
patients in the most recent era with transplantation compared to those not 
transplanted but similar survival of non-urgent candidates with or without 
transplants (Lietz and Miller 2007). This highlighted the benefits of optimal 
medical therapy, matching the benefits of transplantation in ambulatory 
patients. An exception in this study were patients with restrictive 
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cardiomyopathies, inherited cardiomyopathies from systemic diseases, and 
congenital heart diseases.  
In 2008, an Organ Donation Taskforce was commissioned to implement 
recommendations to increase donor numbers. NHS Blood and Transplant (NHSBT) 
integrated the new Directorate for Organ Donation and Transplantation into its 
existing organisation. This involves organ allocation, audit, and maintenance of 
the Organ Donation Register (ODR) and centralising employment and staffing 
from individual transplant centres within the NHS. One of the recommendations 
was to develop a national organ retrieval service (NORS) and to revamp 
allocation and retrieval completely(Martin and Paul 2008).  
NHSBT was also charged with supporting every acute hospital and health board 
in the UK (potential donor centres). This included appointing a liaison clinician 
to improve organ donation engagement within each organisation, allocating 
specialist nurses for organ donation (SNODs) to take on the role of donor 
transplant coordinators and serve as the bridge between local clinicians and 
NHSBT alongside establishing a local donation committee tasked with supporting 
organ donation within the organisation (Murphy and Smith 2012).  
NORS was successfully implemented in 2010 to address the variability of organ 
retrieval support. Another key point in this time was the establishment of legal 
guidance concerning non-heart beating organ donation or donation after 
circulatory death (DCD). This was published in 2009 for England and Wales 
followed by Scotland and Northern Ireland in 2010 and 2011 respectively (Murphy 
and Smith 2012). 
The net result of the implementation of these changes can be seen in Figure 2-2 
where there has been a stark reduction in the number of patients on the waiting 
list with an increase in transplant activity and the number of organ donors.  
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Figure 2-2 Deceased donors, transplants and the transplant waiting list 2007-2017 (NHSBT 
annual report 2016/2017) 
2.2 Patient Listing for Transplantation 
In the UK, current indications for referral for consideration of heart 
transplantation include: 
1. Heart failure with impaired left ventricular systolic function or heart 
failure with reduced ejection fraction (HFrEF) 
2. NYHA III or IV symptoms 
3. Receiving optimal medical treatment (including target or maximum 
tolerated doses of β-blockers, ACE inhibitors, and mineralocorticoid 
receptor antagonists) 
4. cardiac resynchronisation therapy (CRT), implantable cardioverter device 
(ICD) or cardiac resynchronisation therapy defibrillator (CRT-D) (if 
indicated) 
5. evidence of poor prognosis such as 
a. Cardio-Pulmonary Exercise Testing (CPET) 
i. VO2 max <12 ml/kg/ min if on β-blockade, <14 ml/kg/min if 
not on β-blockade with respiratory exchange ratio ≥1.05  
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b. Markedly elevated brain natriuretic peptide (BNP) or N-terminal 
pro-brain natriuretic peptide (NT-proBNP)) serum levels despite 
optimal medical treatment,  
c. prognostic scoring systems such as the heart failure survival score 
(HFSS) or Seattle heart failure model (SHFM)  
6. Other indications outside the above 
a. Persistent haemodynamically compromising ventricular arrhythmias 
refractory to all usual therapy 
b. refractory angina with evidence of recurrent significant myocardial 
ischemia not amenable to conventional treatment,  
c. restrictive and hypertrophic cardiomyopathy with persisting NYHA 
III or IV symptoms refractory to conventional treatment and/or 
recurrent admissions with decompensated HF. (Aetiology should be 
clearly identified to ascertain the presence of systemic disease and 
the risk for recurrence following transplantation (Banner et al. 
2011) 
ISHLT guidelines from 2016 differ slightly from the UK guidelines (Mehra et al. 
2016). It discourages listing patients solely based on cardiopulmonary stress test 
results or on heart failure survival scores, although it notes that combining both 
measures provides an important prognostic benefit. Given the large proportion 
of LVADs in North America, it also calls for a re-evaluation of haemodynamics in 
the bridge-to-candidacy patients to evaluate reversibility of elevated pulmonary 
pressures. It also highlights the need for frailty assessment by 3 of 5 possible of 
the following symptoms 
1. unintentional weight loss of >4.5 kg within the past year 
2. muscle loss 
3. fatigue 
4. slow walking speed 
5. low levels of physical activity 
Patients with significant cognitive impairment should be screened prior to listing 
due to potential issues with compliance to medication. Highly sensitized patients 
should be prioritized for listing due to potential difficulties in obtaining a 
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suitable donor. ISHLT has also removed amyloid heart disease as a 
contraindication to heart transplantation. Chronic infections in the recipient 
such as Human Immunodeficiency Virus (HIV) or hepatitis (B & C) are no longer 
listed as contraindications in the current guidelines (Mehra et al. 2016). 
The current heart allocation systems are managed by NHSBT and the 
Cardiothoracic Advisory Group (CTAG). The ethos of heart allocation is to 
improve survival in selected patients with advanced heart failure prioritising the 
sickest patients at greatest risk of dying while ensuring the risk of 
transplantation is within acceptable limits. This meant that there were 
increasing patients who were transplanted on the urgent listing criteria vs the 
non-urgent listing criteria. In 2013/14, 15% of non-urgent heart patients were 
transplanted within 6 months of listing, compared with 69% transplanted on the 
urgent list. In 2006/7, only 28% of patients on the urgent waiting list were 
transplanted. 
Urgent patients transplanted had a 1-year mortality of 16% compared to non-
urgent patients of 23%, suggesting that urgent transplant outcomes were as good 
as non-urgent transplants (MacGowan et al. 2015). The use of Ventricular Assist 
Devices (VADs) has reduced the number of patients on the urgent waiting list as 
patients who are unable to wait or with less favourable demographics are 
undergoing VAD insertions as opposed to transplants precluding them from 
urgent listing.  
Currently to qualify for the urgent listing is as follows(NHSBT 2017b) 
1) Super Urgent Heart Allocation Scheme (SUHAS) 
a) Patients on short term mechanical circulatory support (MCS)- short-term 
VAD/Extracorporeal membrane oxygenation (ECMO) 
b) a patient meeting criterion for (UHAS) that is not suitable for a long-term 
left VAD. This requires the approval of an arbitration committee 
2) Urgent Heart Allocation Scheme (UHAS) 
a) Patients with an intra-aortic balloon pump; 
b) inpatient dependent on intravenous inotropes. 
c) Adult long-term VAD or TAH patient with one of the following 
complications: 
i) o  Right ventricular failure dependent on inotropes 
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ii) o  Recurrent systemic infection related to VAD/TAH 
iii) Other VAD/TAH issues including recurrent or refractory 
VAD/TAH thrombosis (after agreement by the 
arbitration committee) 
d) Exceptionally sick adult patient with a high risk of dying or having an 
irreversible complication but does not meet urgent listing criteria. (after 
agreement by the arbitration committee)  
e) ACHD arrhythmia patient with refractory arrhythmia (> 1 hospital 
admission over the last 3 months with haemodynamic instability or 
associated with kidney or liver dysfunction 
f) ACHD patients with no option for conventional escalation of therapy. 
Inpatients unsuitable for inotropes and/or VAD with one of the following: 
i)  Bilirubin and transaminases > 2x normal  
ii) Deteriorating renal function (eGFR <50ml/min/1.73m3, or 20% 
reduction from baseline) 
iii) The requirement for dialysis/CVVH for fluid or electrolyte 
management with recurrent admissions (>3 in preceding 3 months) 
with episodes of right heart failure or protein-losing enteropathy 
requiring ascites drainage 
From NHSBT Policy 228//6 
2.3 Donation after Brain Stem Death (DBD) 
Diagnosis of death is a core skill required by medical practitioners in the UK 
(Oram and Murphy 2011). Improvements advanced resuscitation techniques and 
the need for cadaveric organ donation however may pose challenges primarily to 
intensive care staff. The majority of these do present themselves, however, the 
concept of death within the societal context of the distinction between life and 
death can pose a threat.  
In 1967, when Christiaan Barnard carried out the first human heart transplant, 
there were no guidelines for the diagnosis of death of beating heart donors. 
Months later in 1968, the Harvard code of practice set the standard for which 
‘whole brain death’ was defined based on ancillary testing('A definition of 
irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical 
School to Examine the Definition of Brain Death'  1968). The committee agreed 
that withdrawal of life support was possible from patients diagnosed with 
“irreversible coma” or “brain death”. The timing of the report, just months 
after Christiaan Barnard’s feat raised suggestions that this provided the 
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necessary sanctions for organ retrieval and heart transplantation. It was 
therefore legally advised that patients who met the criteria of death via 
ancillary testing were certified dead prior to organ retrieval. These included 
(1) Unreceptivity and Unresponsitivity 
Lack of awareness or responses to externally applied stimuli 
(e.g. Lack of response to intensely painful stimuli-groan, 
withdrawal of limb, quickening of respiration)  
(2) No Movements or Breathing. 
No observed spontaneous muscular movement, respiration or 
response to stimuli. In patients on mechanical ventilatory 
support total absence of spontaneous breathing may be 
established by turning off the respirator for three minutes and 
observing whether there is any effort on the part of the subject 
to breathe (provided plasma carbon dioxide levels are within 
normal limits) 
(3) No reflexes 
Absence of elicitable reflexes. Fixed and dilated pupils 
irresponsive to a direct source of bright light. Negative caloric 
reflexes, no evidence of postural activity (decerebrate or 
decorticate).  
(4) Flat Electroencephalogram (EEG) 
In 1981, the US President’s commission declared that death depended on either 
irreversible cessation of circulatory and respiratory functions or irreversible 
cessation of all functions of the entire brain, leading to the formation of the 
Uniform Declaration of Death Act ('Guidelines for the determination of death. 
Report of the medical consultants on the diagnosis of death to the President's 
Commission for the Study of Ethical Problems in Medicine and Biomedical and 
Behavioral Research'  1981). As cessation of all functions of the brain is 
necessary, any residual electrical and neurohormonal activity in the brain of 
subjects who otherwise met the criteria of death precluded the declaration of 
death. 
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In contrast, the UK Conference of Royal Colleges defined brain death as the 
complete and irreversible loss of function of the brain stem ignoring the 
relevance of residual activity in the upper brain ('Diagnosis of brain death. 
Statement issued by the honorary secretary of the Conference of Medical Royal 
Colleges and their Faculties in the United Kingdom on 11 October 1976'  1976). 
This was based on the work of Mohandas and Chou in 1971 showing that brain 
stem damage was the crucial component of severe brain damage causing 
profound irreversible coma (Mohandas and Chou 1971). The simpler and more 
reliable UK definition is robust and has not evoked similar criticism (Capron 
2001). Currently, the diagnosis of brainstem death (BSD) has to be made by two 
doctors who have been registered for more than five years and are competent in 
the procedure (at least one should be a consultant). Testing should be 
undertaken by the doctors together and must always be performed completely 
and successfully on two occasions in total. Following this, the following 
sequence of events is noted.
 
Figure 2-3 Diagnostic and management algorithm (from A Code of Practice for The 
Diagnosis and Confirmation of Death- Academy of Medical Royal Colleges) 
Identification of Coma 
Clinical evidence of cause of coma 
(possibly supported by neuroimaging, 
neurophysiology, CSF, etc.) 
Exclusion of hypothermia, intoxication, sedative drugs, neuromuscular blocking 
agents, severe electrolyte, acid base or endocrine abnormalities as causative  
Absent Brain-Stem Reflexes  
Absent Motor Response  
Apnoea  
PaCO
2
 > 6.5KPa  
These procedures should be clearly explained to relatives, partners and carers  
CLINICAL DIAGNOSIS OF DEATH  
Yes 
Eligible for Organ Transplant? 
Proceed with Enquiries and Testing 
Prior to Organ Donation 
Prior to Organ Donation 
Disconnect from Ventilator 
Yes No 
Yes 
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2.3.1 Physiology of Brainstem Death 
The number of DBD organ donations has plateaued (NHSBT 2017a). During BSD, 
there is an initial rise in intracranial pressure (ICP) usually as a result of 
intracranial haemorrhage or head injury. There is a progressive mass effect in 
the brain and worsening cerebral ischemia produces venous engorgement and 
brain swelling. This causes a rise in arterial blood pressure to maintain cerebral 
perfusion pressure resulting in a vicious positive feedback mechanism. The 
continued rise of ICP causes herniation of the brain through the foramen 
magnum (Smith 2004). This results in pontine ischaemia and a hyperadrenergic 
response with a catecholamine storm. The increased systemic vascular 
resistance and pulmonary hypertension increases the afterload of both ventricles 
resulting in myocardial ischaemia. A Cushing’s reflex is noted in a third of 
patients by a combination of hypertension and baroreceptor and midbrain 
activation of the parasympathetic nervous system causing bradycardia (Gordon 
and McKinlay 2012). This progresses to the lower end of the medulla causing the 
vagal and cardiomotor nuclei to become ischaemic, resulting in unopposed 
sympathetic stimulation (Smith 2004). 
Experiments in canine models recreating brain stem death have shown that 
during the catecholamine storm, circulating dopamine, adrenaline, and 
noradrenaline concentrations increased by almost 10-fold (Shivalkar et al. 1993; 
Chen et al. 1996). This is accompanied by unopposed vasoconstriction, thereby 
increasing myocardial oxygen demand. Coronary vasoconstriction also occurs, 
causing potentially causing sub-endocardial ischemia. The mismatch between 
myocardial oxygen demand and supply is associated with the initial impairment 
seen in BSD donors (Mikhova et al. 2013). It causes ventricular systolic 
dysfunction in even previously healthy young hearts devoid of any coronary 
vascular disease. 
At the cellular level, animal models have shown BSD induces myocytolysis, 
contraction band necrosis, subendocardial haemorrhage, cell oedema and 
infiltration of mononuclear cells (Shivalkar et al. 1993). Catecholamines also 
induce increases in cytosolic calcium, causing impaired adenosine triphosphate 
(ATP) production. Impaired ATP production causes an increase in free radical 
formation, which directly causes cellular damage (Singal et al. 1998). 
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This phenomenon is similar to Takotsubo cardiomyopathy or stress-induced 
cardiomyopathy (Ako et al. 2006). In a case series by Ako et al, they noted a 
predominantly female patient cohort, presenting with a variety of ST-T segment 
changes and mildly elevated cardiac enzymes that mimic acute coronary 
syndrome. The LV dysfunction, characteristic of Takotsubo cardiomyopathy 
showed a hyperkinetic basal region and akinetic apical half of the ventricle, in 
the absence of CAD which resolved within weeks with a generally favourable 
prognosis.  
The catecholamine surge is a common pathway in both pathologies noted above. 
Coronary vasospasm and subsequent myocardial stunning are believed to be an 
essential pathogenic factor. It does, however, differ from Prinzmental’s angina 
as angiography findings are invariably normal. There is a role of adrenergic 
receptor blockade in treating Takotsubo cardiomyopathy and LVSD in DBD 
donors. Whether this LVSD in DBD donors is transient and therefore likely to 
recover is of interest for organ transplantation, as up to 20% of hearts were 
rejected for poor function (Liou et al. 2017). There have been numerous studies 
reporting good outcomes in recipients from young donors with poor LV function 
(Berman et al. 2010; Rao et al. 2015; Madan et al. 2017). 
Myocardial injury after BSD is common with one study reporting up to 90% of 
patients with evidence of contraction band necrosis (Baroldi et al. 1997). BSD 
studies in the rabbit model also show changes in myocardial gene expression 
(Yeh et al. 2002). After the sympathetic storm, (usually<15 minutes) depletion 
of catecholamines occurs. This is followed by a rapid loss of sympathetic tone 
and loss of peripheral vasomotor activity (Zens et al. 2017). The net result is a 
negatively inotropic environment with a low systemic vascular resistance causing 
profound hypotension, affecting myocardial perfusion as well as other end-organ 
functions.  
Anti-diuretic hormone (ADH)/Arginine Vasopressin (AVP) depletion is common 
post BSD, although the exact mechanism of not well understood. AVP is secreted 
by the supraoptic nucleus located within the magnocellular neurons of the 
hypothalamus. These osmoreceptors are sensitive to changes in the osmotic 
pressure of their extracellular environment (Leng et al. 1999). Excitatory 
glutamatergic input from circumventricular areas, particularly the organum 
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vasculosum of the lamina terminalis is involved in AVP secretion (Leng et al. 
1999).  
It was previously thought that the direct anatomical compression during coning 
may affect the posterior pituitary function. The inferior hypophyseal arteries 
supplying the posterior pituitary region, however, originate from extradural 
segments of the internal carotid arteries, therefore protected from increased 
intracranial pressure (Leclercq and Grisoli 1983). Autopsy studies have shown 
intact regions of the hypothalamus with relatively well-preserved neurons in 
patients with BSD refuting the anatomical compression theory (Walker et al. 
1975; Wijdicks and Pfeifer 2008). One possible explanation is passive leakage of 
AVP from axonal terminals of ischaemic non-viable hypothalamic cells whose 
perikarya have been destroyed. This explains why some patients exhibit anuria 
prior to a polyuric phase (Michael et al. 2014). 
Electrocardiogram (ECG) changes are also commonly seen in BSD donors. ST-
segment changes, T-wave inversions, and arrhythmias are not uncommon(Smith 
2004; Zens et al. 2017). They may reflect ongoing myocardial ischaemia, 
electrolyte imbalances or iatrogenically caused by the administration of 
inotropes. These patients may undergo asystolic cardiac arrest if unsupported. 
Less than 29% of hearts from donors who underwent aggressive cardiopulmonary 
resuscitation were transplantable in one study (Quader et al. 2014). 
Conventional measures to correct haemodynamic instability in these patients 
may worsen the myocardial injury. Excessive inotropic use has also been 
associated with increased myocardial injury in these donors. Around a quarter of 
potential donors may die prior to organ retrieval on maximal conventional 
support (Mackersie et al. 1991). Figure 2-4 highlights the potential factors that 
may result in the loss of a potential BSD donor. 
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Figure 2-4 Factors contributing to haemodynamic instability in the potential organ donor. 
2.3.2 Role of the SNOD 
The regional SNODs are notified if there is a potential DBD donor prior to formal 
tests. The patient is then allocated a specific SNOD. His/her initial task is to 
identify if the patient is on the donor register. The next of kin is also 
approached and given information regarding the organ donation process and the 
families' wishes as well. This process may also be done by medical staff. Data 
from NHSBT however, is suggestive that the presence of the SNOD is significantly 
associated with consent(Vincent and Logan 2012). 
Once consent has been obtained, the SNOD performs a clinical assessment in 
accordance with the Core Donor Data form designed by NHSBT. It contains 
demographic data, clinical findings, and investigation results and is accompanied 
by the collection of blood samples for tissue typing. This data is then relayed to 
all of the transplant centres nationally via an online database called the Organ 
Donation and Transplantation Electronic Offering System (EOS). The sequence of 
this process is determined by the waiting list prioritisation as mentioned in 2.2. 
Recipient transplant centres then decide on whether to provisionally accept or 
decline the donor heart before inspection. This decision is subjective as it is 
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made based on the history of the donor alongside demographic, geographic and 
tissue typing results. If the donor heart is declined by all centres at this stage, 
the cardiothoracic organ retrieval team is not mobilised. 
2.3.3 The SCOUT Project 
Some centres may elect to send a member of the retrieval team to optimise the 
heart prior to mobilising the team. The SCOUT project was piloted to increase 
the number of heart transplantations by increasing the number and quality of 
hearts procured.  
 
 
Figure 2-5 Use of organs from DBD donors in 2016-17 (numbers are organs transplanted as 
a % of total actual organ donors) Source: NHSBT - https://www.odt.nhs.uk/deceased-
donation/best-practice-guidance/donor-optimisation/ 
The traditional model as detailed above lacks information and expertise in 
cardiovascular management for the average/marginal donor in ICUs across the 
UK. It was based on the premise that transplant centres would receive more 
detailed information regarding the function of the heart and if the donor was 
optimised to reduce myocardial damage induced by brainstem death. 
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Trained personnel from the transplant centre are sent to the donor ICU within 2 
hours of road travel as soon as a potential heart donor becomes available. The 
Scout performs serial diagnostic and therapeutic procedures, including 
transoesophageal echocardiography, right heart catheterisation with a Swan-
Ganz catheter and manages the titration of vasopressors, inotropes, and fluid 
resuscitation. Hormone replacement is also advocated if appropriate by the 
Scout. Early donor management was previously performed on an ad hoc basis 
prior to the centralisation of services as part of NORS. The current SCOUT 
project was designed as a feasibility study with a planned prospective trial soon 
after.  
The feasibility study encountered limitations in data collecting and in scientific 
study design due to its retrospective nature and ad hoc basis of early donor 
management.  
In previous iterations, the Scout project had shown promising results in 
increasing the yield of both heart and lung retrievals (Venkateswaran et al. 
2008; Abuanzeh et al. 2015). Scouts initiated infusion of triiodothyronine(T3) in 
depleted donors (as a consequence of endocrinopathy of BSD in keeping with sick 
euthyroid) (Macdonald et al. 2012). Insulin and methylprednisolone infusions are 
also initiated to counteract the inflammatory process and hyperglycaemia that 
occurs post-brain death due to a drop in mentioned hormones levels (as 
elaborated in section 2.3.1). ADH/AVP depletion is commonly seen in BSD, hence 
the role of vasopressin in donor management instead of noradrenaline due to its 
potentially detrimental effects on myocardial function. Intravenous fluids and 
diuretic therapy are guided by the central venous pressure and urine output. 
There is also a lower threshold to administer blood transfusions to these 
potential donors as anaemia may temporarily be obscured by the 
haemoconcentration of neurogenic pulmonary oedema. 
The profound drop in systemic vascular resistance after catecholamine depletion 
can also be misleading. To ensure accurate myocardial contractility and 
function, a donor practitioner will attempt to achieve a cardiac index >2.5 
l/min/m2, central venous pressure and pulmonary capillary wedge pressure <12 
mmHg, mean arterial pressure between 65 and 85 mmHg, with a systemic 
vascular resistance from 800 to 1200 dyn/cm/s (Abuanzeh et al. 2015). The 
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preliminary findings of the Scout project showed a shorter mean duration 
between donor arrival in the operating room and skin incision compared to the 
non-scouted group. Donor hearts were also twice as likely to be accepted for 
transplantation in the scouted group (Barbero et al. 2017)  
Currently, the Scout project has not been implemented across all the centres as 
it remains unfunded. Measures are currently being undertaken by NHSBT and 
CTAG to train potential scouts and allocate funding for this project.  
2.3.4 DBD retrieval 
Patient data is relayed to the transplant centres nationally in a sequence as 
shown in Figure 2-6. If the heart is accepted by one or more centres the regional 
NORS team on call is mobilised. The SNOD is present through the retrieval 
process and serves as the intermediary between the different organ retrieval 
teams as well as the recipient centres. The SNOD also serves as an advocate for 
the donor’s family’s wishes and ensures the relevant documentation is 
accurately completed.  
A multi-organ retrieval takes place in the Donor Hospital as soon as possible 
after the offer has been received and accepted. The cardiothoracic retrieval 
team consists of, a suitably trained cardiac surgeon, a surgical assistant, a scrub 
nurse, and donor perfusionist. This team is supported by an anaesthetist, 
circulating theatre nursing staff from the donor hospital. Further, a separate 
liver, kidney, and pancreas transplant team will usually attend depending on 
which organs are being retrieved. This makes the process a multidisciplinary 
team exercise(NHSBT 2017c). 
The cardiothoracic retrieval teams mobilise with their own equipment and 
sterile instruments including; organ storage bags and ice cool box containing all 
necessary perfusion fluids, blood bottles and specimen pots (for spleen and 
lymph nodes), drugs (antibiotics, steroids, and other relevant drugs), Invasive 
monitoring equipment (e.g. Swan Ganz Catheter), bronchoscopy, paperwork to 
document the cardiovascular and respiratory parameters during assessment and 
operation findings and procedure to travel with the organ to the recipient 
centre.  
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Figure 2-6 Allocation for an adult donor heart.  
From NHSBT (http://odt.nhs.uk/pdf/heart_allocation_policy.pdf) 
On arrival at the donor site, the cardiothoracic retrieval team contacts the 
SNOD, reviews the notes, investigations (including brain stem death testing) and 
consent. On arrival of the abdominal retrieval team, a discussion of the surgical 
strategies for each team is undertaken. This step is crucial especially as the 
anaesthetist and staff at the donor hospital may be inexperienced in the process 
of organ retrieval which requires careful coordination. Special requests are also 
noted during this period (e.g. the use of the Organ Care Systemtm, the dose of 
2 The process of heart transplantation 91 
 
heparin, required length of Inferior Vena Cava for liver surgeons and venting of 
perfusion fluid). The anaesthetic requirements are also entailed by the retrieval 
teams. This includes correcting haemodynamic stability (boluses inotropes may 
be contraindicated if ex vivo perfusion of organs is done), gas exchange 
parameters for calibration of continuous cardiac output, lung compliance, 
amount of tracheal suction, blood testing/results, and blood loss and colloid 
replacement, alongside the administration of prophylactic antibiotics and 
steroids. 
The donor is then transferred to the theatre for an initial assessment by the 
cardiothoracic retrieval team. Pulmonary artery catheterisation and TOE are 
performed where able. Currently, pre-retrieval TOEs are not offered by all 
retrieval teams. The results are relayed back to the recipient centre for further 
instructions or to synchronise the explantation process which may be prolonged 
in a donor on Mechanical Circulatory Support. If the organ is declined at this 
point, it is then offered to the next recipient centre according to Figure 2-6 once 
again. This process may delay the retrieval process and thereby affect the 
function of the other organs, thus careful communication with the abdominal 
team is vital.  
2.3.4.1 Warm Phase 
If the organ is accepted, the donor is prepped and draped. The surgical pause is 
also performed as part of the WHO safety checklist. The knife-to-skin time is 
noted and the warm phase of the organ retrieval process begins. The cardiac 
surgeon performs a sternotomy and opens the pericardium vertically from the 
diaphragm to its inflection at the ascending aorta or arch. Stay sutures are 
placed into the pericardium bilaterally to create a pericardial well (Camp 2010). 
This also prevents the expanding lungs from obscuring the surgeon’s view. The 
heart is visually inspected for function, chamber distension, coronary 
calcification, myocardial contusions, and other anatomic variations. 
Communication with the anaesthetist is vital as any cardiac manipulation may 
compromise cardiac output and cause haemodynamic instability which resolves 
on resting the heart in its anatomical position. Palpation of the coronaries is also 
done to assess subclinical coronary artery disease. Handling the heart may cause 
atrial fibrillation, thus internal defibrillator pads and a defibrillator should be 
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accessible at all times. The cardiac retrieval surgeon mobilizes the aorta from 
the main pulmonary artery. Care is taken during mobilization proximally into the 
root to avoid injury to the coronary arteries. The brachiocephalic vein is 
mobilized off the arch if needed. If concomitant lung retrieval is performed, the 
rest of the arch is dissected and the pulmonary artery mobilised to the 
bifurcation. Once complete, the surgeon isolates the aorta, superior vena cava, 
inferior vena cava using a combination of umbilical tape or vessel sloops. This is 
in preparation for the cold phase. At this point, the final readings of the cardiac 
output monitor are relayed to the recipient centre. 
Once the recipient is in theatre the surgeon should be able to advise an 
approximate time for cross-clamp application. The abdominal dissection usually 
takes slightly longer depending on the number of organs harvested. The 
recipient centre will also advise on the preferred length of atrial cuff especially 
if both the heart and lungs are harvested.  
At this phase, the anaesthetist withdraws the central lines from the patient. This 
includes the Swan Ganz catheter/pulmonary artery catheter (PAC) introduced 
and the central line that may have been inserted in the right internal jugular 
vein.  
Prior to the cold phase commencing, sloops and umbilical tape should be in 
place. The azygous vein should also be identified and either tied off or clamped. 
Perfusion fluid should be prepared with the lines de-aired and passed to the 
surgeon or assistant. In the UK, the perfusion fluid of choice is primarily St 
Thomas’s Solution with one centre using Custodiol® HTK (Histidine-Tryptophan-
Ketoglutarate).  
The volume of perfusion fluid to be administered is calculated based on the 
patient’s body weight. Purse-string sutures are placed into the anterior 
ascending aorta prior to the systemic heparinization of the patient. The 
perfusion cannula is placed into the aorta as shown in Figure 2-7. 
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Figure 2-7 Heart in preparation for the cold phase with the aortic cannula in place, SVC and 
IVC clamped.  Prostaglandin (PGE1) may be administered if concomitant lung retrieval is 
performed. With permission from ‘Heart Transplantation: Donor Operation for Heart and Lung 
Transplantation. Operative Techniques in Thoracic and Cardiovascular Surgery, 15, 125-137. 
(Camp 2010)’ 
2.3.4.2 Cold Phase 
The heart is lifted out of the pericardium to expose the inferior aspect of the 
left atrium. The surgeon then performs a posterior left atriotomy, where a 
suction catheter is placed for when the cardioplegia is flushed. The IVC is also 
cut at this point to allow a healthy cuff for the abdominal retrieval team. This 
causes the heart to be released back into the pericardium. The aortic cross-
clamp is applied to the distal ascending aorta. Cold Cardioplegia (approximately 
4⁰C) is delivered via the aortic root to the coronary arteries at a consistent 
pressure of around 150 mmHg by using a pressure bag. Topical cold saline or 
slush is also used for myocardial protection. If the flow of cardioplegia is 
sluggish, the perfusionist reports this back to the surgeon who checks the 
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position of the aortic cannula and aortic root pressure. Once cardioplegia 
administration is complete, the cardiectomy is completed. The aorta, SVC, right 
atrium, and left atrium are divided and the heart is then on the back table.
 
Figure 2-8 Left atriotomy prior to cardioplegia administration  (heart lifted). With permission 
from ‘Heart Transplantation: Donor Operation for Heart and Lung Transplantation. Operative 
Techniques in Thoracic and Cardiovascular Surgery, 15, 125-137. (Camp 2010)’ 
This step allows direct visualisation of the valves and interatrial septum for 
patent foramen ovale.  The heart is brought to the back table where all the 
valves are carefully examined. Patent foramen ovale is ruled out or fixed and 
any additional surgical issues or anatomic findings are noted.  
2.3.4.3 Standard cold storage 
The heart is then packed in 3 organ storage bags, each filled with cold saline, 
before being packed in ice. A sample of lymph nodes and spleen is also supplied 
alongside the necessary paperwork from the SNOD. This is then sent to the 
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transporter to the recipient centre. The ischaemic time for a heart in cold 
storage should not exceed 4 hours. 
2.3.4.4 Normothermic Ex-vivo Perfusion (Organ Care Systemtm) 
Prior to the cold phase, approximately 1.5 litres of donor blood is removed to 
prime the console. To facilitate this, the patient is placed in a Trendelenburg 
position.  
Instead of placing the heart in organ storage bags, the aorta is secured using the 
supplied cable ties and aortic tip cannula. Pledgeted sutures are sometimes used 
to prevent the aortic tip cannula from slipping. 
 
Figure 2-9 Application of supplied cable ties to aortic tip cannula for OCS retrieval. 
With permission from ‘Organ Care System for Heart Procurement and Strategies to Reduce 
Primary Graft Failure After Heart Transplant. Operative Techniques in Thoracic and Cardiovascular 
Surgery, 20, 322-334. (Tsukashita and Naka 2015)’ 
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The pulmonary artery cannula is secured with purse-string sutures around the PA 
stump and an umbilical tie. The SVC is tied off.
 
Figure 2-10 a) PA cannula inserted into PA stump b) Umbilical tie to secure PA cannula 
With permission from ‘Organ Care System for Heart Procurement and Strategies to Reduce 
Primary Graft Failure After Heart Transplant. Operative Techniques in Thoracic and Cardiovascular 
Surgery, 20, 322-334. (Tsukashita and Naka 2015)’ 
The heart is then placed on the console. Care is taken to reduce the flow of the 
console to permit the connection of the aortic tip cannula without any air being 
introduced into the circuit. The heart is placed with its posterior surface facing 
the surgeon with the IVC oversewn (Figure 2-11).  
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Figure 2-11 Placement of the heart on the OCS console(left). IVC oversewn (right) 
With permission from ‘Organ Care System for Heart Procurement and Strategies to Reduce 
Primary Graft Failure After Heart Transplant. Operative Techniques in Thoracic and Cardiovascular 
Surgery, 20, 322-334. (Tsukashita and Naka 2015)’ 
The heart is massaged to de-air the PA cannula. If the heart does not 
spontaneously contract, the attached defibrillator pads are aligned to the RA 
and the LV and a shock is delivered. The heart is kept at 34oC and transported to 
the recipient site with interval sampling of blood to assess electrolytes, lactates, 
and acid-base balance. The flow can be remotely controlled via the console 
attachment. Epicardial pacing wires can also be attached to the surface of the 
right ventricle is pacing is required. 
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2.4 Donation after Circulatory Death (DCD) 
Christiaan Barnard’s pioneering work in 1967 utilised a heart after circulatory 
death as regulations regarding brainstem death had not been established. Once 
the criteria for declaring brainstem death was formed, the brain-dead patient 
became the ideal multiorgan donor for organ transplantation. Conditions that 
result in BSD are limited. In a review of 71 published series of brain dead 
patients (n=6317) subarachnoid haemorrhage (SAH), traumatic brain injury (TBI), 
or spontaneous intracerebral haemorrhage (ICH) caused BSD in 83% of 
patients(Kompanje et al. 2011). The number of DBD donors has plateaued over 
the years with referral rates reaching well above 90%. 
 
Figure 2-12 Referral rate for DBD vs DCD organ donations. Source: NHSBT 
In DBD donors, the warm ischaemia and anaerobic metabolism were kept to a 
minimum, unlike DCD donors.  
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There are 4 categories of donation after circulatory death as defined by the 
Modified Maastricht Criteria. 
I dead on arrival and have not been resuscitated 
II unsuccessfully resuscitated 
III typical controlled DCD, with planned cardiac arrest 
IV planned donations following brain death (DBD) that suddenly arrest during or after 
the brain death determination. 
Table 2-1 Modified Maastricht Classification of Donation after Circulatory Death 
With permission from ‘An overview of different methods of myocardial protection currently 
employed peri-transplantation’. Vessel Plus; Vol 1, No 4 (2017)(Singh et al. 2017) 
Patients are declared ‘dead by cardiorespiratory criteria following guidance from 
the Association of Medical Royal Colleges' (AoRMC 2016). Death can be diagnosed 
and confirmed after 5 minutes of continuous asystole usually by ECG and intra-
arterial pressure monitoring. Echocardiography can be used as an alternative to 
determining the absence of pulsatility. Any return of cardiac or respiratory 
function necessitates a further observation period. After 5 minutes, the clinician 
confirms the absence of pupillary reaction and motor response to corneal 
stimulation and supra-orbital pressure, prior to recording the time of death 
(Manara et al. 2012). 
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Figure 2-13 The clinical pathway for controlled DCD.  
Adapted from Organ and Tissue Donation after Death, for Transplantation. Guidelines for Ethical 
Practice for Health Professionals 2007 Australian Government, National Health and Medical 
Research Council http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/e75.pdf 
Warm ischaemic time in DCD donation begins at the onset of asystolic arrest. It 
comprises of an agonal phase commencing either from the withdrawal of life 
support or more conventionally when the systolic blood pressure drops to below 
50mmHg until the cessation of circulation (Iyer et al. 2016). The donor is then 
transferred to the operating theatre whereby the aorta and IVC are immediately 
cannulated on laparotomy with cold perfusion initiated. Organ hypoperfusion 
and ischaemia may occur long before the onset of asystole, thereby prolonging 
the true functional warm ischaemic time (Watson and Dark 2012). Functional 
warm ischaemic time has the same variable start point ends with the infusion of 
cardioplegia in the donor. This process brings about profound 
hypoxia/hypoxemia with vasoconstriction and a catecholamine storm which may 
cause right ventricular dysfunction (Iyer et al. 2016). Once life-sustaining 
treatment has been withdrawn a stand-down time for the retrieval team of two 
hours from the time of withdrawal of treatment to death is common although 
protocols may vary slightly (AoRMC 2016).  
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Up to 2008, DCD donor organs retrieved included kidneys, pancreases, livers, and 
lungs. There was an increased incidence of acute tubular necrosis and delay in 
graft function in kidneys, necessitating post-transplant dialysis in up to 50% of 
the patients (Watson and Dark 2012). There was a higher incidence of primary 
non-function, anastomotic and intrahepatic biliary strictures and re-
transplantations in livers transplanted from DCD donors with poorer overall 
survival. However, the survival of these patients was still higher than patients on 
the waiting list (Merion et al. 2006). DCD donor pancreases had a higher 
incidence of graft thrombosis (Johnson et al. 2014). 
Lungs from DCD donors showed equivalent function from standard DBD donors. 
The lungs are inflated during DCD organ donation and thus a unique tolerance of 
the absence of a circulation(Dark 2008). Another reason for this may be the 
absence of the mentioned ‘catecholamine storm’. 
DCD heart transplantation was first attempted in animal models. Gundry et al 
conducted an anoxic arrest model using juvenile baboons to mimic the ICU 
setting of withdrawal of treatment. After a period of asystolic (varying from 15- 
31 minutes, the hearts were implanted in an orthotopic position with 
encouraging haemodynamic parameters. Pathological studies revealed no fibrosis 
or ischaemic damage in all subjects (Gundry et al. 1995). In 2008, the paediatric 
heart transplant team in Denver reported a series of 3 successful DCD heart 
transplantations. They performed this by administering pre-withdrawal 
heparinisation and insertion of femoral cannulae. An observation period of 3 
minutes was used for the first donor prior to the commencement of organ 
retrieval. The patient was cooled using the administration of perfusion fluid via 
the femoral cannulae and topical slush after the sternotomy was performed. The 
observation time was shortened to 1.25 minutes on the recommendation of the 
Ethics committee after the first recipient required mechanical circulatory 
support post-operatively by means of ECMO. While the other two patients 
recovered well (Boucek et al. 2008). Although successful, this format of donation 
was only feasible for short ischaemic times. 
To develop a strategy that was feasible for the safe use of DCD hearts, three 
issues were identified. First, a method to attenuate the effects of warm 
ischaemia had to be developed to ensure DCD hearts did not require recipient 
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and donor colocation as with the Denver paediatric experience or Christiaan 
Barnard’s first operation (Dhital et al. 2017). Pharmacological intervention in 
the patient prior to the declaration of death is prohibited, so pre-conditioning of 
the heart in this period was not permissible. This prevented any mitigation of 
the effects of warm ischaemic, particularly ischaemic-reperfusion injury. Thus, 
the following option is to develop a post-conditioning ‘cocktail’ preferably with 
the cardioprotective solution. Some animal models have shown benefit in 
normokalaemic solutions after cold storage (Rudd and Dobson 2011). Other 
studies have shown benefit but adding an array of post-conditioning agents to 
standard cardioplegic solutions during the administration of cardioplegia. This 
includes sodium-hydrogen inhibitor cariporide (HOE 642) (Scheule et al. 2003), 
MCI-186, a free-radical scavenger and antioxidant by means of lipid peroxidation 
(Kotani et al. 2007), p38 mitogen-activated protein kinase (MAPK) inhibitor 
(Koike et al. 2004), erythropoietin, glyceryl trinitrate and zoniporide (Cs) (Iyer 
et al. 2014a). The second obstacle to DCD hearts is donor organ preservation, 
and the third obstacle was to evaluate the function of the heart prior to 
implantation (post-warm-ischaemic insult). Cold storage would expose the heart 
to two separate bouts of ischaemic reperfusion injury. Ex-vivo perfusion of the 
heart had already been introduced by Barnard’s team in 1984  (Wicomb et al. 
1984). They devised a portable hypothermic perfusion system and trialed it in 4 
patients. Perhaps ahead of its time, its outcomes which were similar to cold 
storage preservation did not support the routine use of ex-vivo perfusion. A 
group in Australia tested the anoxic arrest animal model on greyhounds using 
cold storage and normothermic ex-vivo perfusion (Repse et al. 2010). They 
concluded that a strategy of pre-reperfusion cardioplegia, followed by 
continuous warm blood perfusion, is superior to cold storage. This was 
reproducible in other studies showing continuous perfusion replenished 
myocardial energy stores, reduced the impact of ischaemic reperfusion injury 
and improved cardiac recovery in animal models(White et al. 2013)and unused 
human hearts ((Iyer et al. 2014b; Rosenfeldt et al. 2014). The use of ex-vivo 
perfusion devices also ensured the heart could be assessed prior to implantation. 
To facilitate this, the Organ Care Systemtm (TransMedics Inc, Andover, MA, USA) 
was used. As described in 2.3.4.4, it was intended for use in DBD hearts and via 
its non-inferiority trial PROCEED II (Ardehali et al. 2015). 
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In 2015, the heart transplant team at St Vincent’s Hospital in Australia presented 
their data on the first series of successful DCD heart transplantations using 
normothermic ex vivo perfusion (Dhital et al. 2015). Australian law currently 
does not permit extracorporeal support to restart the circulation in the donor 
whose very death was declared on the basis of the cessation of circulation in the 
absence of certifiable brain death (Dhital et al. 2017). They, therefore, 
employed a technique called direct procurement and perfusion (DPP). After the 
end of the observation period, the patient was taken into the operation theatre 
and intubated. A venous cannula was placed in the atrium to drain 1.5L of donor 
blood into a pre-heparinised bag for priming of the OCS machine. The retrieval 
process from here onwards follows the cold phase as described in 2.3.4.2. In 
addition to St Thomas’s cardioplegia, erythropoietin and glyceryl trinitrate were 
also delivered to the aortic root. The heart was placed on the OCS rig as 
described in 2.3.4.4. Serially samples of lactate concentrations of the perfusate 
were measured using a point of care analyser (iSTAT analyser (Abbott; 
Princeton, NJ, USA) with lactate concentration of <5 mmol/L in the perfusate 
combined with myocardial lactate extraction (coronary inflow lactate>coronary 
effluent lactate) was considered evidence of myocardial viability (Dhital et al. 
2015). The implantation of the heart will be covered in 2.5. 
Another method of retrieval was developed by the team at Papworth Hospital 
coined normothermic regional perfusion (NRP). After declaration of death and 
median sternotomy, a 30,000-unit heparin intracardiac injection was 
administered. They then clamped off the branches of the aortic arch 
(brachiocephalic artery, left common carotid and left subclavian), thereby 
excluding cerebral circulation as per the guidance of AoRMC (AoRMC 2016). The 
ascending aorta and right atrium were cannulated and connected to a makeshift 
ECMO circuit consisting of a centrifugal pump and an oxygenator. NRP was 
commenced to maintain a mean arterial pressure of 50mmHg with a flow of 
5L/min at a temperature of ≥ 35°C (Messer et al. 2016). This in effect restored 
circulation to the cardiothoracic and abdominal organs for transplant while 
excluding the limbs, pelvis, head, and neck. This allowed them to functionally 
assess the heart using a PAC and TOE. Once satisfactory, 500mls of St Thomas’s 
cardioplegia was administered and the heart was placed on the OCS rig as 
described in 2.3.4.4. 
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The rationale for NRP over DPP was based on the biochemical findings at the 
time of retrieval. Following circulatory death, the donor blood becomes 
hyperkalaemic, hyperglycaemic, hypoxic, hypercarbic and acidotic with 
circulating inflammatory markers and catecholamines (Messer and Large 2016). 
This environment may result in poor function of the heart. When transferred to 
the OCS rig, the heart is reliant on the right ventricle (RV) pumping perfusate 
through an oxygenator. In RV failure, this will result in ongoing accumulating 
hypoxia resulting in ischaemic damage or failure. 
In a matched cohort study (NRP vs DPP), despite differences in donation 
withdrawal ischemic time, functional warm ischemic time, OCS perfusion time 
and implant duration time (all shorter for the NRP cohort) no differences were 
noted in patient outcomes post-transplant(Messer et al. 2017). 
2.5 The Implantation 
Preoperative preparation is of paramount importance for the implanting 
surgeon. More patients are presenting with LVADs, previous sternotomies, 
complex congenital surgeries; all of which necessitate careful and diligent 
dissection. Cannulation strategies, communication with the retrieval team and 
correction of anticoagulation should all be planned accordingly. In patients with 
multiple sternotomies, femoral vessels should be exposed in case of injury to the 
heart on re-sternotomy. 
The current aim is to limit the total ischaemic time to <4 hours especially when 
marginal hearts are utilised. The recipient coordinator serves as the liaison in a 
similar way the SNOD serves as the donor coordinator. Factors to note in 
particular include the estimated time for inserting monitoring lines and PAC, 
dissection of the recipient prior to cross-clamp application on the donor, the 
estimated transport time while communicating with the family of the recipient.  
2.5.1 Surgical techniques 
Shumway and Lower first introduced the biatrial anastomosis technique of heart 
implantation, based on Cass and Brock’s animal experimentations as described in 
Chapter 1. This was adopted worldwide as the ‘standard’ technique due to its 
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reproducibility. Several studies, however, have shown the lack of a physiological 
geometry between donor and recipient atrium resulting in atrial dilatation. A 
sequela of this includes arrhythmias and secondary atrioventricular valvular 
incompetence, especially in the tricuspid region (Schnoor et al. 2007). Yacoub 
and Dreyfus (Yacoub et al. 1990; Dreyfus et al. 1991) clinically used a technique 
known as total orthotopic heart transplantation based on the descriptions of 
Webb and Neely (Webb et al. 1959). This involved complete excision of the 
recipient atria and transplantation of the complete atria and ventricles with 
separate bicaval and pulmonary vein anastomosis. This method, however, was 
associated with longer operating times due to the 6 anastomoses needed and 
bleeding from posterior segments of the pulmonary veins. It was also prone to 
anastomotic stenosis in the pulmonary veins (Morgan and Edwards 2005). 
The bicaval was first described in 1989 by Yacoub and Banner and later Sievers 
in 1991(Yacoub and Banner 1989; Sievers et al. 1991). This was the first 
approach to bicaval anastomosis with end-to-end anastomoses both cavae. 
Proponents of this method argue there is a lesser incidence of tricuspid 
regurgitation and maintained the geometry of the right to preserve its 
contractility and sinus node function. These advantages provided potentially 
conferred better haemodynamics. However, overall survival was similar to the 
standard method in all studies to date (Schnoor et al. 2007; Czer et al. 2011; 
Fiorelli et al. 2011; Dell'Aquila et al. 2012). The bicaval technique also does not 
alleviate the conduction issues associated with left atrial to atrial anastomosis 
and may potentially have a prolonged ischaemic time with a risk of developing 
stenosis in either cavae. (Morgan and Edwards 2005). 
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2.6 The Recipient Cardiectomy 
 
Figure 2-14 Bicaval cannulation of the recipient heart with snares in both cavae in 
preparation for cardiectomy 
With permission from ‘Orthotopic Heart Transplantation. Operative Techniques in Thoracic and 
Cardiovascular Surgery’,2010, 15, 138-146. (John and Liao 2010) 
A median sternotomy and pericardiotomy are performed to expose both cavae, 
aorta and pulmonary artery. The pericardium is hitched. Aortic cannulation 
should be in the distal ascending aorta with bicaval venous cannulation. 
Cardiopulmonary bypass is instituted once the Activated Clotting Time (ACT) is 
at permissive. The aortic cross-clamp is applied and the caval snares fastened. 
The aorta and pulmonary artery (PA) should be separated so that the interatrial 
sulcus is clearly appreciated. The aorta and PA are divided distal to their 
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semilunar valves. The SVC is transected at the superior entry (cavoatrial 
junction). The right atrium is transected through the coronary sinus ostium and 
extended laterally through the floor of the fossa ovalis, thereby leaving a large 
cuff of IVC (John and Liao 2010). The left atrial cuff is incised through the roof 
of the left atrium to leave behind a generous cuff with all 4 pulmonary vein 
orifices visible. Ideally, the cardiectomy should be performed just before the 
arrival of the donor heart to reduce ischaemic time. Meticulous haemostasis 
should be performed on the view of Figure 2-15 as access to this region becomes 
difficult once the donor heart is anastomosed.  
 
Figure 2-15 View of the structures after cardiectomy 
With permission from ‘Orthotopic Heart Transplantation. Operative Techniques in Thoracic and 
Cardiovascular Surgery’,2010, 15, 138-146. (John and Liao 2010) 
2.7 Implantation 
The donor heart is removed from cold storage/the OCS rig (following 
administration of cardioplegia) and inspected. The donor aorta and donor PA 
should be separated. The left atrium is divided to create a cuff. This is done by 
splaying open each of the 4 pulmonary veins and carefully trimming back excess 
tissue. The donor heart is finally checked for a patent foramen ovale which 
should be repaired prior to implantation.  
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The left atrial anastomosis is performed by using a long non-absorbable 
monofilament suture (e.g. 3-0 Prolene -model DS5526, 135cm). This is usually 
done starting at the left superior pulmonary vein to the left atrial cuff (close to 
the left atrial appendage). For comfort, this can be done with the heart held at 
the sternal edge before it is lowered into the pericardial space(John and Liao 
2010). The posterior suture line should be completed prior to the anterior suture 
line both using the everting suture technique to avoid thrombus formation. The 
two suture lines are left untied to allow introduction of an LV vent for de-airing. 
 
Figure 2-16 Everting sutures in the left atrium with assistant retracting PA to allow 
completion of the anterior suture line 
With permission from ‘Orthotopic Heart Transplantation. Operative Techniques in Thoracic and 
Cardiovascular Surgery’,2010, 15, 138-146. (John and Liao 2010) 
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2.7.1 Biatrial Anastomosis 
For the biatrial technique, the right atrial anastomosis is started from the 
septum and continued laterally using a long non-absorbable monofilament suture 
((3-0 Prolene -model DS5526, 135cm) as demonstrated below. 
 
Figure 2-17 Right atrial anastomosis (medial to lateral) 
With permission from ‘Orthotopic Heart Transplantation. Operative Techniques in Thoracic and 
Cardiovascular Surgery’,2010, 15, 138-146. (John and Liao 2010) 
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2.7.2 Bicaval Anastomosis 
The IVC anastomosis is performed using 3-0 Prolene (or equivalent) with 4-0 
Prolene for the SVC anastomosis. Care should be taken to avoid kinking of the 
SVC or malalignment. This can be avoided by using the donor right atrial 
appendage as a marker to orientate oneself.  
 
Figure 2-18 IVC and SVC anastomosis (posterior suture lines completed) 
With permission from ‘Orthotopic Heart Transplantation. Operative Techniques in Thoracic and 
Cardiovascular Surgery’,2010, 15, 138-146. (John and Liao 2010) 
The final steps of both techniques are PA and aortic closure. The PA is usually 
trimmed to prevent kinking. Both are closed using continuous sutures by 
completing the posterior suture line and then anterior respectively.  
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Figure 2-19 Aortic anastomosis in biatrial (left) and bicaval (right) techniques (posterior 
suture line complete)  
With permission from ‘Orthotopic Heart Transplantation. Operative Techniques in Thoracic and 
Cardiovascular Surgery’,2010, 15, 138-146. (John and Liao 2010) 
2.7.3 Post-operative period 
Intravenous steroids (Methylprednisolone) are administered prior to removal of 
the aortic cross-clamp. The patient is usually also placed in a Trendelenburg 
position and de-airing is commenced. Once the aortic cross-clamp is removed, 
suction is maintained via the aortic root and/or LV vent cannula. The patient is 
kept on bypass during this period of reperfusion and haemostasis is once again 
confirmed. During this reperfusion time, inotropic support is often required. In 
addition, RV support using pulmonary vasodilators have become increasingly 
popular. This includes nitric oxide, inhaled prostaglandins, and even sildenafil. A 
TOE can be used to assess contractility and valvular function, but also to assist 
in de-airing. Pacing wires and mediastinal drains are placed. The patient is then 
weaned off bypass. It is usually at this point that Primary Graft Dysfunction is 
noted or suspected. Sometimes an intra-aortic balloon pump is placed if there 
are signs of poor contractility in an adequately filled heart. This may even 
require escalation to mechanical circulatory support usually in the form of 
ECMO.  
Variations to the implant anastomosis are not uncommon. In order to minimise 
ischaemic times, some centres elect to perform the left atrial anastomosis 
followed by aortic anastomosis to facilitated earlier release of the cross-clamp 
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and reperfusion of the heart, followed by either SVC (bicaval technique) or right 
atrial (biatrial technique) and pulmonary artery anastomosis.  
2.8 Organ Shortage  
Despite the addition of DCD hearts to the longstanding DBD donor cohort, 
deceased human organ donation rates do not currently meet the demand for 
transplantation. Attempts to improve this discrepancy have led to changes in 
legislation such as the ‘Opt-out’ system for organ donation in Wales which came 
into effect on 1 December 2015. The new initiative, under the Human 
Transplantation (Wales) Act, assumes that everybody approves the use of their 
organs after death unless they choose to opt-out. An agreement with the next-
of-kin, however, must still be sought. Scotland is expected to follow this 
direction in the near future. However, the ‘opt-out’ scheme has not resulted in 
a significant increase in the number of organ donations from Wales. (Hawkes 
2017). 
 
DBD DCD 
Quarter England Wales England Wales 
Jan - Mar 16 67.8 83.3 63.9 46.2 
Apr - Jun 16 65.7 75.0 59.9 52.9 
Jul - Sep 16 62.0 78.6 57.7 50.0 
Oct - Dec 16 70.8 75.0 58.8 54.5 
Jan - Mar 17 71.3 81.3 59.0 66.7 
Table 2-2 Percentage deceased donors from England vs Wales since the implementation of 
the ‘Opt-out’ legislation. 
Source: NHSBT Annual Report (2016/2017) 
A potential reason for the lack of a discernible difference is due to the already 
rising number of potential donors prior to the implementation of the legislation. 
Given the high numbers, the number of possible donors left who are deemed 
eligible are too few. Donor fluctuations also suggest that inferring that the act 
has failed may be premature. Despite not reaching statistical significance, the 
standardised test statistic shows an upward trend towards increasing the number 
of donors as demonstrated in Figure 2-20 for DBD and Figure 2-21 for DCD. The 
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upward swing in both quarterly test statistic towards the higher consent rate in 
the Welsh cohort vs the English cohort may be a better determinant of the 
effectiveness of the current legislation. As noted in Table 2-2, there has been a 
steady rise in DCD rates in Wales which is a possible sequela of this change. A 
public survey noted that most Americans were willing to serve as organ donors 
on death but the current system of ‘opt-in’ does not reflect this (Caplan 2014). 
Thus far, countries like France, Austria, Belgium, and Spain, have legislated 
versions of presumed consent with a consequent positive impact on their DBD 
rates (Byk 2009; Neades 2009).  
 
Figure 2-20 Graphical representation of Standardised Test Statistic of Donor Numbers in 
Wales and England for DBD Donations. 
Source: NHSBT annual reports 2016/2017 
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Figure 2-21 Graphical representation of Standardised Test Statistic of Donor Numbers in 
Wales and England for DCD Donations  
Source: NHSBT annual reports 2016/2017  
2.8.1 Marginal/Extended Criteria Donor Usage 
Donor organ shortage, especially for hearts and increasing waiting list 
mortalities, has resulted in marginal donor hearts being used for higher risk 
recipients and critically ill patients. We review the development of two recipient 
lists as a way to provide cardiac transplantation as an option for recipients who 
would be otherwise ineligible and determine its impact on expanding the donor 
pool (Patel and Kobashigawa 2004). Although many studies have demonstrated 
good long-term outcomes with marginal donor heart usage, some have shown 
increased early mortality (Laks et al. 2003; B. Lima et al. 2006; Samsky et al. 
2013; Taghavi et al. 2013; Bombardini et al. 2014; Cheng et al. 2016).  
The marginal donor usually has one or more of the following features. estimated 
ischemia time longer than 4 hours, LVEF less than 50%, previous donor cardiac 
arrest, LV Hypertrophy(LVH) with an interventricular septum in diastole of more 
than 13 mm, history of alcohol/drug abuse, presence of palpable coronary artery 
disease without coronary angiography, diabetes, donor age>50 years, 
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cerebrovascular accident/stroke as the cause of death, history of hypertension, 
high inotrope requirement (dopamine>10 mcg/kg/min) during donor 
management, elevated cardiac troponin, and left ventricular regional wall 
motion abnormalities (Khush et al. 2013; García Sáez et al. 2014). 
The use of marginal hearts with the OCS as demonstrated by Harefield Hospital 
has been associated markedly improved short-term outcomes and transplant 
activity by allowing the use of organs previously not considered suitable for 
transplantation (García Sáez et al. 2014). A UNOS database analysis 
demonstrated recipients of marginal allografts that were discharged later from 
hospital with no significant difference in overall survival (Khush et al. 2013). 
Other studies addressing the differences in outcomes by using diabetic donor 
hearts showed conflicting results. Analysis of the Eurotransplant registry 
revealed donor diabetes was not associated with increased recipient mortality. 
This study was however criticised for only having 41 diabetic donors suggesting a 
potential selection bias and was too small for subgroup analysis(Smits et al. 
2012). Interrogation of the Cardiac Transplant Research Database noted similar 
findings as the Eurotransplant study but highlighted that in a subgroup of male 
donors (n=85), worse outcomes were associated with diabetes(Stehlik et al. 
2010b). Analysis of the UNOS database failed to demonstrate significant 
interactions between diabetic donors and donor age, recipient gender, recipient 
age, or ischemic time even for diabetic donor hearts that were transplanted into 
diabetic recipients (Taghavi et al. 2013). 
The use of marginal organs is currently justified. However, with advances in 
long-term mechanical circulatory support devices, especially LVADs, this issue 
may be revisited. In 2008, a study comparing HeartMate XVE Left Ventricular 
Assist Device (LVAD) (Thoratec Corporation, Pleasanton, CA) vs extended criteria 
cardiac transplantation (ECCT) was performed. They noted patients with the 
LVAD were more unstable, with a greater need for inotropes or mechanical 
support. Despite this, perioperative and 1-year mortality was similar for the two 
groups but better 3-year survival in the ECCT group (Daneshmand et al. 2010). 
Recently, the same group published a similar study comparing outcomes of 
extended criteria cardiac transplantation (ECCT) vs continuous flow destination 
therapy left ventricular assist device (CF DT-LVAD) ( HeartMate II, Thoratec 
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Corp., Pleasanton, California) (Daneshmand et al. 2015). After matching the 
groups, they noted an improved renal function in the CF DT-LVAD cohort but 
with increased hospital readmission rates.  
Currently, Long term LVADs serve as a potential alternative to OHTx. The rates 
of LVAD implantation over the two decades have increased exponentially and 
surpassing the heart transplantation rates for the first time in 2009. In January 
2010, the HeartMate II LVAD was approved for destination therapy with devices 
in development expected to follow suit. With the advancements in technology 
and improving safety profile of devices, the next generation of devices may well 
present a new dilemma for surgeons and physicians alike especially when it 
comes to accepting marginal organs and may even surpass the reference 
standard of heart transplantation. Currently, the index admission costs of VAD 
implantation is more than double OHTx. This was primarily driven by 
procurement costs and length of stay. However, the cost of OHTx surpasses the 
cost of VAD therapy post-discharge (Marasco et al. 2016).  
Patient satisfaction scores are higher in a post-transplant cohort vs LVAD (Grady 
et al. 2003). A similar outcome with OHTx patients demonstrating higher activity 
levels and better QoL than LVAD (HeartWare, HeartWare International Inc., 
Framingham, Massachusetts) patients at 1-year follow-up (Jakovljevic et al. 
2014). A survey in Sweden showed that 75% of Swedes were willing to accept 
marginal donors but 83% felt it was pivotal they received information about the 
expected functional life of the organ. This suggests that marginal organs are not 
accepted unconditionally (Lundin and Idvall 2003). 
2.8.2 Xenotransplantation 
Another aspect of increasing organs available for transplant is 
xenotransplantation. Xenotransplantation is the interspecies transplantation of 
cells, tissues, and organs, or ex vivo interspecies exchange between cells, 
tissues, and organs is a frequently suggested alternative to allograft 
shortage(Anderson 2006). The early days of xenotransplantation are discussed in 
Chapter 1. 
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Non-human primates (NHP) are genetically the most similar animal to humans. 
However, issues raised regarding the risk of cross-species transmission of 
infection to humans, cost and difficulties in breeding, organ size disparities and 
other impracticalities, as well as ethical issues have largely excluded them from 
further consideration (Ekser and Cooper 2010). Currently, pigs are the most 
commonly studied animal for xenotransplantation as there is considerable 
experience with techniques of transgenesis in pigs that allow insertion of new 
genes, ease of breeding, size, and cost (Cooper et al. 2002). 
Xenotransplantation fell out of favour as xenograft survival times remained 
modest despite advances in immunosuppressive therapy. Over the past decade, 
however, there has been a remarkable improvement in survival of xenografts. 
Several studies have shown that heterotopic heart transplantation into NHP with 
improved survival (Mohiuddin et al. 2012; Muhammad M. Mohiuddin et al. 2014; 
M. M. Mohiuddin et al. 2014). This was primarily achieved by ‘knocking out’ 
certain genes that are immunogenic to humans. Human transgenes, such as 
complement regulatory proteins (human complement regulatory protein) and 
human thromboregulatory protein were then expressed on the donor pig cells 
(Satyananda et al. 2013). One such major advancement was the deletion of gene 
α 1,3-galactosyltransferase in pigs. Primate antibodies directed against 
Galactose-α1,3-Galactose (Gal) epitopes on the vascular endothelium of pig 
organs play a major role in hyperacute and acute humoral xenograft rejection 
(Kuwaki et al. 2005).  
The next was the development of targeted immunosuppression instead of 
generalised immunosuppression. Prior to 1998 most studies used conventional 
therapy of a biological agent (e.g., antithymocyte globulin) and/or 
pharmacologic (e.g., cyclophosphamide, cyclosporine, tacrolimus, and 
corticosteroids). Acute humoral xenograft dysfunction (AHXD) was the primary 
cause of graft failure. Most experiments in this period had to be abandoned due 
to infection (Satyananda et al. 2013). AHXD is poorly understood but is thought 
to be a T-cell mediated phenomenon (Ekser and Cooper 2010).  
Using genetic engineering, initial efforts were made to increase the expression 
of immunosuppressive agents endogenously produced by pig cells. This included 
expressing CTLA4-Ig (Abatacept, Belatacept), which reduced the recipient’s T-
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cell response(Najafian and Sayegh 2000; Koshika et al. 2011). This, however, 
renders the host immune-incompetent and susceptible to infections (Salliot et 
al. 2009).  
Research is now geared towards blockade of T-cell and B-cell mediated 
pathways such as anti-CD20 monoclonal antibodies and anti-CD40 monoclonal 
antibodies used by Mohiuddin and colleagues in their experiments. To date, the 
combination of genetically engineered pigs with a knockout of α-Gal, expression 
of human CD46 and thrombomodulin alongside co-stimulation blockade and B-
cell depletion using the mentioned monoclonal agents have achieved more than 
1-year immunogenic survival in primates with heterotopically transplanted 
hearts (Muhammad M. Mohiuddin et al. 2014). Orthotopically implanted cardiac 
xenografts should be the next step in determining feasibility. 
Xenotransplantation has several ethical implications. Safety and cross-
transmission from the donor animal need to be considered especially with the 
concomitant use of monoclonal antibodies and aggressive immunosuppression. 
Epidemiologists currently recommend an international registry of xenotransplant 
recipients with associated lifetime surveillance as a precaution (Anderson 2006). 
This may be expanded to surveillance of family members and close friends which 
is ethically controversial as it violates individual privacy. Although the 
Declaration of Helsinki and Nuremberg trials dictate that participation in studies 
is voluntary, mandatory clinical monitoring may be needed in this group which 
poses an ethical conundrum (Anderson 2006).  
The cost of xenografts also needs to be considered prior to the integration of a 
xenotransplantation programme. Although transplants are arguably the most 
expensive of all medical procedures, organ shortages and relatively low 
frequency make it less than 0.5% of the national budget in the USA (Anderson 
2006). The introduction of xenotransplantation will quadruple this budget. It 
may even add to the organ shortage problem as it may only serve as a bridge to 
allotransplantation (Anderson 2006). 
 “Xenotransplantation is the future of transplantation, and always will 
be.”-Norman Shumway (Cooper 2012) 
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3.1 Abstract 
Background 
Heart transplantation (HTx) remains the most effective long-term treatment for 
advanced heart failure. Primary graft dysfunction (PGD) continues to be a 
potentially life-threatening early complication. In 2014, a consensus statement 
released by ISHLT established diagnostic criteria for PGD. We studied the 
incidence of PGD across the UK. 
Methods 
We analysed the medical records of all adult patients who underwent heart 
transplantation between October 2012-October 2015 in the 6 UK heart transplant 
centres Pre-operative donor and recipient characteristics, intraoperative details 
and post-transplant complications were compared between the PGD and non-
PGD groups using the ISHLT definition. Multivariable analysis was performed 
using logistic regression.  
Results 
The incidence of ISHLT PGD was 36%. Thirty-day all-cause mortality in those with 
and without PGD was 31(19%) vs 13(4.5%) (p=0.0001). Donor, recipient and 
operative factors associated with PGD were:  recipient diabetes mellitus 
(p=0.031), recipient pre-operative BIVAD(p<0.001) and preoperative ECMO 
(p=0.023), female donor to male recipient gender mismatch(p=0.007) older 
donor age (p=0.010) and intracerebral haemorrhage/thrombosis in donor 
(p=0.023). Intra-operatively, implant time (p=0.017) and bypass time(p<0.001) 
were significantly longer in the PGD cohort. Perioperatively, patients with PGD 
received more blood products (p<0.001). Risk factors identified by multivariable 
logistic regression were donor age (p=0.014), implant time (p=0.038), female: 
male mismatch (p=0.033), recipient diabetes (p=0.051) and pre-operative 
VAD/ECMO support (p=0.012), 
Conclusion 
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This is the first national study to examine the incidence and significance of PGD 
after heart transplantation using the ISHLT definition. PGD remains a frequent 
early complication of heart transplantation and is associated with increased 
mortality. 
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3.2 Background 
Heart transplantation remains the most successful long-term treatment for 
advanced chronic heart failure. Survival after cardiac transplantation has 
improved but primary allograft dysfunction (PGD) remains a significant problem 
and the predominant cause of early mortality during the first month (Taylor et 
al. 2009; Cosio Carmena et al. 2013). In a previous UK study, the incidence of 
PGD was 32% using a study-specific definition comprising of severely impaired 
systolic function affecting one or both ventricles accompanied by hypotension, 
low cardiac output, and high filling pressures occurring in the first 72 hours (in 
the absence of hyperacute rejection and technical surgical factors, such as 
cardiac tamponade) (Dronavalli et al. 2015).  
However, comparative studies of the incidence and outcome of PGD have been 
hampered by the lack of an agreed definition until, in 2014, an international 
consensus statement was developed under the auspices of the International 
Society of Heart and Lung Transplantation (ISHLT).  
The consensus classified graft dysfunction as primary graft dysfunction (PGD) or 
secondary graft dysfunction which had a discernible cause such as hyper-acute 
rejection, pulmonary hypertension, or surgical complications. PGD must be 
diagnosed within 24 hours of completion of surgery. PGD is divided into PGD-left 
ventricle and PGD-right ventricle. PGD-left ventricle is categorized into mild, 
moderate, or severe grades depending on the level of cardiac function and the 
extent of inotrope and mechanical support required. Risk factors for PGD include 
donor, recipient, and surgical procedural factors (J. Kobashigawa et al. 2014).  
In this study, we aimed to ascertain the incidence of PGD using the ISHLT 
criteria and examine pre-operative donor and recipient characteristics as well as 
procedural risk factors for PGD in a study of an unselected national population of 
adult heart transplants. 
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3.3 Methods 
All first-time orthotopic heart transplants in adults from donors after brainstem 
death (DBD) were included in this study. 
From October 2012-October 2015, 450 adult heart transplants that met our 
inclusion criteria were performed in the United Kingdom. Data were collected 
prospectively at the time of the heart transplant and incorporated into the UK 
Transplant database hosted by NHSBT. Data were retrospectively validated from 
case records for each of these patients and additional information necessary for 
the study was extracted from the clinical records. Patients with combined organ 
transplants were excluded from this study. Donor procurement was performed 
by the National Organ Retrieval Service (NORS) with all but one centre using 1 
litre of cold St Thomas’s solution followed by cold stage packed with surrounding 
ice during transportation. One centre utilized the OCS (TransMedics Inc) and 
used Custodiol solution cardioplegia at the beginning and end of the OCS run. A 
Pulmonary Artery Catheter was inserted after the transplantation. If this was not 
possible, primary graft dysfunction was diagnosed using echocardiographic 
parameters as per Kobashigawa et al (J. Kobashigawa et al. 2014). Induction and 
maintenance immunosuppression was as per local hospital protocols. Primary 
Graft Dysfunction was defined using the 2014 ISHLT Consensus (J. Kobashigawa 
et al. 2014). The use of postoperative mechanical support was determined by 
individual surgeons.  
3.4 Statistical Analysis 
Continuous variables were described by mean and standard deviation or by 
median and interquartile range as appropriate. Categorical variables were 
expressed as number and proportion. Baseline characteristics were compared 
between PGD and non-PGD groups using Student’s t-test and Mann Whitney-U 
test as appropriate and chi-square test or Fisher’s exact test for categorical 
variables. Variables with significance of p<0.1 in the unadjusted analysis were 
initially introduced as candidate variables in a multivariable logistic regression 
model for the probability of PGD and removed by stepwise backward 
elimination. We also included variables that have been shown to be predictive in 
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other studies as outlined by the ISHLT consensus statement(J. Kobashigawa et 
al. 2014). Variables were retained in the model if they reduced the model 
deviance significantly (p<0.05). This was done using a complete case dataset to 
ensure appropriate comparison of nested models. A further subgroup analysis 
was performed on just those with PGD using the same methodology to compare 
variables that predict the different severities of PGD as defined. The analysis 
was conducted in Minitab 17 Statistical Software (2010). Minitab, Inc. 
3.5 Results 
450 adults received heart transplants between 1 October 2012- 1 October 2015. 
The mean age was 46.3±13.5 years. 348 (77.3%) of the recipients were males. 
During this period there were 10 Donation after Circulatory Death (DCD) 
transplants and these were excluded from the study. There were also 3 patients 
who were re-transplanted. Their second transplants were excluded from this 
study. Pre-operative, operative and post-operative details of the PGD and non-
PGD cohorts are shown in Table 3-1. The overall incidence of Primary Graft 
Dysfunction was 36.2% (163 patients). There were 7 (1.6%) cases of Secondary 
Graft Dysfunction. These were graft failure secondary to bleeding, hyperacute 
rejection and elevated pulmonary pressures as defined by Kobashigawa (J. 
Kobashigawa et al. 2014). The phenotype and severity of PGD are shown in 
Figure 3-1. 
 
Figure 3-1: Distribution of PGD according to type and severity 
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Table 3-1 Pre-operative characteristics of recipients. 
Recipient Factors PGD (n=163) Non-PGD (n=287) P- value 
Male: Female ratio 127:36 221:66 0.824 
Age (years) 47.1±14.1 46.1±13.8 0.449 
BMI (Kg/m2) 25.68±3.96 25.34±3.98      0.388 
Recipient Creatinine 
(μmol/L) 
98.00 (48) 99.00 (46) 0.217 
Recipient Diabetes Mellitus 19 (11.7%) 17 (5.9%) 0.031 
Recipient Re-sternotomy 33 (20.2%) 47 (16.4%) 0.302 
Pre-operative Inotropes 82 (50.3%) 171(59.6%) 0.056 
Pre-operative ECMO 5 (3.1%) 1 (0.3%) 0.023 
Pre-operative IABP 15 (9.2%) 17 (5.9%) 0.193 
Pre-operative LVAD 25(15.4%) 35(12.2%) 0.345 
Pre-operative BiVAD 20(12.3%) 9(3.1%) <0.001 
Pre-operative RVAD 3(1.8%) 20(7.0%) 0.018 
Pre-operative 
antiarrhythmics 
(Amiodarone) 
58 (35.6%) 111(38.7%) 0.514 
Recipient Aetiology    
Ischaemic Cardiomyopathy 38 (23.3%) 62 (21.6%)  
 
 
 
 
0.464 
Dilated Cardiomyopathy 87 (53.3%) 160 (55.7%) 
Congenital Heart Disease 13 (8.0%) 26 (9.1%) 
HOCM 9 (5.5%) 15 (5.2%) 
Restrictive 
Cardiomyopathy 
5 (3.1%) 8 (2.8%) 
Other 11 (6.7%) 7 (2.7%) 
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We identified donor, recipient and operative risk factors for PGD. Preoperative 
factors that were significantly associated with PGD in the unadjusted analysis 
were recipient diabetes mellitus and female donor-to-male recipient gender 
mismatch as shown in Table 3-1.  
There was no significant difference between the donor-recipient height and 
weight mismatch but the estimated LV mass showed more downsizing of donor-
to-recipient in the PGD cohort as shown in Table 3-2.  
Table 3-2 Pre-operative characteristics of donors 
Donor Factors PGD (n=163) Non-PGD (n=287) p- value 
Donor Cause of death 
Intracerebral 
haemorrhage/Thrombosis 
107 (65.6%) 157 (54.7%) 0.023 
Hypoxic brain injury 21(12.9%) 48 (16.7%) 0.277 
Road Traffic Accident 
(RTA) 
23 (14.1%) 51(17.8%) 0.314 
Meningitis 4 (2.5%) 11 (3.8%) 0.434 
Brain Tumour 3 (1.8%) 8 (2.8%) 0.216 
Other 5 (3.1%) 10 (3.5%) (0.967 
Gender Mismatch 52 (31.9%) 59 (20.6%) 0.007 
Height Mismatch (%) -0.55 (6.8) -1.16 (6.8) 0.166 
Weight mismatch (%) -0.44 (27.8) -3.90 (33.8) 0.464 
Estimated LV mass 
mismatch (%) 
2.76 (25.5) -1.90 (25.3) 0.020 
Donor Age  41.6±12.2 38.5±12.4      0.010 
Donor LVEF (%) 57.77±9.36      58.88±7.41    0.279 
Donor Smoker 74 140 0.489 
Mismatch calculated as [(Measure (recipient) − Measure(donor)/Measure(recipient)] X 100 
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Intra-operatively, implant time and bypass time were significantly longer in the 
PGD cohort. 
Table 3-3 Post-operative details of heart transplant recipients 
Operative Details PGD (n=163) Non-PGD 
(n=287) 
P- value 
Perfusion Solution 
St Thomas 139 (85.3%) 233 (81.2%)  
0.378 
Custodiol 24 (14.7%) 51 (17.8%) 
*Cold Ischaemic Time (mins) 103(66) 99(62) 
 
0.392 
Explant Time (mins) 17 (9) 
 
18 (10) 0.513 
Implant Time (mins) 56(24)  52(24) 0.017 
Warm Ischaemic Time (mins) 72 (28) 70 (27) 0.045 
Total Ischaemic Time (mins) 179 (86) 171(71) 0.426 
Bypass Time (mins) 206(113) 
 
162 (68) 
 
<0.001 
Post-operative details 
Right Atrial Pressure (mmHg)  13.01±4.37      
 
11.98±3.97      0.016 
PA Mean(mmHg)  22.39±6.02      22.43±5.95      0.958 
PA Systolic(mmHg)  31.75±9.52      32.08±9.23      0.789 
PCWP (mmHg)  12.83±4.92     
  
13.53±5.76 0.355 
Transpulmonary Gradient 
(mmHg) 
8.000 (9) 
  
9.000 (8) 0.593 
Cardiac Index  2.5654 (2.4) 
 
3.1074 (1.59) 0.005 
MAP (mmHg)  73.1±15.2       
 
80.9± 16.9 <0.001 
Inotrope Score 14.533(14.56) 
 
9.985(10.43) <0.001 
Blood Products Transfused (units) 9 (11) 5 (6)  <0.001 
RBCs(units) 4(7) 2(3) <0.001 
FFP (units 2.000 (2.8) 
 
2.000 (4) 0.032 
Platelets(units) 2.0000 (2) 
 
1.0000 (2) <0.001 
*Excluding patients on OCS 
Part of ISHLT 2014 severity definition 
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Patients with PGD had increased transfusion of blood products Table 3-3. 30-day 
mortality for patients with primary graft dysfunction was 31(19%) vs 13(4.5%) 
(p<0.001). The 6-month mortality for patients with PGD was 52 (31.9%) vs 18 
(6.3%) (p<0.001). Comparing the PGD groups, there was a significantly higher 30-
day mortality in the severe PGD-LV group vs moderate PGD-LV group 27(30%) vs 
4(5%) respectively, p<0.001). 
The total extracorporeal time for the OCS subset was significantly longer than 
after cold storage (309.4±88.4 minutes vs 100.3±45.8 minutes; p<0.001. 
However, the incidence of PGD was similar to the non-OCS cases (30.3% vs 
37.2%, respectively) (p=0.279). In a subgroup analysis of the OCS cases, 
extracorporeal time was significantly longer in the PGD group (344.9±95 minutes 
vs 294.8±81 minutes; p=0.048) 
The following variables were considered for multivariable analysis of the 
probability of PGD in which 21 (5%) patients were excluded due to missing data.  
Continuous Variables: Recipient age, donor age, explant time, implant 
time  
Categorical Variables: Recipient diabetes, recipient pre-operative 
inotropes, recipient pre-operative VAD/ECMO support, female donor: 
male recipient mismatch, donor smoking history, OCS usage, recipient 
aetiology, donor cause of death and recipient pre-operative IABP usage.  
Bypass time and total intraoperative blood transfusion were excluded from this 
analysis. OCS use was not included because it occurred in a small surgeon-
selected subset. The final model is shown in Table 3-4. 
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Table 3-4 Results of multivariable analysis for risk factors for PGD 
Factors Odds Ratio 95% Confidence Intervals p-value 
Donor age (years) 1.02 (1.0043, 1.0383) 0.014   
Implant time (mins) 1.01  (1.0005, 1.0195) 0.038   
Female: male mismatch 1.74 (1.0464, 2.9086) 0.033   
Recipient diabetes 2.04  (0.9993, 4.1720) 0.051 
Pre-operative VAD/ECMO 
support 
1.79  (1.1371, 2.8295) 0.012 
In donors, the likelihood of PGD increased by 20% for each decade increment in 
donor age. A female donor: male recipient combination was 1.7 times more 
likely to develop PGD.  
Recipients requiring preoperative mechanical circulatory support also conferred 
almost a two-fold increase in the likelihood of PGD. Diabetic recipients were 
more than twice likelier to develop PGD. 
There was also a 1% increase for each minute increment during implantation of 
the heart.  
As an illustrative example, the absolute risk of developing PGD in an average 
donor (40-year old) to an average recipient (non-diabetic, no preoperative MCS, 
implant time = 54 minutes, without female donor to male recipient gender 
mismatch) was 28.7%. This absolute risk increased to 45.1% if there was 
recipient diabetes or 41.9% if there was preoperative MCS. A female donor-to-
male recipient increased the absolute risk to 41.2%. 
The absolute PGD risk of advancing donor age in an average recipient is 
computed in Figure 3-2.  
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Figure 3-2 Probability of PGD with advancing donor age 
 
Figure 3-3 Probability of PGD with increasing Implant Time 
Figure 3-3 shows the effect of advancing implant time (mins) in a 40-year old 
donor to an average recipient, who wasn’t on any MCS support. 
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A further subgroup logistic regression analysis was performed to identify risk 
factors for severe PGD vs mild/moderate PGD on the 163 patients who 
experienced some degree of PGD.  
The variables included for analysis were 
Continuous Variables: Recipient age, donor age, explant time, implant time  
Categorical Variables: Recipient diabetes, recipient pre-operative inotropes, 
recipient pre-operative VAD/ECMO support, female donor: male recipient 
mismatch, donor smoking history, OCS usage, recipient aetiology, recipient re-
sternotomy donor cause of death and recipient pre-operative IABP usage  
This subgroup analysis revealed implant time, female donor: male recipient 
gender mismatch and recipient re-sternotomy to be independent risk factors for 
severe PGD as opposed to mild or moderate PGD as seen in Table 3-5. 
Table 3-5 Results of multivariable analysis for risk factors for severe PGD 
Factors Odds Ratio 95% Confidence 
Intervals 
p- value 
Implant time(mins) 1.02 (1.0003, 1.0342) 0.037 
Female: male mismatch 2.43 (1.0966, 5.3722) 0.026 
Recipient Resternotomy 3.21  (1.3215, 7.8084 0.008 
3.6 Discussion 
This study is the first national study of PGD in an unselected population of adult 
heart transplants using the ISHLT consensus definition. The main findings were, 
first, a high overall incidence of PGD and, second, a significant increase in 
perioperative mortality in the PGD group. Third, the risk factor analysis 
identifies not only donor and recipient factors but potentially modifiable 
procedural risk factors such as surgical implant time and use of blood products. 
Finally, the use of the OCS allowed an extension of the extracorporeal time for 
the donor heart with a similar incidence of PGD. Nevertheless, increasing 
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extracorporeal time in the OCS group was associated with an increase in PGD 
indicating that any protection afforded by OCS was relative, not absolute. 
3.6.1 Incidence of PGD  
There was a relatively high incidence of PGD (36.2%) in this cohort. This finding 
is similar to that reported by Dronavalli et al which reported an incidence of 
about 32% (Dronavalli et al. 2015). The changing patient demographics with the 
increasing use of pre-transplant mechanical circulatory support and increased 
utilization of marginal donors could be a contributory factor as donor age and 
preoperative MCS usage were independent risk factors for PGD(Shekar et al. 
2016). Dronavalli et al also mentioned the lack of echocardiographic criteria 
which reduced the sensitivity of diagnosing PGD in the previous study. There 
were more severe PGD-LV patients (18%) and moderate PGD-LV (16%) than mild 
PGD-LV (1%) and PGD-RV (1%). These findings were similar findings noted in a 
single centre series by Sabatino et al (Sabatino et al. 2017a). The majority of 
their patients were classified as severe PGD (65%) followed by moderate (12%) 
and mild (0%; p < 0.01). The low rates of mild PGD-LV could be as a result of 
earlier intervention by physicians and surgeons by increasing the inotropic 
treatment in response to a low cardiac output state to the point where the 
inotrope score will meet the ISHLT definition of moderate PGD-LV. The clinical 
significance of the mild PGD-LV group is uncertain as there was no 30-day 
mortality in this group. 
3.6.2 PGD-related Mortality 
The 30-day mortality in our cohort was lower than the previous study (19% vs 
37%) and in other studies (Isaac; Brian Lima et al. 2006; Segovia et al. 2011). 
The lack of a standardized definition previously also potentially resulted in more 
conservative definitions of PGD which was the need for instituting MCS. This 
could also explain the improved mortality figures due to the inclusion of 
inotrope dependence as part of the definition. The improved 30-day survival 
could also be a result of improvements in the recognition and treatment of PGD. 
Short-term PGD related mortality rates in our cohort were also similar to those 
described by Squiers et al from a high volume centre in the United States 
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(Squiers et al. 2017b). They had a 30-day mortality rate of 25% in the moderate/ 
severe PGD group. Sabatino et al also reported similar mortality rates in their 
cohort (37% in-hospital mortality)(Sabatino et al. 2017a). However, the mortality 
rate at 6-months remains high in the PGD cohort (31.9% vs 6.3%). There is a 
paucity of data regarding longer-term outcomes following PGD. Kim et al 
retrospectively reviewed a single centre cohort of patients and noted that 
moderate and severe PGD-LV patients had worse long-term outcomes (Kim et al. 
2015). Given the large proportion of moderate and severe PGD-LV patients in our 
cohort, further studies may be needed to evaluate longer-term outcomes of PGD 
survivors vs non-PGD patients.  
3.6.3 Risk Factors 
The increased incidence of PGD reported is multifactorial. It highlights several 
vascular risk factors that may shed light on the aetiology of PGD. Increasing 
donor age and recipient diabetes were both independent risk factors in our 
cohort and have identified in previous studies prior to the ISHLT 
definition(Segovia et al. 2011).  
3.6.3.1 Donor Age 
Donor age was a significant risk factor for both PGD and severe PGD in the 
subgroup analysis. This finding was also noted by Russo by interrogating the 
UNOS database(M. J. Russo et al. 2007). They concluded that the effect of 
ischemic time on survival after heart transplantation is dependent on donor age, 
with a greater tolerance for prolonged ischemic times among grafts from 
younger donors.  
3.6.3.2 Ischaemic Time 
Ischemic time was subdivided into warm and cold ischemic time in our cohort 
(Banner et al. 2008). Warm ischemic time was defined as the explant time + the 
implant time. The implant time was found to be a strong predictor of primary 
graft dysfunction. Marasco et al (Marasco et al. 2012) retrospectively reviewed 
206 patients over a period of around 10 years (June 2001-November 2010). Their 
definition of warm ischemic time included the implant time. They found that 
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poorer survival with a warm ischemia time (WIT) of >80 minutes having a 
compared to WIT group of <60 minutes. Donor age was once again an 
independent predictor of outcome in this cohort.  
3.6.3.3 Recipient Diabetes Mellitus 
The role of recipient diabetes as a predictor of primary graft dysfunction was 
evident in our study as it was in the RADIAL study. The UK prospective Diabetes 
Study trial established a link between microvascular complications and 
glycaemic control('Intensive blood-glucose control with sulphonylureas or insulin 
compared with conventional treatment and risk of complications in patients with 
type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group'  
1998). In recipients with diabetes, there may be a combination of direct glucose-
mediated endothelial damage, oxidative stress from superoxide overproduction 
and production of advanced glycation end-products, which may result in changes 
in endothelial permeability, excessive vascular protein deposition and altered 
blood flow (Brownlee 2001). A recent metanalysis, diabetes mellitus was an 
independent predictor of 1-year mortality post-heart transplant (Foroutan et al. 
2017). They attributed this to the summative increased hazard for comorbidities 
of diabetes at the time of transplant which was also noted by Russo et al (Russo 
et al. 2006). In a subgroup analysis, diabetic recipients with well-controlled 
diabetes had similar survival to non-diabetic patients. Interrogation of the UNOS 
database by Taghavi et al(Taghavi et al. 2013) revealed that of 20,348 patients 
undergoing orthotopic heart transplantation, 496 (2.4%) received hearts from 
diabetic donors. The diabetic donors were likelier to be females and older. The 
recipients of diabetic hearts were also older. However, on multivariable analysis 
of subgroups, neither insulin-dependent diabetes (1.173; 95% CI, 0.884-
1.444; P = 0.268) nor duration of diabetes for more than 5 years (HR, 1.239; 95% 
CI, 0.914-1.016; P =0.167) were risk factors once the groups had been matched. 
A similar finding was noted by Smits in a European cohort(Smits et al. 2012).  
3.6.3.4 Gender Mismatch 
The odds ratio for severe PGD was double that of mild/moderate PGD in female 
donor – male recipient gender mismatched patients in our study. It has also been 
identified as a risk in several previous studies. Jalowiec et al conducted a study 
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on early outcomes after heart transplantation in gender mismatched patients 
(Jalowiec et al. 2012). 74/347 patients received a heart from the opposite 
gender. They concluded that gender-mismatched heart transplant recipients had 
more complications due to rejection and higher resource utilization due to more 
re-hospitalization during the first post-operative year as compared to gender-
matched recipients. Stehlik et al published similar findings with female donor: 
male recipients having a higher risk of post-transplant death (Stehlik et al. 
2010b). Some have postulated the relative differences between the size (body 
surface area) or weight mismatch between female donor and male recipient, 
citing a smaller female donor heart being unable to sustain the demands of a 
larger male patient although there was no significant size mismatch (>20%) 
noted in our cohort (Young et al. 1994; Weiss et al. 2009).  
3.6.3.5 Recipient resternotomy 
Recipient re-sternotomy was identified as a risk factor for developing severe 
PGD in our subgroup analysis. Patients with previous sternotomies develop 
adhesions that complicate the surgical dissection thereby prolonging the 
explantation period and bypass time. They are also at an increased risk of 
infections (Kansara et al. 2014b). This may further exaggerate the inflammatory 
response explaining the need for increased support post-operatively. Analysis of 
the UNOS database revealed an increased risk of all-cause mortality in patients 
with re-sternotomies (Kansara et al. 2014b). 
3.6.3.6 OCS  
It is widely believed that an important factor in the pathogenesis of PGD is acute 
ischemia-reperfusion injury. The donor heart is exposed to variable blood 
pressures, hypothermic storage, warm ischemia and finally reperfusion. The role 
of the OCS in reducing the impact of this has not been studied. A multivariable 
analysis has not been done here owing to the relatively small number of OCS 
transplants during the study period (n=66). However, in the unadjusted analysis, 
the length of time on the OCS machine was a strong predictor of PGD. One 
hypothesis for this phenomenon is the lack of metabolic and excretory functions 
within the OCS circuit to sustain the metabolically active heart within the 
machine. The mean extracorporeal time of hearts on the OCS was significantly 
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longer than cold storage with similar PGD rates. Garcia-Saez et al reported 
improved short-term outcomes from the use of the OCS in extended criteria 
donors (García Sáez et al. 2014). The OCS may have a role in improving the 
logistical limitations of organ procurement. The ex-vivo perfusion of the heart 
allows evaluation of extended criteria allografts prior to implantation. It also 
reduces functional ischemia by means of continuous oxygenation and perfusion 
which may be important in higher-risk recipients who are on MCS. Nevertheless, 
a randomized study of a larger cohort of donors is needed to establish any 
benefit of the OCS in reducing PGD.  
3.6.3.7 Size mismatch 
The height and weight profiles of donors and recipients in our cohort were not 
significantly different in both groups. This could be due to careful donor 
selection and matching process to ensure accurate sizing of the cardiac allograft 
for the recipient. Height mismatch and weight mismatch were negligible in our 
cohort. However, a composite of the two measurements to calculate the 
estimated LV mass showed a higher proportion of downsizing in the PGD cohort.  
We used the following equation which has been published and validated in the 
literature (Bluemke et al. 2008). 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝐿𝑒𝑓𝑡 𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 𝑚𝑎𝑠𝑠(𝑔) = 𝛼 ∗ 𝐻𝑒𝑖𝑔ℎ𝑡0.54(𝑚) ∗ 𝑊𝑒𝑖𝑔ℎ𝑡0.61(𝑘𝑔) 
𝑤ℎ𝑒𝑟𝑒 𝛼 =  6.82 𝑓𝑜𝑟 𝑤𝑜𝑚𝑒𝑛 𝑎𝑛𝑑 8.25 𝑓𝑜𝑟 𝑚𝑒𝑛 
However, this was not a significant finding on multivariable analysis. This could 
be due to the co-efficient weightage which may reflect the potential downsizing 
in a female donor to male recipient gender mismatch using this equation. The 
equation is also limited as there is no correlation with other confounders of LV 
mass such as ethnicity, history of cardiovascular disease and valvular heart 
disease. Size mismatching has been noted in other studies (Russo et al. 2010; 
D'Alessandro et al. 2011a; Sabatino et al. 2017a; Squiers et al. 2017b). 
Transplanted hearts are denervated and thus rely on increased stroke volume to 
augment workload(Robert M. Reed et al. 2014). Consistent increments of stroke 
volume result in increasing filling pressure. Smaller hearts are also prone to 
tachycardia to meet the demands of the previously larger sized heart which is 
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mediated by catecholamine release (Ferretti et al. 2002; Mettauer et al. 2005). 
Tachycardia may worsen episodes of myocardial ischaemia and significantly 
increases the production of oxygen free radicals by increased metabolic 
demand(Critchley et al. 2013). These results in immune infiltration and 
activation, potentially causing acute or chronic rejection.  
Consequently, undersized hearts are shown to undergo pathological cardiac 
hypertrophy, which may cause fibrosis (Mather et al. 1995; Bernardo et al. 
2010). Fibrosis of myocardium and conduction fibres are likely to increase the 
risk of arrhythmias which may be misconstrued as rejection(Thajudeen et al. 
2012).  
3.6.3.8 Bypass time and blood transfusion 
Patients with PGD in our cohort had a significantly longer bypass time. We 
considered that this may have been due to the need to institute further 
treatment by means of insertion of IABP or institution of mechanical circulatory 
support. However, prolonged bypass time in itself is an independent predictor of 
morbidity and mortality in general cardiac surgery (Salis et al. 2008; Ellenberger 
et al. 2017).  
The mechanism of injury from CPB and ischaemic-reperfusion of the myocardium 
is similar; both producing a systemic inflammatory response syndrome (SIRS). 
They result in a hyperdynamic circulatory state due to the vasoplegia reducing 
vascular resistance, platelet and coagulation factor dysfunction, inflammatory 
pathway activation triggered by leucocytes and endothelial cells and finally 
cytokine release and formation of oxygen free radicals (Anselmi et al. 2004). 
Prolonged cardiopulmonary bypass also increases the transfusion requirement(Al-
Sarraf et al. 2011). Our PGD cohort had higher blood transfusion requirements 
compared to the non-PGD cohort. This could once again be a response to the 
vasoplegic state caused by the SIRS effect from either prolonged bypass time or 
PGD itself. Blood transfusion in general cardiac surgery is associated with both 
infection and ischaemic postoperative morbidity, increased hospital stays, 
increased early and late mortality, and increased hospital costs(Koch et al. 
2006; Murphy et al. 2007). In animal models, stored red blood cells have 
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implicated in causing organ hypoxia(d'Almeida et al. 2000). Blood transfusion 
also increases pulmonary vascular resistance thereby affecting right ventricular 
ejection, without improving systemic or regional oxygen utilization(Fernandes et 
al. 2001). 
Given these findings, blood transfusion and cardiopulmonary bypass time may 
both contribute to the worsening of the ischaemic injury caused by PGD.  
3.6.4 Treatment of PGD 
Treatment of PGD is primarily supportive. As the definition of PGD is based on 
the treatment modality, mild and moderate PGD-LV is primarily inotropic 
support. Moderate PGD-LV is also treated with implantation of IABP. Escalation 
from this usually requires ECMO. Most cases of severe PGD-LV involve failure to 
wean from bypass, necessitating the institution of ECMO or short term VAD 
support. PGD-RV is initially treated with inotropic support including agents such 
as milrinone to promote pulmonary vasodilation. An RVAD is cited if right heart 
failure persists(J. Kobashigawa et al. 2014). Due to the shortage of organs and 
the increasing waiting list, re-transplantation is rarely done (3 in this study 
period). 
3.7 Limitations 
This was a retrospective analysis of prospectively collated national data. This 
study design is advantageous because the risk factors were recorded before the 
occurrence of the outcome (PGD). This is important because it allows the 
temporal sequence of risk factors and outcomes to be assessed. Selection bias 
was also minimized by including all adults with heart-only transplants during the 
study period. However, as an observational study, only association and not 
causation can be inferred from the results. Other unrecorded factors may have 
affected the outcome(Sedgwick 2014). 
As the data collected were from different hospitals, variations in practice were 
unaccounted for. This included post-operative immunosuppression regimes, 
choice of inotropes, myocardial preservation methods and MCS experience with 
some centres having a greater proportion of patients on LVADs. We relied on 
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both PAC measurements and Echocardiography for defining PGD in patients 
without devices where possible. Some patients did not have PCWP readings and 
then we were reliant on echocardiographic criteria and vice versa. 
3.7.1 Limitations in PGD definition (ISHLT 2014)  
The ISHLT consensus definition relies on the use of mechanical circulatory 
support to define the more severe forms of PGD.  
It also underestimates the true number of PGD-RV as VA-ECMO institution is the 
commonly used MCS strategy for any low cardiac output state (RV, LV or 
biventricular). There is a significant overlap between the phenotypical 
appearance of post-operative right ventricular stunning which occurs post-CPB 
and PGD-RV. The reliance on an interventional strategy in itself causes an 
inherent overestimation of the true incidence of PGD. For example, in high-risk 
cases, a surgeon may opt to prophylactically insert an intra-aortic balloon pump 
as a precaution which would classify this as moderate PGD-LV. The use of MCS 
was decided by individual surgeons, therefore, is a potential weakness of the 
consensus definition. However, the national multicentre nature of this study is 
likely to have mitigated this problem. 
We performed an exploratory analysis of transplants performed on the OCS 
device but were unable to perform a multivariable analysis because of the 
limited number of cases and events.  
3.8 Conclusion 
PGD remains a significant risk factor for early mortality in heart transplant 
recipients. The standardized definition allows early diagnosis and recognition of 
this condition. There are several donor, recipient and procedural risk factors 
that may be contributory to the pathogenesis of PGD that should be considered 
for predicting outcomes. Further studies are warranted to establish the long-
term outcomes of PGD using the current definition. 
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4.1 Abstract 
Background 
The rates of PGD across Europe are higher than in North America possibly due to 
the increasing use of extended criteria donors because of organ shortage. 
However, there is no scoring system currently available in the literature for 
assessing PGD risk. Our aim was to derive a novel scoring system based on 
prospective data collected nationally in the UK over a 4-year period. We 
compared this scoring system to a previously validated (RADIAL) score in a 
contemporary cohort of patients.  
Methods 
Medical records of all adult patients who underwent heart transplantation (HTx) 
between 1 October 2012- 30 September 2016 in the 6 UK heart transplant 
centres were analysed. Pre-operative donor and recipient characteristics, 
intraoperative details, and post-transplant complications were compared 
between the PGD and non-PGD groups using the ISHLT definition. Multivariable 
logistic regression was used to build the predictive model. An Area Under 
Receiver Operating Characteristics (ROC) curve was used to test the novel 
scoring system (PREDICTA) versus the RADIAL score. 
Results 
613 heart transplants were included in the study. There were 233 patients who 
had PGD. The variables analysed by multivariate modelling included in the model 
were recipient diabetes mellitus, pre-operative mechanical circulatory support 
(ventricular assist devices (VAD)/extracorporeal membrane oxygenation 
(ECMO)), implant time, donor age, and bypass time >180 Minutes. The C-statistic 
of the PREDICTA score was 0.704 vs 0.547 for the RADIAL score indicating an 
acceptable discriminatory value.  
Conclusion 
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The PREDICTA Score is a novel scoring tool with improved ability to predict the 
development of PGD compared to the RADIAL score in a contemporary cohort of 
patients. It may help identify patients who are at risk of PGD and therefore 
allow risk stratification and resource planning for management and therapeutic 
interventions. Further multicentre studies are needed to investigate its 
application in the prevention and early management of PGD. 
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4.2 Introduction 
The incidence of Primary Graft Dysfunction (PGD) in Western Europe is around 
30% (S. Avtaar Singh et al. 2018a). This is due to several factors such as 
increasing donor and recipient age, increased pulmonary vascular resistance in 
recipients, donor and recipient co-morbidities and prolonged ischaemic time 
(Jon Kobashigawa et al. 2014; Nicoara et al. 2018). PGD remains an important 
cause of morbidity and mortality following heart transplantation. Improvements 
in immunosuppression and surgical techniques have resulted in good long-term 
survival post-transplant; however, the rate of PGD has remained unchanged in 
the past decade (Nicoara et al. 2018). To date, there have been no predictive 
models for PGD in using the current definition. A previous centre specific 
definition was used to create a 6-point RADIAL score by Segovia and colleagues 
which considers donor and recipient factors, namely Right atrial pressure ≥ 10 
mm Hg, recipient Age ≥ 60 years, Diabetes mellitus, Inotrope dependence, donor 
Age ≥ 30 years, Length of ischemic time ≥ 240 minutes(Segovia et al. 2011; Singh 
et al. 2019) 
Given the relatively high incidence of PGD across Western Europe, it is 
imperative that a new predictive model is sought to assist in decision-making 
and resource allocation for heart transplantation. This is an area of increasing 
significance with increasing patients on the waiting list with a finite donor pool 
primarily consisting of donors after brainstem death (DBD). Recently, ex-vivo 
normothermic perfusion (EVNP) and hearts from donors after circulatory death 
(DCD) has been used to expand the donor pool. Advancements in mechanical 
circulatory support, especially implantable Left Ventricular Assist Devices 
(LVADs) have also changed recipient demographics. However, the association 
between these procedures and PGD has not been clearly established. Most 
studies in the literature are single-centre studies with the inherent weakness of 
applicability to wider practice. We, therefore, conducted a multicentre, 
national study to establish trends and independent risk factors for PGD after 
heart transplantation. Several risk factors have been identified in previous 
studies which include donor factors, recipient factors, and procedural factors. 
Our aim was to derive a multivariable model to identify and predict PGD. This 
would allow resource provision in high-risk cases to allow early intervention and 
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management of these patients. We then explored the performance of a 
previously validated PGD scoring system, the RADIAL score as a comparison using 
our validation cohort.  Our aim was to develop a predictive risk score for ISHLT-
defined PGD that would be applicable at present with the abovementioned 
developments.  
4.3 Methods 
4.3.1 Patient population 
All consecutive adult patients who underwent first-time orthotopic heart 
transplants from 1 October 2012 – 30 September 2016 from 6 heart transplant 
centres in the United Kingdom were included in our study (n=613). Data were 
collected prospectively at the time of the heart transplant and incorporated into 
the UK Transplant database hosted by NHSBT. Data were retrospectively 
validated from case records for each of these patients and additional 
information necessary for the study was extracted from the clinical records. 
Patients with combined organ transplants (n=23) were excluded.  
4.3.2 Donor Organ Procurement 
4.3.2.1 DBD Donation 
Donor procurement was performed by the National Organ Retrieval Service 
(NORS) with all but one centre using cold St Thomas’s solution followed by static 
cold storage packing during transportation. One centre utilized the Organ Care 
Systemtm (OCS), an EVNP device (TransMedics Inc) and used Custodiol solution 
cardioplegia at the beginning and end of the OCS run. Further details are 
explained in chapter 3. 
4.3.2.2 DCD Donation 
DCD donations were done by direct procurement or normothermic regional 
perfusion. During the duration of the study, only 2 centres performed DCD heart 
transplants. All DCD hearts were placed on the OCS with one centre using 
Custodiol solution cardioplegia and the other using St Thomas’ Solution. Further 
details are explained in chapter 3. 
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4.3.3 Post-operative haemodynamic measurements 
PGD was diagnosed using echocardiographic parameters or invasive cardiac 
monitoring parameters as per the ISHLT definition(Jon Kobashigawa et al. 2014). 
Induction and maintenance immunosuppression was as per local hospital 
protocols. The use of postoperative mechanical support was determined by 
individual surgeons.  
4.3.4  Primary Graft Dysfunction 
Primary Graft Dysfunction was defined by the 2014 ISHLT Consensus(Jon 
Kobashigawa et al. 2014). PGD was diagnosed within 24 hours after the 
completion of transplantation. The severity of left-sided PGD (PGD-LV) was 
determined by the inotrope score, placement of a new intra-aortic balloon pump 
or institution of mechanical circulatory support as detailed by the consensus 
statement. Echocardiographic findings of Left Ventricular Ejection Fraction 
(LVEF) of <40% could also be used for determination of mild/moderate PGD in 
the absence of pulmonary pressure and cardiac monitoring measurements. Right-
sided PGD (PGD-RV) was determined by a right VAD implantation or elevated 
right atrial pressure in the absence of elevated pulmonary pressures. Further 
details are elaborated in chapter 2.  
4.3.5  Statistical Analysis 
Continuous variables were described by mean and standard deviation. 
Categorical variables were expressed as the actual number and proportion. 
Baseline characteristics were compared between PGD and non-PGD groups using 
Student’s t-test and Mann Whitney-U test as appropriate and chi-square test or 
Fisher’s exact test for categorical variables. Survival data were analysed using 
the Kaplan–Meier method and survival curves were compared using the log-rank 
test. Surviving patients were censored at their last known follow-up. p<0.05 was 
considered statistically significant. 
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4.3.5.1  Derivation Cohort 
A number generator was used to randomly select 75% of the cohort for the 
purpose of model derivation (n=460). Variables with significance of p<0.1 in the 
unadjusted analysis above were initially introduced as candidate variables in a 
multivariable logistic regression model for the probability of PGD and removed 
by stepwise backward elimination. Variables were retained in the model if they 
reduced the model deviance significantly (p<0.1). This was done using a 
complete case dataset to ensure appropriate comparison of nested models. The 
goodness of fit of the model to the observed event rates (PGD) was evaluated by 
calculating the Hosmer–Lemeshow statistic. All statistical analysis was 
undertaken using SPSS v.18.0 (IBM Corp., Armonk, NY, USA). 
4.3.5.2 Validation cohort 
The remainder of patients (n=153) were used for validation of the model.  The 
ability of the model to identify patients with PGD was evaluated using the C-
statistic, equivalent to the area under a receiver-operating characteristic 
(AUROC) curve for dichotomous outcomes.  
4.4 Results 
4.4.1 Demographic data 
The demographic details of these patients are listed below in Table 4-1. The 
incidence of PGD was 38%. Patients with PGD had a poorer survival post-
transplant with higher 30-day (18.9% vs 3.9%, p<0.001) and 1-year mortality 
rates (32.6% vs 6.6%, p<0.001). Figure 4-1 depicts the 5-year survival of both 
cohorts. The p-value for the log-rank test for the Kaplan-Meier curve depicting 
survival of the two groups of patients was <0.001. 
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Details PGD (n=233) No PGD 
(n=380) 
p-value 
Age (years) 46.5±13.4 46.2±13.8 0.78 
Recipient height (cm) 172.5±8.5 173.2±9.2 0.35 
Recipient Weight (kg) 76.3±14.4 76.3±14.6 0.99 
Cardiac Index (L/min) 2.22±1.4 3.14±1.2 <0.001 
MAP (mmHg) (L/min/m2) 71.1±13.8 79.1±15.7 <0.001 
Inotrope Score 18.4±11.7 12.4±8.5 <0.001 
Total Ischaemic time(mins) 165.7±60.7 161.0±62.5 0.36 
Cold Ischaemic Time(mins) 101.36±42.7 99.7±47.8 0.6 
Time on OCS (mins) 221.6±155.7 204.7±142.0 0.52 
Number of DBD OCS (%) 32(13.8) 49(12.9)  0.77 
Number of DCD (%) 7 (3) 15(3.9) 0.54 
Explant Time(mins) 19.8±10.1 19.6±11.0 0.83 
Warm Ischaemic Time 
(mins) 
63.5±20.5 57.5±22.2 0.001 
Bypass Time(mins) 218.2±93.1 174.3±66.3 <0.001 
Height Mismatch (%) 1.3±5.0 1.3±5.2 0.99 
Weight Mismatch (%) 5.6±23.4 7.0±24.6 0.099 
Total Units of Blood 
transfused 
10.7±12.1 7.7±30.7 0.096 
Donor Age (years) 41.1±12.6 38.1±12.1 0.003 
Recipient Re-sternotomy (%) 59(25.3) 80(21.0) 0.13 
Recipient Diabetes (%) 40(17.2) 22(5.8) <0.001 
Pre-operative Inotropes (%) 120(51.5) 215(56.6) 0.22 
Donor Smoker (%) 119(51.1) 190(50.0) 0.43 
Pre-operative Recipient 
ECMO (%) 
6(2.6) 1(0.3) 0.015 
Pre-operative Recipient VAD       
LVAD (%) 38(16.3) 45(11.8) 0.94 
RVAD (%) 3(1.3) 9 (2.4) 0.35 
BIVAD (%) 29(12.4) 27(7.1) 0.026 
Donor Male: Recipient 
Female (%) 
24(10.3) 32(8.4) 0.43 
Donor Female: Recipient 
Male (%) 
45(19.5) 49(13.0) 0.11 
Table 4-1 Demographic details of all patients undergoing heart transplantation in the United 
Kingdom (01/10/2012-30/9/2016) 
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Figure 4-1 Kaplan-Meier curves depicting the survival of PGD and non-PGD patients. 
(Log-rank= p<0.001) 
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4.4.2  Cohort comparisons 
To ensure the applicability of data, demographic data of both cohorts were 
compared. The demographic data of both cohorts are shown in Table 4-2, 
depicting no statistically significant differences between the derivation and 
validation cohort of patients.  
Details Derivation Cohort 
(n=460) 
Validation 
Cohort (n=153) 
p-value 
Age (years) 46.6±13.4 45.3±14.4 0.304 
Recipient height (cm) 172.6±9.3 173.9±7.9 0.352 
Recipient Weight (kg) 76.7±14.1 75.2±14.2 0.274 
Cardiac Output(L/min) 5.1±2.4 5.3±2.7 0.526 
Cardiac Index (L/min) 2.96±1.2 3.00±1.46 0.238 
MAP (mmHg) (L/min/m2) 71.1±13.8 79.1±15.7 0.763 
Inotrope Score 14.7±10.8 14.3±8.5 0.663 
Total Ischaemic time(mins) 163.7±63.7 163.0±57.3 0.931 
**Time on OCS (mins) 262.3±122.1 246.9±97.2 0.663 
Explant Time(mins) 19.8±9.8 19.7±12.4 0.973 
Implant Time(mins) 55.5±21.1 57.5±20.6 0.306 
Bypass Time(mins) 185.1±82.9 192.7±86.7 0.342 
Donor Height (cm) 174.6±9.0 175.1±8.6 0.533 
Donor Weight (kg) 79.3±14.9 79.2±13.7 0.941 
Donor Age (years) 39.6±12.7 38.3±11.9 0.272 
Donor Smoker (%) 233(50.7) 76(49.7) 0.834 
DCD (%) 20(4.3) 5(3.3) 0.559 
M:F ratio 336:124 122:31 0.099 
Recipient Diabetes Mellitus (%) 46(10.0) 16(10.5) 0.871 
Recipient Re-sternotomy (%) 99(21.5) 40(26.1) 0.237 
Pre-operative ECMO (%) 6(1.3) 1(0.7) 0.687 
Pre-operative VAD (%) 106(23.0) 45(29.4) 0.113 
Gender Mismatch (%) 114(24.8) 42(27.5) 0.512 
Table 4-2 Demographic details of the derivation and validation cohorts of patients. 
** Only DCD and EVNP donations 
The incidence of PGD in the derivation cohort was 38.3%(n=176) and 37.5%(n=57) 
in the validation cohort.  
There was no statistically significant difference between the total ischaemic 
time (for hearts procured using cold storage) for the derivation cohort(n=374) 
and the validation cohort(n=133) (163.7±63.7 mins vs 163.0±57.3 minutes, 
p=0.93). No differences were noted between the time on OCS (for hearts 
procured using EVNP) for the derivation cohort(n=86) and the validation 
cohort(n=20), (262.3±122.1 mins vs 246.9±97.2 mins, p=0.66). 
 
4 PREDICTA -A model to predict Primary Graft Dysfunction after adult 
heart transplantation in the United Kingdom 150 
 
4.4.2.1 Derivation Cohort 
The demographic details of the derivation cohort are listed below.  
Recipient Variables PGD (n=176) No PGD (n=284) 
P- value 
Male: Female ratio 125:51 211:73 0.44 
Age (years) 47.1±13.5 46.3±13.3 0.54 
Recipient Height (cm) 172.0±8.8 173.0±9.5 0.27 
Recipient Weight (kg) 76.8±14.0 76.6±14.7 0.93 
Recipient BMI (kg/m2) 25.9±3.9 25.5±3.9 0.33 
Recipient Creatinine (μmol/L) 105.7±45.7 106.7±38.1 0.38 
Recipient Re-sternotomy (%) 42(23.9) 57(20.1) 0.34 
Recipient Diabetes (%) 27(15.3) 19(6.7) 0.003 
Recipient pre-operative Inotropes 
(%) 
90(51.1) 171(60.2) 0.056 
Pre-operative ECMO (%) 5(2.8) 1(0.4) 0.033 
Pre-operative IABP (%) 15(8.5) 17(6.0) 0.25 
Pre-operative LVAD (%) 26(14.8) 32(11.3) 0.27 
Pre-operative BiVAD (%) 21(11.9) 16(5.6) 0.016 
Pre-operative RVAD (%) 3(1.7) 8(2.8) 0.45 
Pre-operative amiodarone usage 63(35.8) 116(40.8) 0.28 
Recipient Aetiology    
Ischaemic Cardiomyopathy (%) 40(22.7) 54(19.0)  
 
 
 
0.34 
Dilated Cardiomyopathy (%) 95(53.9) 147(51.8) 
Congenital Heart Disease (%) 18(10.2) 28(9.9) 
Other (%) 23(13.1) 55(19.4) 
Table 4-3 Recipient variables between PGD and non-PGD patients in the derivation cohort 
Continuous data are shown as mean ± SD with categorical data shown as an absolute number and 
(percentage). Recipient aetiology shown in grey. MI: Body Mass Index, ECMO: Extracorporeal 
Membranous Oxygenation, LVAD: Left Ventricular Assist Device, BiVAD: Biventricular Ventricular 
Assist Device, RVAD: Right Ventricular Assist Device, IABP: Intra-Aortic Balloon Pump 
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Donor Factors PGD (n=176) No PGD (n=284) P- value 
Donor Height (cm) 174.9±9.1 174.4±9.2 0.59 
Donor Weight (kg) 80.1±15.4 79.0±13.6 0.45 
Estimated Donor LV Mass (g) 148.6±26.9 149.9±28.1 0.64 
Gender Mismatch (%) 26.1 23.9 0.60 
Height Mismatch (%) 2.0±7.6 1.5±8.0 0.54 
Weight mismatch (%) 8.0±30.9 5.6±28.2 0.41 
Estimated LV mass mismatch (%) 3.81±22.9 4.13±22.8 0.81 
Donor Age  41.6±12.6 38.4±12.6 0.007 
Donor LVEF (%) 57.7±10.3 58.9±7.8 0.3 
Donor Smoker (%) 88(50.0) 147(51.7) 0.722 
Donor Cause of death    
Intracerebral haemorrhage/Thrombosis (%) 106(60.4) 164(57.8)  
 
 
 
0.31 
Hypoxic brain injury (%) 12(6.7) 27(9.5) 
Road Traffic Accident (RTA) (%) 22(12.7) 47(16.6 
Meningitis (%) 4(2.2) 12(4.3) 
Other (%) 32(17.9) 34(11.8) 
DCD (%) 6(30) 14(70)  
0.44 DBD (%) 170(38.6) 270(61.4) 
Table 4-4 Donor variables between PGD and non-PGD patients in the derivative cohort 
Continuous data are shown as mean ± SD with categorical data shown as an absolute number and 
(percentage). Donor cause of death shown in grey. LV: Left Ventricle, LVEF: Left Ventricular 
Ejection Fraction, DCD: Donation after Circulatory Death, DBD: Donation after Brainstem Death 
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Operative Details PGD (n=176) Non-PGD 
(n=284) 
P- value 
Perfusion Solution 
St Thomas (%) 146(83.0) 242(85.2)  
0.52 Custodiol (%) 30(17.0) 42(14.8) 
EVNP (%) 33(18.7) 54(19.0)  
0.94 Cold Storage (%) 143(81.3) 230(81.0) 
*Cold Ischaemic Time (mins) 102.5±44.1 99.6±48.6 
 
0.33 
**Time on OCS 221.8±155.8 232.2±136.9 0.72 
Explant Time (mins) 20.0±10.7 20.5±10.5 0.60 
Implant Time (mins) 59.6±21.1 53.0±20.7 0.001 
Total Ischaemic Time (mins) 166.9±63.7 160.5±62.9 0.11 
Bypass Time (mins) 196.3±77.3 
 
187.9±76.2 0.095 
Post-operative details 
Right Atrial Pressure (mmHg)  13.8±4.4 11.7±4.1      <0.001 
PA Mean(mmHg)  22.0±6.0  22.2±5.3 0.93 
Cardiac Index  2.2±1.3 3.1±1.1 <0.001 
MAP (mmHg)  71.5±13.0       78.7±15.8 <0.001 
Inotrope Score 18.9±12.4 12.3±8.8 <0.001 
Blood Products Transfused 
(units) 
8.6±11.3 9.0±34.7  0.078 
Table 4-5 Perioperative and postoperative variables between PGD and non-PGD patients in 
the derivative cohort 
Continuous data are shown as mean ± SD with categorical data shown as an absolute number and 
(percentage). OCS donors denoted with **. EVNP: Ex-vivo Normothermic Perfusion, PA: 
Pulmonary Artery, MAP: Mean Arterial Pressure  
*Non-OCS donors 
 ** OCS donors 
Denotes measures used in the current ISHLT PGD definition 
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From the unadjusted analysis, variables with p<0.1 were included in the 
multivariable analysis. Continuous data were stratified into categorical variables 
with reference categories. Five variables were identified as significant 
predictors of PGD on multivariable analysis. These include 1 donor variable 
(donor age), 2 recipient variables (recipient diabetes mellitus and pre-operative 
recipient MCS), and 2 procedural variables (implant time and bypass time).   
Variable Odds Ratio 95% Confidence 
Intervals 
P-value 
Recipient Diabetes 
Mellitus 
3.04 (1.49, 6.21) 0.002 
Pre-operative MCS 2.73 (1.35, 5.55) 0.009 
Implant time   0.021 
≤45 Minutes Reference Category   
46-60 Minutes 1.80 (1.11, 2.93)  
61-90 Minutes 1.96 (1.22, 3.15)  
>90 Minutes 2.15 (1.01, 4.60)  
Donor Age   0.025 
<21 years  Reference Category   
21-40 years 1.44 (0.72, 2.85)  
41-50 years 1.81 (0.89, 3.67)  
>50 years 2.60 (1.26, 5.37)  
Bypass Time >180 
minutes 
2.53 (1.75, 3.66) 0.000 
Table 4-6 Multivariable analysis of risk factors for PGD from the derivation cohort 
Binary variables in grey, non-binary variables in white. Odds ratios depicted with 95% Confidence 
intervals. MCS: Mechanical Circulatory Support 
An additive score was formulated using the odds ratios (rounded) of binary 
variables with an ordinal scoring system for the non-binary variables with 
respect to the odds ratio. The scoring system was entitled PREDICTA 
(Preoperative mechanical circulatory support in the recipient, Diabetes mellitus 
in the recipient, Cardiopulmonary bypass time>180 minutes, implant Time, 
donor Age) score with the breakdown of its derivatives listed below in Table 4-7. 
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Variable Points 
Pre-operative Mechanical Circulatory Support 3 
Recipient Diabetes Mellitus 3 
Cardiopulmonary Bypass Time >180 minutes 2 
Implant Time   
≤45 Minutes 0 
46-60 Minutes 1 
61-90 Minutes 2 
>90 Minutes 3 
Donor Age   
<21 years  0 
21-40 years 1 
41-50 years 2 
>50 years 3 
Total __/14 
Table 4-7 The PREDICTA score points allocation 
For binary variables, points are allocated as 0 or values depicted in the following boxes. For 
continuous variables, points are allocated based on the values they lie in.  
 
Figure 4-2  PREDICTA score for predicting PGD post-heart transplantation.  
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
<2 2-3 4-5 6-8 >9
Actual PGD 23.26% 27.05% 34.21% 55.74% 61.90%
Predicted 17.85% 32.11% 55.92% 72.13% 80.95%
No of patients 43 122 152 122 21
PREDICTA score for PGD 
Actual PGD Predicted
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The PREDICTA score was calculated by using the values as listed in Table 4-7. 
Rates of actual and predicted PGD were calculated for patients were calculated 
based on the number of risk factors present in the multivariable model. The PGD 
rate increased significantly as the scores increased 
4.4.2.2 Validation cohort 
A PREDICTA score of <3 indicated a low risk for PGD, and a score of >9 coincided 
with a high risk of PGD (>60%). A score of 4-8 indicated a moderate risk for PGD 
with the risk of PGD crossing the 50% mark at 4-5.  
We used the validation cohort to compare the predictive value of the PREDICTA 
score vs the RADIAL score, a validated published PGD predictive score. Area 
under Receiver Operating Characteristics curves was used to compare the 
observed and expected rate of moderate/severe PGD in this cohort (PREDICTA 
Score >4). The AUROC curves are depicted in Figure 4-3. 
The C-statistic of the PREDICTA score was 0.704 vs 0.547 for the RADIAL score 
indicating a good predictive value.  
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Figure 4-3 AUROC curves depicting the predictive value of the PREDICTA score vs RADIAL 
score in the Validation cohort. 
  
 
Test Result Variable(s) Area 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
PREDICTA 0.704 0.619 0.790 
RADIAL 0.547 0.453 0.640 
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4.5 Discussion 
The incidence of PGD in the UK from October 2012-October 2016 was 38% as 
defined by the ISHLT consensus statement. The risk factors identified from the 
derivation cohort included recipient diabetes mellitus, prolonged 
cardiopulmonary bypass time, increasing donor age, pre-operative mechanical 
circulatory support usage and prolonged implant time. The 30-day and 1-year 
mortality were significantly higher in the PGD cohort as shown in Figure 4-1. The 
rate of PGD in our study was also higher when compared to recent single centre 
studies reported in the literature ranging from 10-31% (Seguchi et al. 2016; 
Sabatino et al. 2017b; Squiers et al. 2017a; Nicoara et al. 2018; Pozzi et al. 
2018; Sasha Still et al. 2018). Older studies prior to the consensus statement 
have shown a PGD range of between 2.5-24% with varying centre specific 
definitions of PGD (Jon Kobashigawa et al. 2014). Our previous multicentre study 
showed an incidence of 36% with little variation over the 3 years (S.S. Avtaar 
Singh et al. 2018). We strictly adhered to the ISHLT guidelines thereby 
preventing under-estimation of the true PGD rate by using both LVEF and/or 
inotrope score definitions with corresponding cardiac monitoring studies in all of 
our patients which may have led to the significantly higher number.  
A variety of donor, recipient and procedural factors have been identified in the 
literature to be associated with PGD. However, given the variability in 
definitions and the different periods analysed, there was significant 
heterogeneity noted in risk factors. Some of the risk factors that have been 
suggested include donor age (Sabatino et al. 2017b), pre-operative mechanical 
support, length of ischaemic time (Sabatino et al. 2017b) and recipient diabetes 
mellitus (Sabatino et al. 2017b); all of which were noted in our study. Other risk 
factors such as recipient age (D'Alessandro et al. 2011a), pre-operative recipient 
amiodarone therapy (Wright et al. 2017), recipient inotropic support (Segovia et 
al. 2011), donor inotropic support (D'Alessandro et al. 2011a), donor-to-recipient 
size mismatching (Gong et al. 2018), and donor aetiology of death (D'Alessandro 
et al. 2011a), did not possess predictive value in our study.  
Recipient age was not noted to be significant in more recent studies, potentially 
due to improving medical and device therapy. Recipient amiodarone therapy was 
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not noted to be an increased risk factor for PGD in our study and other previous 
studies (Macdonald et al. 1991; Chelimsky-Fallick et al. 1992; Rivinius et al. 
2016; Cooper et al. 2017). Amiodarone therapy may reflect the pro-
arrhythmogenic state of unwell patients and therefore be a surrogate for the 
critical state of these patients. Analysis of the ISHLT registry highlighted 
increased mortality in recipients with previous amiodarone therapy; however, 
recipient age was a major confounder with more older patients receiving 
amiodarone (Cooper et al. 2017). Pre-operative inotropic support in both the 
donor and recipient were not risk factors for PGD in our study. This could 
possibly reflect the increasing use of VADs in recipients with escalating inotropic 
requirements in the current era and better donor management strategies 
including the use of vasopressin as an inotropic sparing agent (McKeown et al. 
2012). The universal improvement in donor management could also explain the 
lack of difference in donor aetiology of death as a risk factor for PGD.  
We emulated the methodology for LV mass prediction to study the effect of 
donor-recipient mass mismatch as a potential cause for PGD as suggested by 
Gong et al (Gong et al. 2018). However, there was no significant difference in 
the predicted mass mismatch between the two groups, with no donor under-
sizing >30%.  
Prolonged bypass time was noted to be a risk factor for PGD post-transplant. 
Although the aetiology of PGD is multifactorial, the unifying pathophysiology is 
the occurrence of ischaemic reperfusion injury (IRI) (Alam et al. 2015). There 
are a variety of neutrophil-mediated post-ischaemic inflammatory responses that 
propagate this condition, alongside the formation of free radicals that result in a 
cascading series of insults resulting in the inability of the implanted graft to 
meet the circulatory requirements of the recipient. Efforts to minimise the 
effects of IRI include minimising ischaemic time and bypass time has been used 
to good effect in general cardiac surgery (Beyersdorf 2009). Although reperfusion 
occurs while the heart is on the cardiopulmonary bypass circuit, the adequacy of 
reperfusion especially to the ventricles is uncertain (Roshanali et al. 2008). 
Prolonged bypass time also causes vasoplegia with reduced vascular resistance 
with platelet and coagulation factor dysfunction, further contributing to IRI 
(Anselmi et al. 2004). 
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The RADIAL score was the only validated scoring system for prediction of PGD. 
Segovia and colleagues validated it in a Spanish cohort of heart transplant 
patients using a centre specific definition of PGD (Segovia et al. 2011). It 
consists of 6 risk factors derived from a multivariable analysis of 621 heart 
transplants between 1984 and 2006 with a PGD incidence of 9%. From this study, 
they noted that an increased right atrial pressure ≥ 10 mm Hg, recipient age ≥ 60 
years, recipient diabetes mellitus, recipient inotrope dependence, donor age ≥ 
30 years, and length of ischemic time ≥ 240 minutes to be significant risk 
factors. We did not find the RADIAL score to be predictive of PGD in our cohort 
as demonstrated by Figure 4-1. This similar finding was noted by Alina et al 
(Nicoara et al. 2018). They attributed this to the different periods in which the 
heart transplantations had occurred. Certainly, there were increasing numbers 
of re-sternotomies with an increasing number of patients on both short-term and 
long-term mechanical assist devices compared to those in the studies by both 
Carmena(Cosio Carmena et al. 2013) and Segovia(Segovia et al. 2011). The 
donors in our cohort of patients were older as well, in keeping with the general 
trend noted worldwide and especially in Europe with an increased number of 
donors which would be considered extended criteria in previous eras forming a 
substantial proportion of donors today (L. H. Lund et al. 2017). Total ischaemic 
time has been described as a predictor of mortality by Banner et al (Banner et 
al. 2008). However, when looking at it in greater detail, the inclusion of total 
ischaemic time (summation of warm ischaemic time/implant time and cold 
ischaemic time) resulted in a reduced odds ratio when compared to warm 
ischaemic time alone. Similar findings were noted by Marasco’s group (Marasco 
et al. 2012). Warm ischaemic time also proved detrimental in kidney 
transplantation (Tennankore et al. 2016). In addition, the introduction of DCD 
and EVNP has also reduced total ischaemic times and negated the use of static 
cold storage. 
We used a random number generator to ensure there were equal numbers of 
patients in the validation and derivation cohort with DCD and EVNP which were 
more prevalent in the later years of the study. This is the first scoring system 
derived from multiple centres to include patients who have undergone 
transplants using DCD and EVNP hearts. It is, therefore, a more accurate 
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representation of the cohort of patients undergoing heart transplantations in the 
current era.  
We report a 30-day mortality of 18.9% (n=44) in the PGD cohort, majority 
(88.7%) of whom required MCS and therefore were classed as severe PGD. The 
in-hospital mortality, however, was 22.7%. A recent study by Sabatino (Sabatino 
et al. 2017b) reported a higher in-hospital mortality of 12% for moderate PGD 
and 68% for severe PGD. Nicoara and colleagues (Nicoara et al. 2018) reported 
an in-hospital mortality of 23% in the PGD cohort while Squiers et al (Squiers et 
al. 2017a) reported an in-hospital mortality of around 25%. These figures are 
indicative of the nature of the condition which has high post-operative mortality 
and morbidity. Identification of risk factors using scoring systems like the 
PREDICTA score or RADIAL score may, therefore, assist in resource allocation and 
planning. 
4.6 Limitation 
There are several limitations to our study. The multicentre nature of the study 
introduces several different peri-transplant protocols, especially in post-
operative management. The choice of inotropes and escalation of therapy is 
determined by centre specific experience and clinician familiarity. The 
retrospective nature of the study may also introduce uncontrolled biases that 
may have influenced decision-making at the time of transplantation. The score 
was tested in a UK cohort of patients and may require external validation to 
ascertain feasibility and suitability in other centres.  
I was unable to collect accurate cumulative dosages of amiodarone therapy. I 
was, however, able to ascertain if a recipient had previously received 
amiodarone. The relatively small sample size is also a limiting factor in this 
study. However, to date, this is the largest multicentre PGD study in the 
literature.  
4.7 Conclusion 
This is the first comprehensive national validated model for PGD after heart 
transplantation using the ISHLT definition. It identifies the donor, recipient and 
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procedural risk factors for PGD. The PREDICTA score is able to accurately predict 
PGD and is superior to the RADIAL score when used in recent cohorts of patients. 
It may help identify patients who are at risk of PGD and therefore allow risk 
stratification and resource planning for management and therapeutic 
interventions. Further multicentre studies are needed to determine the 
applicability of the PREDICTA score in other centres.  
  
 
  
 
5 The Glasgow Experience of extended 
myocardial protection: A novel method of 
implantation to reduce primary graft dysfunction 
after heart transplantation 
  
5 The Glasgow Experience of extended myocardial protection: A novel 
method of implantation to reduce primary graft dysfunction after heart 
transplantation 163 
 
5.1 Abstract 
Background 
With the increasing demand for organs with a limited supply of donors, novel 
techniques such as ex-vivo normothermic perfusion have garnered increasing 
interest. We present a series of patients who underwent heart transplantation at 
our unit using a novel implantation technique to reduce PGD.  
Methods 
All recipients at our centre received inhaled nitric oxide during induction. On 
arrival to theatre, the donor heart is removed from cold static storage and 
placed in an ice slush basin. A small aortic cross-clamp is applied distal to the 
donor ascending aorta.  An antegrade infusion of 600mls of cold blood 
cardioplegia followed by cold oxygenated blood (4-6oC) is infused to achieve a 
mean aortic root pressure of 60-70 mmHg employing a constant pressure-
variable CPB flow pump with an in-situ leucocyte depleting filter. This 
continuous antegrade perfusion is maintained throughout the left atrium and 
Aortic anastomosis with a left ventricular vent in situ. Upon completion of the 
aortic anastomosis, a warm cardioplegia hotshot is infused into the aortic root 
followed by removal of the recipient aortic cross-clamp. 
Systemic perfusion is initiated with continued aortic root and LV venting. The 
remaining anastomoses are carried out in the usual fashion sequentially. 
We compared our experience with this method with a contemporary national UK 
cohort (2015-2016) of patients (Control Group). We performed multivariable 
logistic regression comparing the Glasgow Experience to the control group PGD 
as the outcome measure. Confounders adjusted for include donor age, recipient 
diabetes mellitus, urgent listing status, bypass time and total ischaemic time. 
Results 
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140 (72.1 %) patients were male. 36(18.6%) of the patients had ischaemic 
cardiomyopathy. The odds ratio of PGD in the control group was 2.99 (95% CI 
1.02- 8.75) when compared to the Glasgow Experience. 
Conclusion 
This novel approach is associated with significant reductions in PGD rates with a 
trend towards improved 1-year survival. Larger studies are needed to show 
differences after further adjustment for known confounders of PGD. We believe 
this novel technique is safe, cost-effective and reproducible.  
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5.2 Introduction 
The high rates of PGD across Europe have resulted in a renewed interest in 
perfecting myocardial protection techniques to increase the yield of organs 
retrieved. With the increasing demand for organs from a limited supply of 
donors, novel techniques such as the use of ex-vivo normothermic perfusion have 
also been introduced although the cost of the equipment limits its widespread 
usage. Despite this, the incidence of PGD remains unchanged(S.S. Avtaar Singh 
et al. 2018). Improving myocardial protection may play a role in reducing the 
incidence of PGD and improving early mortality rates.  
Wheeldon and co-workers noted that up to 55% of the surveyed transplant 
centres used some form of reperfusion during heart transplantation (Wheeldon 
et al. 1992). This includes intermittent cold blood or oxygenated crystalloid 
cardioplegia during implantation of the heart followed by the administration of 
‘hot shots’ as described by Buckberg (Buckberg 1989).  
We present a cohort of patients who underwent heart transplantation at our unit 
using a novel implantation technique aimed to reduce PGD. We used a national 
cohort of patients (UK-wide) who received heart transplants within this period as 
controls. Our co-primary outcome measures were the incidence of PGD and all-
cause mortality at 1 year.  
5.3 Objectives 
The Glasgow method of implantation was first introduced following a review by 
CTAG triggered after the unit was identified as an outlier. We identified the 
geographical limitations of the unit (being furthest north with the largest zonal 
allocation but the smallest population) as a risk factor and implemented several 
proven techniques to reduce warm ischaemic time to improve outcomes. We 
audited our results and compared it with the national average. 
We utilised the enhanced recovery technique (ERAS) of employing a summation 
of marginal gains to improve outcomes. This serves as a proof of concept prior to 
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application for an animal model study to identify biochemical improvements to 
supplement the clinical outcomes. 
5.4 Method 
5.4.1 Operative technique 
All recipients at our centre receive inhaled nitric oxide at 20ppm during 
induction of anaesthesia. On arrival to theatre, the donor heart is removed from 
cold static storage and placed in an ice slush basin. 
An aortic cross-clamp is applied onto the donor ascending aorta. An aortic root 
cannula (model 23009, DLPTM (11 Fr (9ga) (13.3cm) Aortic Root Cannula, 
Medtronic Inc., Minneapolis, MN) is inserted and secured in the ascending aorta, 
close to the aortic root anteriorly. 
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Figure 5-1 Insertion of DLP cannula in the aortic root of donor heart 
An antegrade infusion of adenosine (12mg) followed by 700mls solution of blood 
cardioplegia and St Thomas’s solution (4:1), at 4ºC followed by cold oxygenated 
blood (4-6oC) is infused to achieve a mean aortic root pressure of 60-70 mmHg 
with flows of 200-300 ml/min employing a constant pressure-variable CPB flow 
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pump through an in-situ leucocyte depleting filter (Pall LeukoGuard LG Arterial 
Filter (Pall Biomedical, Portsmouth, UK). 
 
Figure 5-2 Administration of Adenosine to the aortic root (donor heart) 
This continuous antegrade perfusion is maintained throughout the left atrium 
and aortic anastomosis with a left ventricular vent in situ. 
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Figure 5-3 LA anastomosis with a vent in situ 
Upon completion of the aortic anastomosis, the Y-limb of the DLP cannula is 
then connected to a de-airing channel for de-airing of the ascending aorta and 
aortic root followed by gradual rewarming of infused blood before removal of 
the recipient aortic cross-clamp.  
Systemic perfusion is initiated with continued aortic root and LV venting. The 
remaining anastomoses are carried out in the usual fashion sequentially with 
5 The Glasgow Experience of extended myocardial protection: A novel 
method of implantation to reduce primary graft dysfunction after heart 
transplantation 170 
 
pulmonary artery, inferior vena cava and superior vena cava with normothermic 
systemic perfusion and ventricular pacing. 
 
Figure 5-4 Pulmonary artery anastomosis (Aortic Cross-Clamp released) 
5.4.2 Statistical Methodology 
We compared our experience with this method with the national UK cohort 
(2015-2016) of patients (Control Group). Transplanted hearts procured using 
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normothermic ex-vivo perfusion (TransMedics Organ Care System (OCS) Andover, 
MA, USA) were excluded from the study. Continuous variables were described by 
mean and standard deviation. Categorical variables were expressed as a 
percentage. Baseline characteristics were compared between the intervention 
and control groups using Student’s t-test and Mann Whitney U test as 
appropriate and chi-square test or Fisher’s exact test for categorical variables. 
Variables with significance of p<0.1 in the unadjusted analysis were initially 
introduced as candidate variables in a multivariable logistic regression model for 
the probability of PGD and removed by stepwise backward elimination. Other 
variables of interest that have been shown to contribute to PGD were also 
included in the multivariable analysis. Variables were retained in the model if 
they reduced the model deviance significantly (p<0.05). Analysis was conducted 
in Minitab 17 Statistical Software (2010), Minitab, Inc.  
5.5 Results 
A total of 194 patients were studied; 28 patients were in the Glasgow group and 
166 in the control group. The mean age of the recipients was 47.5±13.7 years 
and the donors were 38.2±12.1 years.  
The incidence of PGD was 39.2% (n=76) with 14.9%(n=29) of patients having 
severe PGD requiring institution of advanced mechanical circulatory support 
within 24 hours of transplantation. The demographic details of the patients in 
the 2 groups are as follows.  
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Table 5-1 Pre-operative characteristics of recipients 
Details Glasgow (n=28) Control (n=166) p-value 
Male: Female ratio  21:7 119:47 0.456 
Age (years) 48.6±11.6 46.8±13.8 0.581 
BMI (Kg/m2) 25.3±3.6 25.7±3.8 0.583 
Creatinine (μmol/L) 93.3±28.9 104.1±37.7 0.147 
Diabetes Mellitus (%) 0 15.2 0.026 
Urgent listing status 
(INTERMACS 1-3) 
85.7 59.6 0.005 
Pre-operative LT LVAD (%) 10.7 9.9 0.990 
Recipient Re-sternotomy (%) 35.7 23.5 0.169 
Recipient Aetiology    
Ischaemic Cardiomyopathy 21.4 18.0  
 
 
 
 
0.426 
Dilated Cardiomyopathy 67.9 55.4 
Congenital Heart Disease 0 7.8 
HOCM/ Restrictive 
Cardiomyopathy 
7.1 12.0 
Other 3.6 6.6 
  
5 The Glasgow Experience of extended myocardial protection: A novel 
method of implantation to reduce primary graft dysfunction after heart 
transplantation 173 
 
 
Donor Factors Glasgow (n=28) Control (n=166) p- value 
Donor Cause of death    
 
 
 
 
0.198 
Intracerebral haemorrhage (%) 67.8 53.6 
Hypoxic brain injury (%) 17.9 26.0 
Road Traffic Accident (%) 3.6 9.7 
Meningitis (%) 3.6 9.0. 
Intracerebral malignancy (%) 7.1 1.8 
Donor Gender (M: F) 18:10 117:49 0.510 
Donor Age  36.5±11.4 38.5±12.2 0.409 
Donor BMI (kg/m2) 27.1±4.9 25.8±4.5 0.135 
Donor LVEF (%) 60.7±6.1 58.2±9.3 0.267 
Donor Smoker (%) 45.4 56.0 0.349 
Height Mismatch (%) 1.2±8.0 1.2±8.0 0.659 
Weight mismatch (%) 10.7±17.7 5.7±25.2 0.389 
Estimated LV mass mismatch (%) * -7.5±23.0 -7.6±30.5 0.997 
Donor: Recipient Gender Mismatch (%) 25.0 25.0 0.973 
Table 5-2  Pre-operative characteristics of donors 
Mismatch calculated as [(Measure (recipient) − Measure(donor)/Measure(recipient)] X 100 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝐿𝑒𝑓𝑡 𝑣𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 𝑚𝑎𝑠𝑠(𝑔) = 𝛼 ∗ 𝐻𝑒𝑖𝑔ℎ𝑡0.54(𝑚) ∗ 𝑊𝑒𝑖𝑔ℎ𝑡0.61(𝑘𝑔) 
𝑤ℎ𝑒𝑟𝑒 𝛼 =  6.82 𝑓𝑜𝑟 𝑤𝑜𝑚𝑒𝑛 𝑎𝑛𝑑 8.25 𝑓𝑜𝑟 𝑚𝑒𝑛 
LV Mismatch calculated by 
(𝒑𝑯𝑴𝒓𝒆𝒄𝒊𝒑𝒊𝒆𝒏𝒕 − 𝒑𝑯𝑴𝒅𝒐𝒏𝒐𝒓)
𝒑𝑯𝑴𝒓𝒆𝒄𝒊𝒑𝒊𝒆𝒏𝒕
∗ 𝟏𝟎𝟎 
(R. M. Reed et al. 2014) 
There were more diabetic recipients in the control group and a higher incidence 
of pre-operative urgent listed patients in the Glasgow group. All other donor and 
recipient demographic parameters were comparable across the groups. 
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Details Glasgow 
(n=28) 
Control (n=166) P-value 
Total Ischaemic time (min) 154.3±52.1 170.0±46.4 0.143 
Cold Ischaemic time (min)  116.9±48.2 100.8±46.4 0.093 
Explant Time(min) 20.6±9.9 18.9±12.3 0.502 
Implant time (min) 50.3±20.3 63.9±17.5 0.020 
Bypass Time (min) 217.6±64.2 189.8±87.4 0.11 
Inotrope Score (units) 14.6±7.9 14.5±7.9 0.987 
Post-operative Cardiac Index  2.8±0.8 2.8±1.1 0.975 
Post-operative Right Atrial Pressure (mmHg) 11.2±3.2 12.9±4.8 0.023 
Post-Operative Mean Arterial Pressure 
(mmHg) 
72.2±9.8 73.8±13.8 0.491 
Post-Operative Pulmonary Capillary Wedge 
Pressure (mmHg) 
10.4±5.2 16.0±6.4 0.004 
Post-Operative Mean Pulmonary Arterial 
Pressure (mmHg) 
18.5±6.0 23.2±5.7 0.002 
Post-operative ECMO (%) 14.3 15.1 0.590 
Post-operative newly inserted IABP (%) 17.8 22.9 0.552 
30-day Mortality (%) 0 9.6 0.088 
1-year Survival (%) 96.4 83.7 0.059 
Post-operative PGD (%) 21.4 42.2 0.038 
Post-operative PGD-RV (%) 0 3.6 0.387 
Table 5-3 Post-operative outcomes of both cohorts 
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Post-operative outcomes showed similar total ischaemic times for both groups 
with similar rates of MCS and IABP institution rates. The cold ischaemic time was 
longer in the Glasgow group as part of the operative technique although this did 
not reach statistical significance (p=0.093). Bypass times were also longer in the 
Glasgow cohort (p=0.013). 
The Glasgow Experience patients had a lower pulmonary capillary wedge 
pressure and mean Pulmonary Arterial Pressure compared to the control group 
with an overall reduction in post-operative PGD rates. The mortality at 1 year 
was not significantly different between the groups.  
We did not include the PCWP, mPAP, and CVP in the multivariable analysis as 
they were part of the diagnostic criteria of PGD. Parameters included in the 
multivariable analysis to assess independent predictors of PGD included bypass 
time, donor age, recipient diabetes status, urgent listing status alongside 
grouping (Glasgow vs Control). The results of the multivariable analysis are 
presented in Table 5-4 
Risk factor β coefficient OR (95% CI) p-value 
Donor Age 0.035   1.036(1.008, 1.065) 0.010 
Bypass Time 0.011 1.01 (1.005, 1.017) <0.001 
Grouping (Control) 1.102 2.99(1.02, 8.75) 0.033 
Diabetes Mellitus 2.00   6.29 (2.19, 18.04) 0.001 
Table 5-4 Independent predictors of PGD from multivariable logistic regression 
The odds ratio of PGD in the control group was 2.99 (95% CI (1.02, 8.75)) when 
compared to the Glasgow Experience. 
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5.6 Discussion 
5.6.1 Functional warm ischaemia time 
This novel technique utilizes a minimisation in functional warm ischaemic time 
by antegrade perfusion of the donor graft using cold blood cardioplegia alongside 
topical cooling. Cardioplegia negates the electromechanical energy consumption 
associated with myocyte contraction thereby reducing myocardial oxygen 
demand. In addition, the topical cooling reduces enzymatic reactions which in 
turn reduces cellular metabolism (Banner et al. 2008). Several studies have 
shown similar findings with prolonged warm ischaemia linked with an increased 
incidence of PGD. Avtaar Singh and colleagues highlighted the role of prolonged 
warm ischaemia time as an independent predictor of PGD(S.S. Avtaar Singh et 
al. 2018). Marasco’s group noted that warm ischaemic time in excess of 80 
minutes was associated with reduced survival when compared to a warm 
ischaemic time of fewer than 60 minutes(Marasco et al. 2012). Both the studies 
also noted donor age to be a significant independent predictor of PGD and 
survival as noted in our cohort. Conversely, prolonged cold ischaemic time was 
not associated with PGD in our cohort. These findings were also noted by the 
UCLA group in which cold ischaemic times of > 300 minutes were not associated 
with adverse outcomes (Mitropoulos et al. 2005). This could be due to 
attenuation of ischaemic reperfusion injury (IRI) which is thought to be the 
pathophysiological basis of PGD. Registry data from ISHLT is difficult to interpret 
given the overlapping results of warm and cold ischaemic time, commonly 
presented as a total ischaemic time (Lars H. Lund et al. 2017b). Other solid 
organ transplantation studies have also shown a direct correlation between 
increased warm ischaemic time and IRI(Zhai et al. 2013; Tennankore et al. 
2016). Ischaemia promotes the expression of proinflammatory factors and 
bioactive agents such as leucocyte adhesion molecules, cytokines, endothelin, 
thromboxane A2 while repressing ‘protective’ factors like constitutive nitric 
oxide (NO) synthase, thrombomodulin, and prostacyclin (Eltzschig and Collard 
2004).  
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The use of continuous antegrade oxygenated cold blood perfusion ensures 
universal cooling of the heart. The oxygen delivery is impaired at hypothermia as 
the dissociation curve of haemoglobin is displaced toward the left, and oxygen 
delivered to the tissues is mainly transported in the dissolved form. However, as 
opposed to cold crystalloid, oxygenated blood has a buffer capacity of the 
imidazole nucleus of the haemoglobin molecule (Bachet et al. 1999). Cold blood 
cardioplegia usage also resulted in lower post-operative cardiac enzyme levels 
when compared to cold crystalloid cardioplegia in general cardiac procedures 
(Braathen and Tønnessen 2010).  
5.6.2 Ischaemic reperfusion injury 
The length of ischaemia has a direct effect on cell dysfunction leading to cell 
injury or death, with reperfusion being the ideal treatment option. Reperfusion 
restores oxygen delivery to facilitate aerobic ATP generation while flushing out 
H+ accumulation from anaerobic states. Jennings initially described an 
accelerated state of necrosis on reperfusion in 1960, coining the term 
reperfusion injury (Jennings et al. 1960). It arises due to rapid generation of 
reactive oxygen species, increased intracellular calcium due to attenuated ATP-
dependent exchangers, the opening of Mitochondrial Permeable Transition Pores 
(MPTP) which dissipates mitochondrial membrane potential, and endothelial 
dysfunction accompanied by activation of inflammatory pathways leading to a 
vicious cycle of increasing tissue injury (Yellon and Hausenloy 2007).  
5.6.3 Inhaled Nitric oxide (NO) 
We hence utilized targeted therapeutic strategies to attenuate IRI. Inhaled NO 
may play a role as a preconditioning factor alongside a pulmonary vascular 
dilator. NO has antioxidant properties not related to alterations in neutrophil 
migration or adhesion but by reduction by NO of superoxide anion-mediated 
tissue toxicity which may account for much of the protective effect of NO during 
IRI (Phillips et al. 2009). It also acts as an oxygen radical scavenger (Massoudy et 
al. 1995). It attenuates the effects of reperfusion by competitively binding to 
cytochrome-c oxidase. This prevents abrupt resumption of the electron transport 
chain during reperfusion with oxygen-rich blood which would result in the 
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generation of oxygen radicals (Jones and Bolli 2006). Its role in reducing RV 
afterload is well established in the literature (Lindberg et al. 1994; Fullerton et 
al. 1996) as is its role as a coronary vasodilator (Quyyumi et al. 1995). The thin-
walled RV is more compliant thus accommodates right-sided venous return well 
but struggles against acute increases in afterload, resulting in dilation and 
impaired contractility (Hurford and Zapol 1988; Vonk Noordegraaf et al. 2017). 
Reducing the afterload may, therefore, assist the rewarming RV contraction and 
prevent dilation. The coronary vasodilatory effect may also allow greater 
reperfusion and controlled rewarming of the donor graft on release of the aortic 
cross-clamp.  
5.6.4 Leukocyte depleting filter 
We use a leukocyte depleting filter (LDF) in all cases to prevent leukocyte-
mediated IRI. Leukocyte activation results in chemotaxis, leukocyte-endothelial 
cell adhesion and transmigration.  Activated leucocytes release toxic oxygen 
radicals, proteases and elastases, resulting in increased microvascular 
permeability, oedema, thrombosis, and parenchymal cell death while activating 
a positive feedback loop resulting in increased transmigration(Carden and 
Granger 2000). The role of LDF in reducing myocardial reperfusion injury in 
general cardiac surgery is well understood with reductions in biochemical 
markers and post-operative inotropic requirements without any difference in 
clinical outcomes (Han et al. 2013). In heart transplants, it has been shown to 
reduce creatinine phosphokinase-MB and thromboxane B2 post-reperfusion (Pearl 
et al. 1992). Another trial showed similar results with reduced markers of 
reperfusion injury, easier wean off cardiopulmonary bypass and lower need for 
inotropic support post-operatively (Dvorak et al. 2006). 
5.6.5 Ischaemic Pre-conditioning 
Ischaemic preconditioning has been shown to improve ventricular function and 
reduce myocardial neutrophil accumulation and apoptosis in experimental 
models (Kloner and Jennings 2001). It is associated with an increase in 
extracellular adenosine production with experimental studies highlighting the 
role of A1, A2a and A3 ADO receptor involvement in endogenous cardioprotective 
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responses (Auchampach et al. 1997; Linden 2001). The administration of 
adenosine to the donor graft during perfusion permits the preconditioning effect 
enhances coronary vasodilation while slowing the sinoatrial nodal pacemaker 
rate, delaying atrioventricular nodal impulse conduction and reducing atrial 
contractility; all of which may contribute to ensuring the heart is arrested while 
cardioplegia is administered after removal from cold storage. In heart valve 
replacement operations, it has been shown to reduce cTnI, IL-6 and IL-8 release, 
resulting in less myocardium injury in ultrastructure after surgery(Liu et al. 
2009).  
5.7 Limitations  
The study has some limitations. Due to the multicentre nature of the control 
group, regional variations between patient management strategies such as 
inotropic preference and choice of immunosuppression cannot be accounted for. 
Some standardized criteria are established by the Cardiothoracic Advisory Group 
(CTAG) and the National Health Service Blood and Transfusion to keep the 
variations to a minimum. The current experience at our centre with the nascent 
method is relatively new, hence the smaller numbers in the Glasgow cohort. We 
were unable to collect biomarkers to assess the biochemical changes postulated 
by this method. 
Another major limitation is the number of patients with diabetes in the control 
group. As identified in Chapter 3, diabetes is an independent predictor of PGD. 
Despite covariate adjustment, the true impact of diabetes mellitus on outcomes 
remains unknown. Other methods that could have been used such as propensity 
score stratification, propensity score matching and propensity score inverse 
probability weighting all have their limitations in smaller cohorts, without 
accounting for confounding and is less precise(Elze et al. 2017). Ongoing studies 
or animal model studies may highlight the impact of diabetes mellitus towards 
outcomes using this method. 
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5.8 Conclusion 
This novel approach is associated with significant reductions in PGD rates with a 
trend towards improved 1-year survival. Larger studies are needed to show 
differences after further adjustment for known confounders of PGD. We believe 
this novel technique is safe, cost-effective and reproducible. 
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6.1 Abstract 
Background 
There are 0.9 catheterization labs per 100,000 inhabitants in Scotland for 
percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), 
which are much less accessible to patients in remote and rural areas. An 
uncommon but sinister sequela following AMI is cardiogenic shock (CS) that could 
be refractory to inotropic support. CS complicates 5-15% of AMIs occurring in ST-
segment Elevation Myocardial Infarctions (STEMIs). Outcomes of CS are poor with 
mortalities of up to 90% reported in the literature in the absence of experienced 
care (9). We report our experience as the tertiary referral centre in Scotland for 
MCS and heart transplantation over 8 years. 
Methods 
A retrospective review of prospectively collected data was undertaken on all 
patients registered to the MCS service. The database was interrogated for 
patient demographics, type of mechanical circulatory support and duration of 
MCS support, PCI-outcomes and survival to 30-days. Time-To-Event analysis was 
performed using patient survival as the primary outcome measure.  
Results 
Twenty-three patients (16M:7F) were included. The median age of the patients 
as 50 years (45-56 years). VA-ECMO was the initial MCS of choice in 17(73.9%) 
patients with BIVAD for 4(17.4%) patients and LVAD for 2(8.7%) patients. 30-day 
mortality was 21.8% in this cohort, however, survival to discharge was 52.2%.  
Eleven (47.8%) patients recovered without the need for any further support, 
however, only 9 (81.8%) patients in this subgroup survived to discharge. Three 
(13%) patients received a durable LVAD. In this subgroup, one patient was 
transplanted whereas two patients died due to complications while on support. 
The median length of in-hospital MCS support was 4 days. The median in-hospital 
stay was 27 days. 
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Long-term follow up of up to 8 years demonstrates a high mortality beyond 30-
days up to the first 6-months post MCS support.  
Conclusion 
MCS usage in these patients carries a high mortality in the early post-
implantation period. However, there is a significant benefit to patients who 
survive the initial bridging period to recovery or destination therapy 
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6.2 Introduction 
In the preceding decades, Scotland has drastically reduced the mortality from 
coronary heart disease (72% reduction in 2009 compared to 1950)(Lewsey et al. 
2015). Despite this, post-MI mortality remains among the highest in Western 
Europe(Lewsey et al. 2015), branding  Scotland as the ‘sick man of Europe’ 
(McCartney et al. 2012). The inequalities in Scottish morbidity and mortality 
have resulted in an overall increase in health inequalities across the United 
Kingdom(Hanlon et al. 2005). Ischaemic heart disease is associated with a higher 
level of disability-adjusted life years (DALY) than any other condition in 
Scotland, mirroring not just the UK, but also DALY in the Global Burden of 
Disease Survey('Global, regional, and national disability-adjusted life-years 
(DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-
2015: a systematic analysis for the Global Burden of Disease Study 2015'  2016). 
There are 0.9 catheterization labs per 100,000 inhabitants in Scotland for 
percutaneous coronary intervention (PCI) for acute myocardial infarction 
(AMI)(Hagen et al. 2015), which are much less accessible to patients in remote 
and rural areas. An uncommon but sinister sequela following AMI is cardiogenic 
shock (CS) that could be refractory to inotropic support. CS complicates 5-15% of 
AMIs occurring in ST-segment Elevation Myocardial Infarctions (STEMIs)(Babaev et 
al. 2005; Goldberg et al. 2009; Aissaoui et al. 2012). Outcomes of CS are poor 
with mortalities of up to 90% reported in the literature in the absence of 
experienced care(Reynolds and Hochman 2008).  
Initial management of CS consists of identifying incidental complications e.g. 
acute left ventricular rupture or mitral regurgitation, assessing haemodynamics, 
and optimising the reperfusion in the culprit coronary artery. Clinical trials of 
therapeutic interventions have not led to changes in practice. The results of the 
Intra-Aortic Balloon Pump in Cardiogenic shock II (IABP-SHOCK II) trial 
highlighted the lack of survival benefit from the routine use of IABP therapy for 
this condition(Thiele et al. 2012). The only available option for patients with 
refractory, life-threatening illness would be the institution of mechanical 
circulatory support (MCS), involving either Extracorporeal Membranous 
Oxygenation (ECMO) or Ventricular Assist Devices (VADs). MCS can potentially 
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improve survival, however, the evidence is lacking. EURO-SHOCK (ID754946-2), 
which is a clinical trial funded by the EU-Horizons 2020 7th Framework 
programme, will address this gap. EURO-SHOCK is a multicentre, randomised, 
controlled trial of management involving ECMO vs. standard care without ECMO 
in patients with cardiogenic shock post-MI. Given the current gap in knowledge, 
we studied the outcomes following the use of MCS for treatment of cardiogenic 
shock post-AMI in Scotland during an 8-year period.  
6.3 Methodology 
6.3.1 Patients 
All patients who were referred to the MCS service in the Golden Jubilee National 
Hospital from January 2009 - August 2017 following primary PCI-treated ST-
segment elevation MI (STEMI) with refractory cardiogenic shock were included in 
this study.  
A retrospective review of prospectively collected data was undertaken on all 
patients registered to the MCS service. The database was interrogated for 
patient demographics, type of mechanical circulatory support (Veno-arterial 
Extracorporeal Membranous Oxygenation/Ventricular Assist Device) and duration 
of MCS support, PCI-outcomes and survival to 30-days. Time-To-Event analysis 
was performed using patient survival as the primary outcome measure. Kaplan-
Meier curves were used to graphically display data of 30-day survival. Students t-
tests and Mann-Whitney U tests were used to analyse data for 30-day survival for 
continuous data with Fisher’s exact test used for categorical data. The study was 
registered with the Clinical Governance and Audit Department at the Golden 
Jubilee National Hospital with a data protection registration number Z7996020  
6.4 Results  
Twenty-three patients (16M:7F) were included. The median age of the patients 
as 50 years (45-56 years). VA-ECMO was the initial MCS of choice in 17(73.9%) 
patients with BIVAD for 4(17.4%) patients and LVAD for 2(8.7%) patients. 30-day 
mortality was 21.8% in this cohort, however, survival to discharge was 52.2%.  
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Eleven (47.8%) patients recovered without the need for any further support, 
however, only 9 (81.8%) patients in this subgroup survived to discharge. Three 
(13%) patients received a durable LVAD. In this subgroup, one patient was 
transplanted whereas two patients died due to complications while on support 
(VAD thrombus, Disseminated Intravascular Coagulation).  
The median length of in-hospital MCS support was 4 days (4-43 days). The 
median in-hospital stay was 27 days (9-41 days). The 30-day mortality data of 
survivors vs. non-survivors are as follows. 
Details 
 
Total 
(n=23) 
Survivors 
(n=18) 
Non-Survivor 
(n=5) 
p-value 
Age (years) 50 (11)  50 (9.3) 56 (16) 0.289 
Male gender (%) 65 72  60  0.599 
BMI (kg/m2) 28.2±3.3 28.7±2.7 27.2±4.1 0.337 
Hypertension (%) 13 (3/23) 6 (1/18) 40 (3/5) 0.021 
Smoker (%) 35 (8/23)  38 (7/18) 20 (1/5) 0.621 
Diabetes Mellitus (%) 4 (1/23) 0 20 (1/5) 0.217 
Blood Group A (%) 48 (11/23)  44 (8/18) 60 (3/5) 0.640 
Table 6-1 Preoperative demographics of survivors and non-survivors 
The first column highlights the total cohort with survivors and non-survivors highlighted in 
the succeeding columns. Continuous variables are expressed as median (Interquartile 
Range) while categorical variables are depicted as percentages (numerator= total affected/ 
denominator (sample size)) 
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Details  
 
Total (n=23) Survivors (n=18) Non-Survivor 
(n=5) 
p-value 
Post PCI MAP mmHg 47.9±8.1 48.1±8.7 47.0±5.4 0.755 
Creatinine μmol/L 200.7±109.2 198.4±87.9     201±120 0.951 
PCI - MCS initiation 
time (hours) 
7 (18.5) 8 (19.5) 4 (2) 0.370 
CPR in Cath Lab % (n) 48 (11/23) 39 (7/18) 80 (4/5) 0.155 
IABP in Cath Lab % (n) 91 (21/23) 94 (17/18) 80 (4/5) 0.395 
Bilirubin mg/dL 11.5 (11) 11 (11) 16 (10) 0.551 
AST u/L 463 (457.5) 383 (396.5) 825 (1298) 0.052 
ALT u/L 174 (234) 164 (201.5) 258 (487) 0.126 
HsTnI ng/L 18057(11241) 18057(12422) 20211(12708) 0.559 
Pulmonary oedema at 
presentation % (n) 
78 (18/23) 72(13/18) 100 (5/5) 0.545 
Culprit Vessel 
Isolated LAD % (n) 39 (9/23) 39 (7/18) 40 (2/5) 0.999 
Isolated RCA % (n) 26 (6/23) 33 (6/18) 0 0.272 
Isolated LCx % (n) 4 (1/23) 0 (0/18) 20 (1/5) 0.217 
Isolated LMS% (n) 9 (2/23) 11 (2/18) 0 0.999 
>1 vessel involvement 
% (n) 
22 (5/23) 17 (3/18) 40 (2/5) 0.291 
Table 6-2  PCI demographics of survivors’ vs non-survivors 
The first column highlights the total cohort with survivors and non-survivors highlighted in 
the succeeding columns. Continuous variables are expressed as median (Interquartile 
Range) while categorical variables are depicted as percentages (numerator= total affected/ 
denominator (sample size)) 
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Details  
 
Total 
(n=23) 
Survivors (n=18) Non-Survivor 
(n=5) 
p-value 
ECMO (%) 74 (17/23) 72 (13/18) 80 (4/5) 0.999 
VAD (%) 26 (6/23) 28 (5/18) 20 (1/5) 0.999 
Post MCS Lactate 
(mmol/L) 
6.64±3.64 6.07±3.22 8.60±5.03  0.339 
PaO2/FiO2  0.402±0.135 0.394±0.133 0.444±0.169 0.675 
Post MCS MAP 
(mmHg) 
64.83±6.76 64.44±7.59 66.20±3.90 0.494 
Inotrope Score 25.0±18.3 18.1±10.2  50.0±22.1 0.035 
Platelet (x 103 
units/ u/L) 
211.4±81.2 216.9±87.1 176.2±61.6 0.267 
CRRT post-MCS 48(11/23) 61(11/18) 0(0/5) 0.037 
Sequential Organ 
Failure 
Assessment Score 
(SOFA) 
8.00±2.35 8.22±2.51  
 
7.20±1.64 0.307 
Table 6-3 Postoperative details of the patients 
The first column highlights the total cohort with survivors and non-survivors highlighted in 
the succeeding columns. Continuous variables are expressed as Mean±SD while categorical 
variables are depicted as percentages (numerator= total affected/ denominator (sample 
size)) 
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Complications  
 
Total 
(n=23) 
Survivors 
(n=18) 
Non-Survivor 
(n=5) 
p-value 
Pump Thrombus % (n) 8 (2/23) 6 (1/18) 20(1/5) 0.395 
Bleeding % (n) 13 (3/23) 11 (2/18) 20(1/5) 0.539 
ICH % (n) 13 (3/23) 11 (2/18) 20(1/5) 0.539 
TIA/Stroke % (n) 13 (3/23) 17 (3/18) 0(0/5) 0.999 
Distal Limb Amputation % (n) 8 (2/23) 11 (2/18) 0(0/5) 0.999 
Ischaemic colitis % (n) 4 (1/23) 0(0/18) 20(1/5) 0.999 
Malignant Arrhythmia % (n) 8 (2/23) 11(2/18) 0(0/5) 0.999 
Aspiration pneumonia 4 (1/23) 0(0/18) 20(1/5) 0.250 
Table 6-4 Post-operative complications of survivors vs non-survivors 
The first column highlights the total cohort with survivors and non-survivors highlighted in 
the succeeding columns. Variables are depicted as percentages (numerator= total affected/ 
denominator (sample size)) 
6.4.1 Removal of MCS 
Death post-removal of the MCS device was caused by malignant arrhythmia 
(n=2). 
6.4.2 Post 30-day survival 
Three (13%) of patients underwent heart transplantation and are well at up to 6 
years post-operatively.  
Patients who were successfully weaned had a mean ejection fraction of 
35.6±10.2% and received ongoing heart failure medical therapy.  
 
Figure 6-1 Kaplan Meier curve showing 30-day survival 
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Long-term follow up of up to 8 years is depicted in Figure 6-2. The curve 
demonstrates a high mortality beyond 30-days up to the first 6-months post MCS 
support.  
 
Figure 6-2 Kaplan Meier Curve showing outcomes at up to 8 years follow up 
6.5 Discussion  
For the first time, we have documented MCS therapy and related outcomes in a 
contemporary Scottish population of patients with AMI complicated by CS. More 
than 79.2%of patients survived to 30-days. This result compares favourably to 
other studies investigating outcomes of patients receiving MCS therapy in 
AMI/CS. In the ENCOURAGE study, approximately half of the cohort survived to  
30-days (Muller et al. 2016). One other North American study reported a 30-day 
mortality rate of 41%(Truby et al. 2015). Most other publications report a 30-day 
survival rate of 23-76% survival rate in this specific patient cohort(Hendry et al. 
1999; Kar et al. 2011; Tang et al. 2013)  
Among the survivors, 16.7% subsequently underwent heart transplantation.   
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There are challenges to comparisons of outcomes in post-AMI-CS patients 
between studies, not least because of the heterogeneity in patient populations 
and practice. comparing outcomes of existing studies, however, is complicated 
by the variability of the cohorts as CS comprises a wide spectrum of clinical and 
haemodynamic instability. There is substantial heterogeneity with presentations 
of the patients with several factors being predictors of poor outcomes in larger 
studies. A literature review revealed older age (Zeymer et al. 2004; Babaev et 
al. 2005), signs of end-organ hypoperfusion(Sleeper et al. 2010), involvement of 
the LAD artery(Zeymer et al. 2004; Klein et al. 2005; Sleeper et al. 2010), 
severity of disease (triple vessel disease)(Zeymer et al. 2004) and renal failure 
(identified by elevated creatinine)(Zeymer et al. 2004; Klein et al. 2005). Our 
cohort was limited in size. Nonetheless, our findings indicate 30-day mortality 
results are similar to or potentially better than prior cohort studies.  
We concentrated on the presenting pathology (AMI with CS) and not the device 
(VAD vs ECMO) as we felt most patients would receive a strategy that was either 
escalated or de-escalated based on recovery. Patients who were improving, for 
example, were stepped down from ECMO to a VAD (short term or long term). 
ECMO was the treatment of choice in most patients as in the acute phase, 
almost all the patients presented with acute pulmonary oedema.  
Almost half (47.8%) of the patients had their support successfully weaned from 
ECMO and/or VAD without any further support device or transplantation. 
Myocardial recovery has been reported in previous publications(Combes et al. 
2008; Brechot et al. 2013; Abrams et al. 2014). Veno-arterial ECMO (VA-ECMO) is 
readily available and can be rapidly instituted percutaneously negating the need 
for operating theatre resources. Some limitations to ECMO have been reported in 
the literature. This includes inadequate left ventricular decompression as 
emptying depends on the native ejection function of the ventricle. Decreasing 
the flow rate on the ECMO circuit also reduces afterload alongside using 
inotropes such as dobutamine to improve contractility and decrease ejection. 
This may result in pulmonary hypertension, oedema and bleeding(Pagani et al. 
1999).   The interaction between the tubing surfaces causes activation of 
monocytes and the release of interleukins 1 and 6(Pennington et al. 1985). Some 
of the decompression can be attenuated by IABP insertion. It is associated with a 
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smaller left ventricular dimension and a lower pulmonary artery pressure by 
restoring pulsatility and decreasing left ventricular afterload(Petroni et al. 
2014). IABP may also reduce the mean of cerebral blood flow during myocardial 
stunning, and increases the mean flow during cardiac recovery(Risnes et al. 
2006). Activation of clotting cascades is the predominant reason for bleeding 
complications. Frequent echocardiograms are done at our unit to ensure there is 
adequate decompression of the right and left ventricles. Another deleterious 
effect of VA ECMO is the neurological morbidity. Brain death has been reported 
in up to 21% in adults treated in ECMO centres. Up to 50% of patients have 
evidence of cerebral injury(Risnes et al. 2006). In our cohort, 26.1% of patients 
had evidence of a cerebral injury. The same deleterious effects of ECMO are also 
noted in VADs (about 20%)(Backes et al. 2012).  
Myocardial ischaemia is commonly the preceding event in CS(Reynolds and 
Hochman 2008; Thiele et al. 2010). It impairs myocardial contractility which in 
turn reduces stroke volume. An impeded cardiac index causes tissue 
hypoperfusion, which includes coronary hypoperfusion causing worsening 
myocardial ischaemia, resulting in a vicious cycle. Serum lactate, creatinine, 
and AST are used as surrogates of organ hypoperfusion in our study. Initial 
compensatory vasoconstriction arises from catecholamine release to increase 
blood pressure but systemic inflammatory response syndrome (SIRS) mediated 
pathological release of vasodilatory agents results in a net reduction in cardiac 
index. This acts in conjunction with the reduction in left ventricular function as 
a result of myocardial stunning from the primary insult. There is a small window 
of reversibility afforded during myocardial stunning by reperfusion which is 
facilitated by early reperfusion(Kajimoto et al. 2013). Capillary leakage from 
SIRS causes tissue oedema and a reduction in circulating volume.  
Decision making for MCS is also an important part of the discussion. Traditional 
ethical principles are not straightforward when applied to ECMO patients as it is 
often seen as the ceiling of therapy available. A survey of self-reported 
physicians with vast experience in VA-ECMO revealed the majority of physicians 
felt physicians should have the right to discontinue management over the 
family’s objection(Meltzer et al. 2016). MCS is a costly intervention thereby 
complicating the decision-making process with finite resources available for 
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clinicians in the National Health Service (NHS). In our unit, a multidisciplinary 
team is consulted to ensure an informed decision that takes into account all 
facets of care prior to initiating MCS support.  
6.6 Limitations 
The data presented represents the first reported series of patients in Scotland 
with AMI complicated by CS treated with MCS. However, as it is a retrospective 
study with a small cohort of patients, the reproducibility of the results may vary 
and may not capture the European or British population as a whole. There is a 
selection bias in the sample as only patients who were deemed potentially 
salvageable were included in the study, which may comparisons with other 
studies difficult.  
6.7 Conclusion 
MCS usage in these patients carries a high mortality in the early post-
implantation period. However, there is a significant benefit to patients who 
survive the initial bridging period to recovery or destination therapy. Further 
prospective studies are needed to identify predictors of long term survival.  
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7.1 Abstract 
Background 
Heart transplantation is still the only definitive treatment for advanced heart 
failure refractory to medical management. Patients often require inputs from a 
multitude of disciplines due to the significant physical and physiological insults 
incurred which include mechanical circulatory support, inotropic usage, 
nutritional deficits, critical care weakness, and immunosuppression. There is a 
paucity of scoring systems available that incorporate the multimodal treatment 
that these patients undergo. We, therefore, devise the Glasgow Transplant 
Score(GTS) using a modified Delphi method. 
Methods 
We tested to model on a single centre retrospective cohort study to evaluate the 
GTS in a clinical setting. We compared the GTS to the other available scoring 
tools; CASUS, SOFA, and Euroscore. All patients who underwent heart transplants 
at the Golden Jubilee National Hospital, Clydebank, the National Heart 
Transplant Unit of Scotland between May 2012-September 2016 were included in 
the study. Data on the pre-operative condition, intraoperative parameters, and 
postoperative course retrospectively analysed. The postoperative scores were 
calculated by using the most abnormal value for each element of care at the 5th 
post-operative day (POD5).  
The primary outcome for the study was mortality which was defined as death 
within 30 days after surgery. The secondary outcome of the study was Primary 
Graft Dysfunction (PGD). The accuracy of outcome prediction by the GTS, 
CASUS, SOFA, and Euroscore systems and the comparisons between the four 
scoring systems for predicting ability was assessed with area under the receiver 
operating characteristic (AUROC) curves. 
Results 
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56 patients were included in the study. There was a 14.2% 30-day mortality in 
this cohort. The GTS score fared well in terms of predicting mortality, PGD and 
ICU stay (AUC 0.855,0.881,0.885 respectively). 
Conclusion 
The Pilot study illustrates the GTS is a good scoring tool for predicting outcomes 
post-heart transplantation. Ongoing prospective studies are needed to further 
validate this score in a multicentre setting. 
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7.2 Introduction 
Heart transplantation is still the only definitive therapy for end-stage heart 
failure. Patients undergoing transplants require tailored management in their 
surgery, intensive aftercare and organ support, physiotherapy and cardiology 
input. Although there have been several scores available for cardiac surgery 
patients, to date there is none incorporates all the facets of care mentioned.  
Preoperative scoring systems such as the European System for Cardiac Operative 
Risk Evaluation (EUROSCORE) are widely used in cardiac surgery although but is 
not applicable in a transplant setting as it was primarily intended for the general 
cardiac setting(Nashef et al. 1999). It is also a pre-operative scoring tool which 
does not consider intra-operative or anaesthetic complication which may differ 
significantly from the initial predicted risk. Other scoring systems like the 
Sequential Organ Failure Assessment (SOFA) provides a broadly applicable value 
that allows for the calculation of both the number and the severity of organ 
dysfunction in six organ systems (respiratory, coagulation, liver, cardiovascular, 
renal, and neurologic)(Jones et al. 2009). The Cardiac Surgery Score (CASUS) was 
first introduced in 2005 to provide a predictive scoring system for cardiac 
surgical patients in the Intensive Care Unit (ICU) setting(Hekmat et al. 2005). It 
takes into account the acute pathophysiology of the post-cardiopulmonary 
bypass setting has shown to be effective at predicting outcomes post-cardiac 
surgery and has been validated in large cohorts (Khosro Hekmat et al. 2010). 
This scoring system provides a day-to-day update on the patients’ physiological 
status to allow assessment of trends to tailor management. The CASUS score, 
however, fails to incorporate the functional state of the patient with outcomes 
solely focused on surgical and intensive care parameters.  
We, therefore, devised the post-operative Glasgow Transplant Score (GTStm), a 
multidisciplinary scoring system that is represented as a polygon to allow a 
quantitative and qualitative approach in guiding care. The polygon allows a 
quick visual appreciation of the ‘score’ to assess trends and highlight areas of 
additional input needed.  
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7.3 Methodology 
We employed a modified Delphi method to specify variables for consideration in 
the Glasgow Transplant Score as detailed below. Clinical governance approval 
was provided by the Golden Jubilee National Hospital and an audit number was 
obtained.  
7.3.1 Panel Selection 
There were initially 10 experts contacted to participate in the modified Delphi 
process. Experts were chosen based on their experience in each of the 
abovementioned fields. The panel consisted of intensivists, cardiac surgeons, 
physiotherapists, dietitians, heart failure cardiologists and clinical psychologists 
with experience in heart transplantations. Each panel expert identified potential 
factors that were relevant to outcomes post-transplantation prior to the 
literature review. 
7.3.2 Systematic review of the literature 
A systematic review of the literature was performed to identify best practice 
evidence for parameters of interest to be included in the score using MEDLINE 
from 1946 to April 2017 was searched for English-language literature. The search 
strategy combined headings and keywords for “heart transplantation” and 
“primary graft dysfunction” or “management” or “treatment”. A core group was 
formed by a cardiac surgeon, intensivist and research fellow. The members of 
the core group screened the literature review to retain necessary titles and 
discard irrelevant studies. Reference lists from selected studies were also 
screened to potentially highlight additional papers. The second screening was 
performed independently by each member of the core group prior to the final 
selection process.  
7.3.3 Email Voting and Vetting  
The initial draft containing all the parameters of interest from the initial 
selection process was circulated to all the members of the panel accompanied 
by descriptions of each variable. Experts then selected whether to include or 
exclude each parameter. They were also given the opportunity to justify their 
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decisions in the comment section as well as suggest parameters of interest that 
may have been left out during the literature review process. A cut off value of 
80% agreement was needed to include/exclude a parameter in the study based 
on work by Eubank(Eubank et al. 2016). At the conclusion of round 1, 30 
parameters were selected (5 Cardiac surgery, 5 Cardiology, 5 Intensive Care, 5 
Physiotherapy, 5 Dietetics, and 5 Psychology) 
7.3.4 Face-to-face discussion 
In round 2, a group meeting (face-to-face) was arranged. Panelists discussed and 
voted on each parameter and decided on whether to retain or reject each 
parameter, with an 80% agreement for either. The final Post-Transplant GTS 
consisted of 9 parameters.  
 
Figure 7-1 Modified Delphi Process of Selection of Parameters for Inclusion 
Final Set of Parameters 
Measurable elements of care for each sub-specialty of the multidisciplinary team 
for post-operative phases of the patients undergoing transplants that were 
Literature Review 
• 423 Citations reviewed 
• 48 Citations were selected by the core group 
 
Round 1 (Email Voting and Vetting)  
• 48 Citations circulated to the panellists 
• 30 Parameters selected (5 by each facet of care) 
 
 lect 
Round 2 Final selection 
• 30 Parameters reduced to 9 parameters after 
deliberation by panellists 
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chosen are highlighted below. A 5-point scale was appointed to each of the 
measurable elements to allow vector plots for the polygon.  
The elements are as follows. 
7.4 Elements of the Post-op GTSTM and Summary of 
Deliberations 
 
Table 7-1. Post-op GTSTM elements of care 
7.4.1.1 LVEF (%) 
The first parameter selected was Left Ventricular Ejection Fraction (LVEF). 
Ejection fraction is one of the strongest predictors of mortality in patients with 
left ventricular systolic dysfunction(Cintron et al. 1993; Hughes et al. 1993; 
Pouleur et al. 1993). In several landmark studies, the Department of Veterans 
Affairs Cooperative Vasodilator-Heart Failure Trials (V-HeFT VA Cooperative 
Studies Group) and The Studies of Left Ventricular Dysfunction (SOLVD) 
investigators, the relationship between LVEF and mortality was established. Cut-
offs for percentages of LVEF for the scale were set as per the European Society 
of Cardiology and American Society of Echocardiography guidelines(Lang et al. 
2005). 
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7.4.1.2 Inotrope score 
The recent ISHLT consensus statement for stratifying Primary Graft 
Dysfunction(PGD) severity(J. Kobashigawa et al. 2014) used cutoffs for inotrope 
scores as defined by Wernovsky in determining the severity of PGD (mild <10, 
moderate >10) (Wernovsky et al. 1995a). Increasing use of inotropes was 
indicative of increasing support required as well as the vasoplegic status of the 
patient. Subsequent studies revealed high inotropic scores were associated with 
prolonged ICU stay, duration of mechanical ventilation and time to negative 
fluid balance(Gaies et al. 2010). Shahin and colleagues evaluated the 
relationship of inotrope use to morbidity and mortality in a cohort of 
consecutive patients undergoing cardiac surgery(Shahin et al. 2011). They 
concluded that inotrope exposure was associated with increased hospital 
mortality and renal dysfunction in cardiac surgery patients.  
7.4.1.3 Serum Creatinine  
Deviation from baseline serum creatinine was selected based on the Acute 
Kidney Injury Network criteria for Acute Kidney Injury(AKI) (Mehta et al. 2007). 
A study in Edinburgh revealed how AKIN scores (compared to RIFLE 
(Risk/Injury/Failure/Loss/End-stage)) were more sensitive at picking up AKIs 
(12.4% vs 6.5%)(Duthie et al. 2014). The AKIN score however also includes urine 
volumes which we have omitted from our study as this may be artificially 
influenced by renal replacement therapy and administration of diuretics. 
7.4.1.4 Bilirubin & Aspartate aminotransferase (AST) 
Bilirubin levels may be elevated post-transplant due to increased pressure in 
from a hypofunctioning right ventricle or hepatocyte necrosis and inflammation 
from decreased perfusion. A similar phenomenon is noted with AST levels as 
well. Both of these markers, therefore, serve as indirect representations of right 
ventricular function post-transplant.  
Sabzi and colleagues showed that AST was the most sensitive test for 
postoperative evaluation of hepatic function in hypothermic and normothermic 
cardiopulmonary bypass (Sabzi and Faraji 2015). AST is a liver enzyme that is 
often elevated in response to declining right heart function. It is also an 
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indication of decreased liver perfusion resulting in hepatocyte necrosis(Anker et 
al. 2003). A study by Vakilian (Vakilian et al. 2015)  highlighted that a pre-
operatively elevated AST was predictive of increased post-operative inotrope use 
Vakilian et al., 2015).  
Bilirubin has also been used in several other studies as a predictive marker of 
increasing end-organ hypoperfusion and liver congestion. The CASUS score is one 
such example(K. Hekmat et al. 2010). A raised bilirubin in combination with 
mechanical circulatory support is also linked with poorer outcomes. The 
mechanism for this could be due to increased haemolysis as well as possible 
reduced perfusion. 
Overall, these two liver function tests correlate well with increasing 
cardiopulmonary bypass time and overall graft function.  
7.4.1.5 Lactate 
Scalea et al found that up to 80% of critically ill patients who have normal blood 
pressure and have adequate urine output may remain in a state of compensated 
shock(Scalea et al. 1994). Measures of oxygen extraction variables and gastric 
intramucosal pH have been explored as viable alternatives but did not 
distinguish survivors from non-survivors over time. The two most commonly used 
markers in assessing the resuscitation of critically ill patients remain base deficit 
and lactate(Joynt et al. 1997). 
In cardiac surgery, tissue perfusion is at risk during the perioperative period with 
the association of low blood flow with metabolic acidosis and accumulation of 
lactate perioperatively has been well established.  
With the improvements in cardiopulmonary bypass and overall hemodynamic 
management, severe peri- and postoperative hypoperfusion has become rare 
however several lines of evidence suggest that episodes of less severe 
hypoperfusion and borderline tissue oxygenation are relatively common, 
although generally well tolerated. Measurement of blood lactate levels is widely 
used to assess the adequacy of tissue perfusion(Takala et al. 1996). 
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Hyperlactatemia can occur even in the absence of tissue hypoperfusion(Raper et 
al. 1997). Intraoperative catecholamine administration intraoperatively can lead 
to increased lactate levels owing to their action on oxidative glucose 
metabolism(Stainsby et al. 1987). 
Hyperlactataemia has a bimodal distribution in the perioperative period. An 
early increase in lactate levels, arising intraoperatively or soon after intensive 
care unit admission is highly suggestive of tissue ischaemia and is associated with 
a prolonged intensive care unit stay, a prolonged requirement for respiratory 
and cardiovascular support and increased postoperative mortality. Late-onset 
hyperlactataemia occurs 4 to 24 hours after completion of surgery and is 
typically associated with preserved cardiac output and oxygen delivery but has a 
longer duration of ventilation and intensive care unit length of stay than those 
with normolactataemia(O'Connor and Fraser 2012). 
Hajjar and colleagues revealed that patients in whom complications developed 
had higher lactate levels immediately after ICU admission, 6 hours and 12 hours 
after admission(Hajjar et al. 2013). 
This also identified patients with worse outcomes including a higher rate of 30-
day mortality after cardiac surgery. Also, a lactate level exceeding 3 mmol/L at 
6 hours after surgery is independently associated with a 3.3 times risk of a major 
complication after cardiac surgery, including death. Another study revealed an 
association between higher lactate levels at ICU admission and complications 
that included longer duration of mechanical ventilation and length of ICU 
stay(Maillet et al. 2003).  
Polonen’s group showed that normalizing lactate concentrations, as a 
therapeutic goal is associated with decreased morbidity and hospital length of 
stay in patients undergoing cardiac surgery(Polonen et al. 2000).  
7.4.1.6 Mechanical Circulatory Support (MCS) 
PGD is the leading cause of early mortality following orthotopic heart 
transplantation. However, a widely approved definition for PGD was not 
available, albeit the clinical characteristics of hypotension despite adequate 
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filling pressures and the absence of hyperacute rejection and tamponade were 
used as a guide(J. Kobashigawa et al. 2014). The ISHLT consensus statement 
(2014) produced a definition of PGD alongside grading systems for severity. This 
included the use of Intra-Aortic Balloon Pumps (IABPs) and Ventricular Assist 
Devices (VADs)/Extracorporeal Membranous Oxygenation (ECMO) as predictors of 
outcome. The use of any MCS device is classified as a severe PGD. ECMO is a 
recognized treatment for PGD. In a case series of 366 consecutive heart 
transplants, post-operative ECMO institution in the recipient occurred in 40 
cases of cardiopulmonary failure.  The recipients included 35 males and 5 
females with an overall median age of 42.3 years. More than 70% of the patients 
were successfully weaned with an overall survival exceeding 50%. Although ECMO 
provided temporary MCS rescuing some recipients with post-transplant 
cardiopulmonary failure, no patient receiving ECMO support for >4 days survived. 
(Chou et al. 2010) 
For VADS, several annual reports from the International Society for Heart and 
Lung Transplantation registry reported increased early post-transplant mortality 
in patients supported with VADs(Taylor et al. 2006; Trulock et al. 2007). 
The implantation of IABPs is used for a variety of reasons. However, in advanced 
heart failure, it denotes moderate primary graft dysfunction. It is used to 
stabilize patients in end-stage heart failure, is safe, well-tolerated, and bridging 
acutely decompensated patients to transplantation, Complications are few and 
manageable. Following IABP and HTx, short- and long-term survival, biochemical 
and invasive and non-invasive haemodynamic outcomes were similar to those in 
electively transplanted patients(Gjesdal et al. 2009). 
7.4.1.7 Grip Strength 
Grip strength is a way of quantifying the amount of static force that a hand can 
squeeze around a dynamometer. It is associated with increased mortality in a 
host of chronic conditions as a marker of general nutrition. Poor handgrip 
strength is highly prevalent among Heart failure patients as a result of the 
derangement of muscle structure and metabolism, contributing to exercise 
intolerance, frailty, and mortality. The Columbia group noted that in patients 
with advanced HF before VAD implantation (2.3 ± 4.9 days pre-VAD) handgrip 
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strength correlated with serum albumin levels. They also found that patients 
with a handgrip strength <25% of body weight had an increased risk of mortality, 
increased postoperative complications, and lower survival after VAD 
implantation(Chung et al. 2014). 
Grip strength is also commonly used as a gauge to frailty. Frailty is common 
among patients with HF. One study concluded that frailty is a strong and 
independent predictor of ED visits and hospitalizations and should be 
incorporated into the clinical evaluation of patients with HF(McNallan et al. 
2013). 
7.4.1.8 Mobility  
One tool that has been extensively validated and compared favourably with 
others is the Elderly Mobility Scale (EMS). It evaluates an individual’s mobility via 
seven functional activities including bed mobility, transfer, and reactions to 
perturbations. We based the bed mobility, mobility and physical transfer aspect 
of our physiotherapy polygon based on some of the common assessors used in 
this scale. This included the independence of mobility in bed, transfers and 
personal care(Smith 1994). Other similar tools that we adapted from includes 
the Berg Balance Score(Berg et al. 1995). Both these tests showed good inter-
operator reliability with a high rate of reproducibility(Chiu et al. 2003).  
A sit to stand test was employed as another marker for frailty. The primary focus 
of this test is lower limb strength. The use of the sit to stand test has been 
validated in other cohorts. One such example is Millor et al (2013) whose study 
concluded that parameters such as velocity peaks, impulse, and orientation 
range are able to differentiate between adults and older populations with 
different frailty levels during the 30-second sit to stand test(Millor et al. 2013). 
It has also been employed by the Centre for Disease Control (CDC) with relevant 
cut-offs that have been employed in this score. (CDC 2017). 
7.5 Polygon Formation 
To allow visual representation of the data, a 9 Point radial plot (Polygon) was 
created using Microsoft Excel 2013. Values on each spoke of the polygon 
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corresponded to the numerical value of the score above. Each of the lines was 
connected to represent a performance polygon for each patient. The higher the 
score as determined by Table 7-1, the further the radiation of the polygon from 
the centre. The use of polygons to display the score was adapted from the 
Chelsea Critical Care Physical Assessment Tool(Corner et al. 2013). 
7.6 Pilot Study  
We conducted a single centre retrospective cohort study to evaluate the GTS in 
a clinical setting. We compared the GTS to the other available scoring tools; 
CASUS, SOFA, and Euroscore. All patients who underwent heart transplants at 
the Golden Jubilee National Hospital, Clydebank, the National Heart Transplant 
Unit of Scotland between May 2012-September 2016 were included in the study.  
7.6.1 Patients 
Our sample comprised of all adult patients who underwent heart transplants 
during this period. Data on the pre-operative condition, intraoperative 
parameters, and postoperative course retrospectively analysed. The 
postoperative scores were calculated by using the most abnormal value for each 
element of care at the 5th post-operative day (POD5). No data was missing.  
The primary outcome for the study was mortality which was defined as death 
within 30 days after surgery. The secondary outcome of the study was Primary 
Graft Dysfunction. 
7.6.2 Statistical analysis 
Statistical analyses were performed using Statistical Package for the Social 
Sciences (SPSS) Version 22 (IBM Corp. Released 2013. IBM SPSS Statistics for 
Windows, Version 22.0. Armonk, NY: IBM Corp.). The level of statistical 
significance was set at 5%. A Kolmogorov-Smirnov test was used to indicate the 
normality of the quantitative variables prior to performing Students ‘T’ Tests for 
continuous data. Categorical data were analysed using a Chi-Squared Test. Non-
Parametric data were analysed using the Mann-Whitney U test. Continuous data 
were presented using Mean values ± Standard deviation. The accuracy of 
outcome prediction by the GTS, CASUS, SOFA, and Euroscore systems and the 
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comparisons between the four scoring systems for predicting ability was assessed 
with area under the receiver operating characteristic (AUROC) curves. 
7.7 Results 
56 patients were included in the study. There was a 14.2% 30-day mortality in 
this cohort. Patient demographics, intraoperative and post-operative outcomes 
are demonstrated below  
Recipient Variable Survivors 
(n=48) 
Non-Survivors 
(n=8) 
P-value 
Age (years) 46.1±12.9 46.1±12.5 0.998 
Male sex (%) 72.9 75.0 0.902 
Body Mass Index  25.4±3.5 27.3±3.9 0.220 
Non-ischaemic 
Cardiomyopathy (%) 
79.2 62.5 0.301 
Table 7-2 Preoperative Demographic data of both groups of patients 
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Intraoperative Survivors 
(n=48) 
Non-Survivors 
(n=8) 
P-value 
Cardiopulmonary 
bypass time (mins) 
222.3±75.7 329.0±105.1 0.024 
Total Ischaemic 
Time (mins) 
179.3±52.2 180.8±36.7 0.924 
Cold Ischaemic 
Time (mins) 
136.6±50.3 128.5±40.8 0.625 
Donor Age (years) 41.8±11.1 41.0±12.1 0.865 
Table 7-3 Intraoperative details of both groups of patients 
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Post-operative  Survivors 
(n=48) 
Non-Survivors 
(n=8) 
P-value 
Hours of mechanical 
ventilation  
110.4±164.2 135.0±97.4 0.565 
Inotrope Score 5.7±7.2 21.2±13.3 0.035 
Renal Replacement  
Therapy (%) 
6.3 50 0.001 
ECMO (%) 31.3 75.0 0.018 
IABP (%) 56.3 62.5 0.741 
Primary Graft 
Dysfunction (%) 
54.2 100 0.014 
Post-operative 
Ventilation 
Time(hours) 
128.5±40.8 136.6±50.3 0.565 
GTS score 30.6±6.9 16.9±10.1 0.006 
CASUS score 7.9±6.2 20.1±3.0 <0.001 
SOFA score 6.4±3.4 15.9±2.8 <0.001 
Euroscore 22.0±14.1 13.8±7.8 0.029 
Table 7-4 Postoperative outcomes of both groups of patients 
The accuracy of outcome prediction by the scoring systems for predicting ability 
was assessed with area under the receiver operating characteristic (AUROC) 
curves. The outcomes of interest were 30-day mortality, Primary Graft 
Dysfunction and ICU length of stay>14 days in survivors. 
7.7.1 GTSTM  
 
Figure 7-2 ROC Curve showing GTS prediction and mortality 
Area under the curve for GTStm and mortality is 0.855 
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Figure 7-3 ROC Curve showing GTS prediction and PGD 
Area under the curve for GTStm and PGD is 0.881 
 
Figure 7-4 ROC Curve showing GTS prediction and prolonged ICU stay 
Area under the curve for GTStm and prolonged ICU stay is 0.885 
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7.7.2 SOFA & CASUS 
 
Figure 7-5 ROC Curve showing SOFA and CASUS prediction and Mortality 
Area under the curve for SOFA is 0.991, while the area under the curve for 
CASUS is 0.936. 
 
Figure 7-6 ROC Curve showing SOFA and CASUS prediction and PGD 
Area under the curve for SOFA is 0.812, while the area under the curve for 
CASUS is 0.826. 
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Figure 7-7 ROC Curve showing SOFA and CASUS prediction and prolonged ICU stay 
Area under the curve for SOFA is 0.907, while the area under the curve for 
CASUS is 0.897. 
  
7 The Post-Operative Glasgow Transplant Score (GTSTM) 213 
 
7.7.3 Euroscore 
 
Figure 7-8 ROC Curve showing Euroscore prediction and mortality 
Area under the curve for Euroscore is 0.688 
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Figure 7-9 ROC Curve showing Euroscore prediction and PGD 
Area under the curve for Euroscore is 0.688 
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Figure 7-10 ROC Curve showing Euroscore prediction and prolonged ICU stay 
Area under the curve for Euroscore is 0.592 
7.7.4 Qualitative analysis using performance polygons 
A composite polygon showing mean results of all patients (Survivors Vs Non-
Survivors) is depicted in Figure 7-11 whereas a composite polygon showing 
outcomes of patients with and without PGD is depicted in Figure 7-12. 
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Figure 7-11 Polygons depicting GTS of survivors vs non-survivors (Grip strength omitted 
due to incomplete datasets). 
 
Figure 7-12 Polygons depicting GTS of patients with PGD and No PGD (Grip strength 
omitted due to incomplete datasets). 
7.8 Discussion 
The DELPHI method was originally designed to apply expert opinion to a 
selection of questionnaires interspersed with controlled opinion feedback(Dalkey 
and Helmer 1963). Although initially used for military strategic planning, it is 
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now utilised in the healthcare setting to determine consensus for a pre-defined 
problem. One such example is the consensus statement for the management of 
medical conditions such as Barrett’s Oesophagus (Bennett et al. 2012), renal cell 
carcinoma (Wood et al. 2013) and rotator cuff tears(Eubank et al. 2016). It is a 
technique that incorporates individual judgements and combining them to 
address an incomplete state of knowledge(Powell 2003). We utilised this method 
to incorporate elements of frailty into practice. The GTS incorporates 
biochemical, clinical and functional assessments of the patient thereby providing 
a more holistic scoring system that can be used to facilitate multi-disciplinary 
meeting discussions.  
A key strength of the Delphi method is that it provides a summation of 
judgements which in theory is more accurate than that of individuals(Rowe et 
al. 1991). Informal consensus discussions without the Delphi methodology may 
be influenced by more ‘powerful’ individuals, which may, therefore, overlook 
the other facets of care in decision-making(Murphy et al. 1998). This may also be 
influenced by personality traits and seniority(Rowe et al. 1991).The first part of 
the Delphi method, in which panelists anonymously select parameters allows 
objectivity to the outcome, thereby promoting the sharing of responsibility. This 
has been shown to reassure participants(Lindeman 1975).  
One of the criticisms of the Delphi method includes the assumption that 
panelists contribute equally and are not duly influenced or persuaded to conform 
rather than express true agreement. This may, therefore, mirror other informal 
consensus agreements that allow the abovementioned biases(Goodman 1987). 
Panelists are assumed to provide objective and neutral solutions or responses. 
Lay persons were not included in our Delphi methodology. This was to minimise 
discrepancies arising due to cognitive bias or emotions(Hussler et al. 2011). 
A variation from the ‘true’ Delphi method that we employed was the face-to-
face discussion. We felt this may deprive panelists of critiquing and seeking 
clarification and deliberation which we felt would drive the selection 
process(Walker and Selfe 1996). The final process in our methodology also 
allowed the generation of alternatives and applicability of the scoring system in 
a real-world setting(Ali 2005).  
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A major strength of this study is the incorporation of the whole multidisciplinary 
team to mimic a real-life setting. The scalar representation of each variable 
allows a uniform depiction of the patient’s clinical condition with experts in 
each field able to interpret the results of other fields and vice versa. This also 
allows the quantification of frailty measures alongside biochemical and clinical 
parameters for each patient.  
Another major highlight of the GTS is the qualitative depiction of the dataset in 
the polygons. This allows easy interpretation and appraisal of the clinical 
condition of a patient while highlighting areas of increased need of support. 
Performance polygons are a simple but powerful way to represent data over 
multiple domains(Cook et al. 2012). They can also be used as a comparison 
between patients or at different time points to enhance their value as a 
potential driver of change and quality improvement(Cook et al. 2012). This also 
permits a continuous assessment by assessing the change of shape of the 
polygons to show improvement or worsening of parameters from the end of the 
bedside. This visual depiction also serves as a guide for patients and relatives to 
monitor progress within the hospital setting as they provide a visual 
representation of data that is easily understood by observers. The use of 
polygons in medicine also allows the merging of fundamentally unconnected data 
that have similar vectors (move in the same direction).  
The quantitative score of the GTS has similar AUCs as the other ICU post-
operative scoring systems for ICU stay and mortality. However, the GTS also has 
good predictability for Primary Graft Dysfunction which is an important 
recognised complication of heart transplantation. The Euroscore performed 
poorly compared to the other scoring systems. However, it should be noted that 
it is primarily a pre-operative risk assessment tool designed for general cardiac 
surgery and thus may accurately predict outcomes post-heart transplantation. 
SOFA and CASUS showed good predictability of mortality as it highlights the 
common pathway of tissue hypoperfusion and end-organ dysfunction.  
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7.9 Limitations 
7.9.1 Outcomes 
The GTS fared well when compared to the Euroscore but did not perform as well 
with CASUS and SOFA. There are several reasons to explain this. There were 
limited numbers of patients in the study. In addition, CASUS and SOFA which are 
intensive care centered measures are more sensitive at identifying the acutely 
unwell patients within the intensive care setting as opposed to the GTS which 
works on trending improvements to identify progress. The utility of the score is 
therefore aimed at different outcomes. While GTS, which assesses frailty may 
identify patients at risk of poor outcomes, CASUS and SOFA are useful for 
identifying more objective markers of poor outcomes. The utility of frailty 
assessment in the post-operative setting is limited, however, its role in 
measuring ongoing progress may be of benefit especially to the multimodality 
treatments offered by the MDT.  
7.9.2 Data 
The consensus statements were not wholly supported by level 1 studies. Most of 
the literature on heart transplantation and primary graft dysfunction is based on 
observational studies and analysis of large databases like UNOS or ISHLT. Where 
possible, data was sourced from well-designed randomised controlled trials. In 
order to ensure ubiquitous applicability of the scoring system, we opted to 
include routine measurements in clinical practice such as AST and lactate while 
omitting more obscure and costly tests that are only available at certain centres 
such as SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily A-like protein 1 (SMARCAL-1)(Aharinejad et al. 2009). 
Consistent level 2 and 3 studies have been used numerous times to provide 
strong recommendations and assuming level 1 studies that are underpowered or 
poorly conducted as being superior to level 2 studies should be done with 
caution(Burns et al. 2011).  
7.9.3 Polygons 
The polygon formation also assumes equal weightage of all the parameters 
within the GTS. An ordinal scale of 0-5 was formed with 5 being the most 
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favourable outcome. The weightage of the values and escalation from one 
category to the next is assumed to be a linear progression. This is a major 
assumption as there may be a large number of patients who may fall within a 
category of the scale (e.g. 3). The Glasgow Coma Scale as introduced by 
Teasdale and Jennett was also initially criticised for lacking weightage. This 
mathematical imprecision has a bearing also on clinical accuracy and precision. 
For instance, in the present structure of the scale, the same sum score could be 
produced by totally different clinical states. The was also overall motor 
dominance at both the lower and higher ends of the scale(Bhatty and Kapoor 
1993). A large scale prospective study is currently being developed for the GTS 
to provide weightage to the scales to allow a more uniform comparison. The 
initial iteration of the GTS is primarily a proof of concept in which the polygons 
can be used to display a patient’s condition, and evolution of the polygon over 
time to highlight areas of increased input required. Once weightage has been 
established, it may then be possible to calculate the area of the polygon for 
quantitative analysis. A known limitation with any polygons is the requirement 
for large databases of robust data to generate meaningful, reliable polygons. 
However, this holds true for any other data representation method(Cook et al. 
2012). 
7.9.4 Unadjusted confounders 
Another limitation of the GTS is the potential confounding effects of the 
variables. A patient on ECMO/IABP would be limited on the mobility scale or a 
patient with a low ejection fraction may require increased inotropes, potentially 
need MCS support and therefore not be able to mobilise. This also holds true for 
most other scoring systems such as CASUS or SOFA whereby one organ failure 
may lead to ongoing organ failure as tissue hypoperfusion is the common 
pathophysiological pathway. We, however, believe that the trend of the scores, 
as opposed to a score in isolation, will, therefore, highlight improvements and 
be of greater utility. We envisage the polygons to be available in a digital format 
by the patient’s bedside with continuous input, thereby evolving to highlight 
improvement or worsening of the clinical and physiological conditioning of the 
patient.  
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7.10 Conclusion 
Post-GTS is a novel scoring tool that can be used to guide MDT decision making 
in the post-operative period for cardiac transplant patients. More data is needed 
to provide weightage and further enhance its predictive ability. 
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8 Conclusions 
The objectives achieved with this thesis are as follows 
8.1.1 The incidence of PGD in the UK (Chapter 3) 
The first aim of the thesis was to ascertain the true incidence of PGD in the UK. 
To date, there was no accurate incidence reporting due to the lack of a unifying 
definition. Dronavalli and colleagues (Dronavalli et al. 2015) used a definition 
that was similar to the ISHLT consensus statement. This thesis, however, is 
based on a contemporaneous cohort of patients which highlights changing 
demographics of the donors, recipients, the introduction of ex-vivo 
normothermic perfusion devices and the start of the Donation after Circulatory 
Death era worldwide and in the UK (Chapter 2). To date, this is the largest 
national study worldwide to identify the true incidence of PGD in the UK. As part 
of the changes made and ongoing data collection initiatives led by my work and 
integrated into NHSBT’s data collection, PGD rates are now reported 
prospectively which allows ongoing monitoring and incidence reporting. 
8.1.2  To identify risk factors for PGD according to ISHLT 2014 
consensus statement 
The lack of a consensus statement prior to 2014 made identification and 
comparison of PGD difficult. The findings of these were included in chapter 3. 
We created a multivariable logistic regression model to identify risk factors 
within our cohort of patients. We were also able to highlight the role of warm 
ischaemic time as opposed to total ischaemic time as a risk factor which has not 
been noted in studies derived from the United Network for Organ Sharing (UNOS) 
database due to limitations of data collection. From the risk factors noted, we 
provided potential pathophysiological mechanisms to highlight the role of 
ischaemic reperfusion injury with accumulation of succinate as the common 
pathway based on previous studies done on other transplanted organs (Section 
1.12.2.4). Future studies should incorporate ameliorating the risk factors 
identified to reduce the risk of PGD. Ongoing work is underway with CTAG 
commencing a trial to identify the role of different cardioplegic solutions in 
myocardial protection (St Thomas’s solution vs Custodioltm). 
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8.1.3 A scoring system 
Another aim was to create a ubiquitous, easy to use, reproducible scoring system 
to allow benchmarking of PGD rates using observed vs expected analysis as a 
statistical quality control assessment. We derived the PREDICTA score (Chapter 
4) based on a contemporary cohort of patients with good predictability. This 
would allow continuous monitoring of outcomes to identify outliers using the 
VLAD plot. This serves to improve outcomes by improving measures to manage 
PGD such as resource allocation (MCS, theatre space, ICU staffing) and 
subconsciously via the Hawthorne effect of altering by increasing vigilance. This 
tool could potentially serve as a governance tool for NHSBT to improve clinical 
effectiveness by auditing outcomes and ease the implementation of cost-
effective novel technologies within a public healthcare system. Future studies 
should concentrate on the search for a biomarker to improve the precision of the 
PREDICTA score. To date, the ideal biomarker has not been identified but 
further studies along the ischaemic reperfusion pathway may yield measurable 
by-products for quick point-of-care testing in the near future. 
8.1.4 Cold antegrade perfusion 
The Glasgow method of implantation described in Chapter 5 has improved short-
term post-transplant survival. The retrospective nature of the study, however, 
has several confounders that should be addressed. This should be performed via 
a proof of concept study using animal models (e.g. Juvenile Landrace Pigs) to 
ascertain if the clinical improvement noted by this method is shown at a 
biochemical or cellular level. The use of antegrade cardioplegia has multiple 
advantages from a surgical perspective as detailed in Chapter 5. This could then 
extend to a low fidelity model of continuous cold perfusion during transportation 
(vs the ex-vivo normothermic perfusion models). In addition, the role of 
extracorporeal removal of cytokines using devices such as the CE-marked 
CytoSorb whole blood adsorber needs to be explored in addition to the leukocyte 
depleting filter. I plan to undertake training in animal model handling to co-
supervise the next Ph.D. candidate with regards to implementing the 
abovementioned techniques.  
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8.1.5 Post-MCS-MI  
Outcomes post-MCS-MI have improved with improved referral pathways and early 
initiation of therapy. This study has also led to the creation of an online referral 
form to assist decision-making prior to initiation of MCS, which places a 
significant burden on the NHS. Our unit has been included in the EURO-SHOCK 
trial of evaluating early MCS initiation in patients with cardiogenic shock. 
Recruitment began in October 2019 and we await the outcomes of this trial to 
identify patients who would benefit from this. This would invariably increase the 
number of candidates for long-term VAD/heart transplantation in the near 
future. 
8.1.6 Frailty assessment for transplantation 
A major limitation of this thesis is the lack of frailty assessment biomarkers and 
tools. Whilst frailty is common among heart failure patients, the abstract nature 
of it often prevents an accurate diagnosis. We, therefore, aim to conduct an 
observational study on frailty that is currently awaiting ethical approval. This 
study would include hand-grip strength testing, baseline cognitive assessments, 
baseline nutritional assessments, and deprivation index to identify the 
biopsychosocial model of the heart failure patient and evaluate outcomes 
following heart transplantation. The study was well-received at the CTAG 
clinical trials meeting in August 2018 and we are aiming to recruit candidates by 
the end of 2020. 
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9 Personal Reflection 
I was informed by a colleague at a conference that a Ph.D. is a journey and not a 
destination. This has held through for a novice researcher in me. I recall the 
interview process for the appointment whereby I was informed that my research 
portfolio was ‘light’. In the process of completing this thesis, I was fortunate 
enough to have met pioneers such as Sir Terence English, Dr. Jon Kobashigawa, 
and Professor John Dark, all of whom have significantly contributed to the field 
of cardiothoracic organ transplantation. I was invited to chair a session with Dr. 
Kobashigawa at ISHLT in 2018, 2019 and again in 2020. Professor Al-Attar 
poignantly recalled how I barely knew what primary graft dysfunction was at the 
start of my thesis, and now am rubbing shoulders with the ‘experts’.  
Throughout this thesis, we had to accommodate changes within the 
transplantation setting. The advent of OCS usage and DCD implied a change in 
the definition of ischaemic time. The lack of nationally collected data on frailty 
meant that we had to use a modified Delphi method to create the GTS and trial 
it locally. Improved understanding of risk factors for PGD allowed us to 
implement suitable changes to the standardise out transplantation process 
locally using the ‘Glasgow Method’. We also noticed an increasing number of 
patients with STEMI’s with cardiogenic shock referred to our tertiary centre for 
mechanical circulatory support, which prompted the study in chapter 6.  
If I had a chance to start over, I would study the clustering of PGD, to identify if 
PGD in one organ from a donor is linked to poor function in other organs 
retrieved from the same donor. I would also link this with PGD in lungs to 
identify an association. The role of DCD vs DBD should also be further explored 
to ascertain the role of brainstem death for PGD.  
Part of my work has resulted in prospective collection of data for PGD analysis 
for each centre within the UK using a programmed excel sheet to identify 
patients in the mild and moderate category without needing circulatory support 
by means of IABP or advanced MCS as to date, little is known about the 
significance of mild or moderate PGD without IABP and outcomes.  
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My experience throughout the past few years has also improved my confidence 
in public speaking and enhancing my appreciation for critical appraisal of 
research presentations and publications as I have been invited to review multiple 
articles with PGD as the subject by peer-reviewed journals. 
I, therefore, wish to thank the University of Glasgow for providing me with the 
support to undertake this thesis. I am currently applying for a National Training 
Number in Cardiothoracic surgery and hope this serves a good platform for 
ongoing research in the near future.  
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Figure 10-2 Data Collection Sheet 2 
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